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ABSTRACT	  
The	  prevalence	  of	  HIV-­‐1	  is	  highest	  in	  Sub-­‐Saharan	  Africa.	  Protective	  immune	  responses	  directed	  against	  HIV	  are	  complex	  and	  involve	  both	  cellular	  and	  humoral	  immunity.	  Based	  on	  the	  recent	  finding	   that	   the	   best	   correlate	   of	   protection	   against	   the	   first	   protective	   prophylactic	   RV144	  vaccine	  were	  HIV-­‐specific	  antibody	  responses,	  including	  those	  mediating	  natural	  killer	  (NK)	  cell	  antibody-­‐dependent	   cellular	   cytotoxicity	   (ADCC),	   there	   has	   been	   considerable	   interest	   in	  measuring	  alternative	  roles	  for	  HIV-­‐specific	  binding	  antibodies.	  The	  aim	  of	  this	  MSc	  dissertation	  was	   to	   optimise	   and	   compare	   two	   high-­‐throughput	   flow	   cytometry	   based	   approaches	   -­‐	   the	  GranToxilux	  and	  PanToxilux	  assays	   -­‐	   to	  measure	  HIV-­‐specific	  ADCC	  responses.	  To	  do	   this,	  NK	  cells	  from	  a	  panel	  of	  healthy	  HIV-­‐negative	  individuals	  were	  screened	  for	  their	  ability	  to	  directly	  kill	  the	  tumour	  cell	  line	  K562,	  as	  a	  measure	  of	  direct	  NK	  cell	  cytotoxicity.	  The	  individual	  with	  the	  highest	  granzyme	  B	  and	  caspase	  activity	  against	  K562	  cells	  was	  chosen	  as	  the	  universal	  NK	  cell	  donor	   for	   this	   study.	   For	   the	   ADCC	   assay	   optimisation,	   plasma	   from	   a	   panel	   of	   HIV-­‐1	  seropositive	  individuals	  was	  screened	  for	  binding	  antibody	  titres	  against	  HIV	  subtype	  C	  gp120	  by	  ELISA,	  and	  confirmed	  by	  western	  blot.	  Plasma	  from	  a	  panel	  of	  HIV	  seronegative	  individuals	  was	  included	  as	  negative	  controls.	  The	  ADCC	  assay	  was	  optimised	  to	  include	  subtype	  C	  gp120-­‐coated	  CEM.NKRCCR5	  cells	  as	   target	  cells.	  This	  dissertation	   further	  describes	  detailed	  titrations,	  validations	   and	   refinements	   of	   both	   the	   GranToxilux	   and	   PanToxilux	   assays	   to	  measure	   both	  direct	   NK	   cell	   killing	   and	   HIV-­‐specific	   ADCC	   activity,	   and	   finally	   presents	   the	   optimised	  protocols	  for	  both	  assays.	  The	  PanToxilux	  assay	  (which	  measured	  both	  granzyme	  B	  and	  caspase	  activity)	   measured	   higher	   levels	   of	   direct	   NK	   cell	   killing	   of	   K562	   tumour	   cells	   than	   the	  GranToxilux	   assay	   (p<0.05).	   In	   the	  ADCC	  assays	   in	  which	  NK	   cell	   killing	  was	  directed	   against	  gp120-­‐coated	  CEM.NKRCCR5	   cells	   in	   an	   antibody-­‐dependent	  manner,	   plasma	   from	  HIV-­‐positive	  individuals	  yielded	  significantly	  higher	  levels	  of	  ADCC	  activity	  than	  the	  HIV-­‐negative	  controls.	  In	  contrast	   to	   the	   direct	   killing	  measurement,	   the	   GranToxilux	   assay	  measured	   similar	   levels	   of	  ADCC	  killing	  as	   the	  PanToxilux	  assay	  while	  having	  significantly	   lower	  background	  cytotoxicity	  against	   target	   cells	   coated	  with	   HIV	   negative	   serum	   (p=0.0028).	   In	   conclusion,	   the	   study	   has	  optimised	  and	  compared	  both	  the	  GranToxilux	  and	  PanToxilux	  assays	  to	  measure	  HIV-­‐specific	  ADCC	  within	   the	   laboratory,	   that	  will	   be	   useful	   for	   future	   studies.	   The	   PanToxilux	   assay	  was	  more	   sensitive	   for	   detecting	   direct	   NK	   cell	   killing	   of	   K562	   cells	   than	   the	   GranToxilux	   assay,	  although	  both	  assays	  performed	  similarly	  at	  detecting	  HIV-­‐specific	  ADCC	  activity	  against	  gp120-­‐coated	  CEM.NKRCCR5	  cells.	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1.1.	  Introduction	  Acquired	   Immune	   Deficiency	   Syndrome	   (AIDS),	   caused	   by	   Human	  Immunodeficiency	  Virus	  (HIV)	  (Sharp	  et	  al.,	  2011),	  was	  first	  described	  in	  1981	  in	   New	   York	   (reviewed	   by	   Greene,	   2007)	   and	   first	   isolated	   by	  Montagnier	   in	  France	  and	  by	  Gallo	   in	   the	  USA	  (Gallo	  and	  Montagnier,	  2003).	  Since	   then,	  HIV	  has	   become	   a	   pandemic	  with	  HIV	   type	  1	   (HIV-­‐1)	   being	   the	   predominant	   type	  circulating	  worldwide	  and	  infecting	  ~60	  million	  people	  and	  causing	  >25	  million	  deaths	  (UNAIDS,	  2013).	  HIV	  type	  2	  (HIV-­‐2)	  is	  largely	  restricted	  to	  West	  Africa,	  although	  some	  spread	  to	  other	  parts	  of	  Africa,	  Europe,	  India	  and	  the	  USA	  have	  been	  described	  (Campbell-­‐yesufu	  and	  Gandhi,	  2011).	  Internationally,	  Africa	  has	  experienced	   the	   greatest	   AIDS/HIV	  morbidity	   and	  mortality,	   with	   the	   highest	  prevalence	   for	   HIV-­‐1	   infection	   being	   in	   Sub-­‐Saharan	   Africa	   (UNAIDS,	   2013).	  Sub-­‐Saharan	   Africa,	   which	   only	   has	   12%	   of	   the	   world	   populations	   but	   ~30	  million	  people	  are	  living	  with	  HIV,	  has	  71%	  of	  the	  total	  number	  of	  HIV-­‐infected	  people	  in	  the	  world	  (Figure	  1.1,	  UNAIDS,	  2013).	  In	  this	  region,	  it	  was	  estimated	  that	  2.7	  million	  people	  were	  infected	  in	  2010	  alone	  (UNAIDS,	  2012).	  	  	  In	   Sub-­‐Saharan	   Africa,	   HIV	   disproportionately	   affects	   women	   than	  men,	   with	  women	  accounting	   for	  58%	  of	  all	   those	   infected,	  77%	  of	   those	  who	  are	  newly	  infected	   between	   the	   ages	   of	   15-­‐24	   years,	   with	   a	   prevalence	   that	   is	   3-­‐7	   fold	  higher	   among	   adolescent	   females	   than	   adolescent	  males	   (Abdool-­‐Karim	   et	   al.,	  2010;	  UNAIDS,	  2012).	   Factors	   such	  as	  poverty,	   gender	   inequality	   and	  gender-­‐based	  violence	  are	  contributors	  to	  this	  high	  prevalence	  observed	  in	  women	  as	  compared	   to	   their	   male	   counterparts	   in	   Sub-­‐Saharan	   Africa	   (Shannon	   et	   al.,	  2012).	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Figure	   1.1.	   HIV-­‐1	   prevalence,	   incidence	   and	   AIDS	   deaths	   in	   Sub-­‐Saharan	   Africa	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how	  to	  eradicate	  HIV	  from	  those	  who	  are	  infected	  as	  well	  as	  protect	  those	  who	  are	  currently	  not	  HIV-­‐infected.	  	  
1.2.	  HIV	  genes	  and	  organisation	  HIV	  is	  a	  lentivirus	  belonging	  to	  the	  retroviridae	  family	  (reviewed	  by	  Sharp	  and	  Hahn,	  2011).	  A	  mature	  virion	  has	  a	  diameter	  of	  ~100nm,	  making	  it	  medium	  size	  relative	  to	  other	  viruses.	  Figure	  1.2	  illustrates	  the	  organization	  of	  the	  enveloped	  HIV	  particle.	  The	  virion	   is	   enveloped	  by	  a	   lipid	  bi-­‐layer	  derived	   from	   the	  host	  cell	  when	   the	   virion	  buds	  off	   from	   the	   infected	  host	   cell	   (Carlson	   et	   al.,	   2008;	  Garoff	  et	  al.,	  1998).	  The	  envelope	  contains	  glycosylated	  proteins	   (gp)	  120	  and	  41,	  cleaved	  from	  the	  gp160	  precursor	  by	  the	  host	  proteases	  (reviewed	  by	  Harris	  et	   al.,	   2011;	   Pollara	   et	   al.,	   2013).	  Within	   the	   envelope	   of	  HIV,	   the	   viral	   capsid	  composed	  of	  p24	  protein	  contains	   three	  major	  enzymes	  (a	  protease,	   integrase	  and	  reverse	  transcriptase)	  and	  two	  identical	  single-­‐stranded	  positive	  sense	  RNA	  strands	  bound	  to	  the	  nucleocapsid	  proteins	  (reviewed	  by	  Balasubramaniam	  and	  Freed,	  2012).	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Figure	   1.2.	   Structure	   of	   the	   HIV	   virion	   showing	   the	   two	   identical	  
encapsulated	   single-­‐stranded	   genomic	   RNA	   strands.	  The	   gp120,	   gp41	   and	  p17	   proteins	   are	   outside	   the	   envelope,	   while	   p24,	   integrase,	   protease	   and	  reverse	   transcriptase	   are	   encapsulated	   by	   the	   envelope	   (taken	   from	  php.med.unsw.edu.au/medwiki/index.php?title=Immunopathogenesis_of_HIV/AIDS).	  	  HIV	   has	   a	   9.2	   kb	   genome,	   which	   contains	   9	   genes	   including	   structural	   genes	  (Env,	   Gag	   and	   Pol),	   regulatory	   genes	   (Rev	   and	   Tat)	   and	   accessory	   genes	   (Vif,	  Vpu,	   Nef	   and	   Vpr)	   (Table	   1.1;	   Briggs	   et	   al.,	   2003;	   Frankel	   and	   Young,	   1998;	  Harrich	  and	  Hooker,	  2002;	  Kirchhoff,	  2010;	  Kogan	  and	  Rappaport,	  2011;	  Malim	  and	  Emerman,	  2008;	  Marin	  et	  al.,	  2003;	  Melar	  et	  al.,	  2007;	  Pollard	  and	  Malim,	  1998;	  Sierra	  et	  al.,	  2005;	  Suhasini	  and	  Reddy,	  2009). 
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Table	  1.1.	  Summary	  of	  HIV	  genes,	  proteins	  and	  their	  main	  functions 
	  
1.3.	  HIV	  life	  cycle	  HIV	  is	  transmitted	  through	  bodily	  fluids	  including	  semen,	  blood,	  breast	  milk	  and	  vaginal	   secretions	   (Keele	   and	   Estes,	   2011;	   Sarnquist	   et	   al.,	   2013;	   Sharp	   and	  Hahn,	   2011).	   The	   predominant	   routes	   of	   transmission	   include	   unprotected	  sexual	   intercourse,	   breastfeeding,	   needle	   sharing	   and	   transmission	   through	  direct	  contact	  with	  blood	  (Sarnquist	  et	  al.,	  2013).	  	  
!
Genes% Proteins% Function%%
%Proteins!encoded!by!the!structural!genes!(Frankel!and!Young,!1998;!Sierra!et!al.,!2005)!Env! gp41!! Mediates!virus!fusion!to!the!target!cell!by!achoring!envelope!glycoprotein!complex!to!host!surface!membrane.!! gp120! Forms!complexes!with!gp41!and!binds!to!CD4!and!chemokine!receptors!on!target!cells.!Gag! p24! Encapsidates!genomic!RNA!and!viral!enzymes.!! p17! Important!for!virion!maturation!and!stability.!!! P9!nucleocapsid! Ensures!packaging!of!the!single!stranded!genomic!RNA!into!virions.!Pol! p31!integrase! Mediates!integration!of!reverse!transcribed!DNA!into!the!host!cell!DNA.!! p6!prolineVrich!protein! Important!in!virion!assembly!and!release.!! P66/p51!reverse!transcriptase! Generates!complementary!DNA!from!the!virus!RNA!genome.!! p10!protease! Mediates!cleavage!of!Gag/Pol!polyproteins.!Proteins!encoded!by!the!regulatory!and!accessory! nes!(Harrich!and!Hooker,!2002;!Kirchhoff,!2010;!Malim!and!Emerman,!2008;!Marin!et!al.,!2003)!Rev! p19! Responsible!for!transcription!regulation!and!mRNA!nuclear!transport.!Tat! p14!transcriptional!activator! Regulates!reverse!transcription!of!the!virus!genome!and!the!release!of!virions!from!infected!cells.!Nef! p27! Down!regulates!cell!surface!expression!of!the!CD4!molecule.!Play!a!role!in!the!virus!infectivity!by!enhancing!viral!replication!!and!therefore!maintaining!high!viral!load.!Vif! p23! Protects!the!virus!from!APOBEC!inhibition.!Vpr! p14!viral!protein!R! Plays!a!role!in!the!virus!replication,!specifically!nuclear!import!of!the!preVintegration!complex.!Vpu! P16!viral!protein!U! Involved!in!CD4!degradation!and!efficient!release!of!viral!particles!from!the!infected!cells.!
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1.3.1.	  Infection	  of	  host	  cells,	  HIV	  binding	  and	  entry	  HIV	   infects	   new	   hosts	   by	   binding	   to	   specific	   host	   cell	   surface	   receptors.	   The	  primary	  HIV	  entry	  receptor	  is	  the	  CD4	  trans-­‐membrane	  protein	  found	  on	  T	  cells	  and	   cells	   of	   the	   macrophage	   lineage	   (König	   and	   Zhou,	   2004;	   Schubert	   et	   al.,	  1998).	  HIV’s	  envelope	  protein	  gp120	  contains	  five	  relatively	  conserved	  domains	  (C1-­‐C5)	  and	  five	  variable	  loops	  (V1-­‐V5)	  which	  interacts	  with	  CD4	  (reviewed	  by	  Wilen	   et	   al.,	   2012).	   Binding	   of	   the	   gp120	   to	   the	   host	   CD4	   receptor	   causes	  rearrangements	   of	   the	   variable	   loops	   V1,	   V2	   and	   V3	   regions,	   leading	   to	  formation	   of	   a	   bridging	   sheet	   (Kwong	   et	   al.,	   1998;	   Wilen	   et	   al.,	   2012).	   The	  bridging	  sheet	  is	  important	  in	  engaging	  the	  virus	  with	  the	  co-­‐receptors	  (Kwong	  et	  al.,	  1998).	  	  Host	   chemokine	   receptors	   CCR5	   (C-­‐C	   chemokine	   receptor	   type	   5)	   and	   CXCR4	  (C-­‐X-­‐C	  chemokine	  receptor	  type	  4)	  are	  the	  necessary	  secondary	  co-­‐receptors	  for	  HIV	  entry	  (Kwong	  et	  al.,	  1998;	  Llano	  and	  Est,	  2005;	  Sterjovski	  et	  al.,	  2011).	  CCR5	  is	  found	  on	  T	  cells	  and	  macrophages,	  while	  CXCR4	  is	  only	  found	  on	  CD4+	  T	  cells	  (Baba	  et	   al.,	   2000;	  Trkola	   et	   al.,	   1999).	  HIV-­‐1	   strains	   that	  utilise	   the	  CCR5	   co-­‐receptor	   are	  known	  as	  macrophage	   tropic	   (M-­‐tropic)	   viruses,	   and	   strains	   that	  utilise	  the	  CXCR4	  are	  known	  as	  T	  cell-­‐tropic	  (T-­‐tropic)	  viruses	  (Sharp	  and	  Hahn,	  2011).	   Some	  HIV	   strains	   can	   utilise	   both	   co-­‐receptors	   and	   are	   known	   as	   dual	  tropic	   viruses	   (Li	   et	   al.,	   2012;	   Xiang	   et	   al.,	   2014).	   It	   has	   been	   shown	   that	   the	  binding	  avidity	  and	  tropism	  of	  HIV	  to	  new	  target	  cells	  depends	  on	  the	  protein	  structure	  of	  the	  gp120	  (Harris	  et	  al.,	  2011;	  Kwong	  et	  al.,	  1998;	  Sterjovski	  et	  al.,	  2011).	  Once	  HIV	  gp120	  has	  interacted	  with	  CCR5	  or	  CXCR4	  co-­‐receptors,	  a	  gp41	  fusion	  complex,	  consisting	  of	  six-­‐helix	  bundle	  formation,	  is	  formed	  which	  result	  in	  viral	  fusion	  with	  the	  host	  cellular	  membrane	  leading	  to	  entry	  of	  the	  virus	  into	  the	  host	  cell	  (Figure	  1.3;	  reviewed	  by	  Wilen	  et	  al.,	  2012).	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Figure	  1.3.	  Entry	  of	  HIV	  into	  the	  host	  cell	  using	  viral	  envelope	  proteins.	  HIV	  gp120	  and	   gp41	   (1)	   bind	   to	   CD4	   (2)	   causing	   conformational	   changes	   in	   the	   envelope.	   This	  brings	  the	  virus	  in	  close	  proximity	  with	  the	  co-­‐receptors	  (CCR5	  or	  CXCR4),	  allowing	  co-­‐receptor	   binding	   and	   initiating	   formation	   of	   six-­‐helix	   bundle	   (4),	   which	   leads	   to	  membrane	  fusion	  (taken	  from	  Wilen	  et	  al.,	  2012).	  	  
1.3.2.	  HIV	  replication	  and	  integration	  within	  host	  cells	  Following	  HIV	  virus	  fusion	  with	  the	  new	  host	  cell,	  the	  viral	  core	  is	  released	  into	  the	   cytoplasm	   of	   the	   cell.	   HIV	   uncoating	   involves	   viral	   proteins	   Nef,	   Vif	   and	  other	  host	  cellular	  factors,	  leading	  to	  the	  release	  of	  virus	  RNA	  genome	  into	  the	  cytoplasm	  (Briggs	  et	  al.,	  2003;	  Balasubramaniam	  and	  Freed,	  2012;	  Sierra	  et	  al.,	  2005).	   HIV	   reverse	   transcriptase	   enzyme	   use	   viral	   positive	   strand	   RNA	   as	   a	  template	   for	  synthesis	  of	   the	  negative	  strand	  DNA	  (Frankel	  and	  Young,	  1998).	  Following	  formation	  of	   linear	  double	  stranded	  DNA,	  a	  pre-­‐integration	  complex	  is	   formed,	   consisting	   of	   host	   proteins,	   viral	   proteins	   and	   DNA,	   that	   is	  translocated	  to	  the	  nucleus	  (Friedrich	  et	  al.,	  2011).	  Viral	  DNA	  is	  transported	  into	  the	  nucleus	  and	  integrated	  into	  the	  host	  DNA	  by	  the	  integrase	  enzyme	  forming	  a	  provirus	  (Friedrich	  et	  al.,	  2011).	  The	  provirus	  is	  replicated	  along	  with	  the	  host	  chromosome	   when	   it	   divides	   (Mogensen	   et	   al.,	   2010).	   This	   produces	   viral	  proteins,	  which	  then	  move	  to	  the	  cell	  surface	  and	  form	  new	  virions	  which	  bud	  off	   from	  the	  host	  cell,	   ready	   to	   infect	  a	  new	  target	  cell	   (Briggs	  and	  Kräusslich,	  2011).	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1.3.3.	  Clinical	  course	  of	  HIV	  infection	  in	  humans	  During	   viral	   replication,	   HIV	   causes	   damage	   to	   the	   host	   immune	   system	   by	  lysing	   infected	   CD4+	   T	   cells,	   leading	   to	   destruction	   of	   lymphoid	   tissues	   and	  immune	   deficiency	   (Lane,	   2010;	   Weber,	   2001).	   The	   clinical	   course	   of	   HIV	  infection	  has	  broadly	  been	  divided	   into	   three	  phases:	   the	  acute	  phase,	  chronic	  phase	   (asymptomatic)	   and	   the	   symptomatic	   phase	   of	   infection	   (Lane,	   2010;	  Pantaleo	   et	   al.,	   1993).	   A	   more	   detailed	   Fiebig	   staging	   algorithm	   has	   been	  implemented	  for	  further	  definition	  within	  the	  acute	  (early)	  phases	  of	  infection,	  useful	   for	   initial	  diagnosis	  of	  HIV	   (Fiebig	  et	  al.,	  2003).	  Fiebig	  staging	  proposes	  that	  the	  acute	  phase	  of	  HIV	  infection	  is	  further	  divided	  into	  6	  phases	  based	  on	  the	  emergence	  of	  host	   immune	  markers	  (Figure	  1.4;	  reviewed	  by	  Cohen	  et	  al.,	  2010).	  These	  phases	  are	  defined	  as	  follows:	  
• The	  acute	   phase	  of	   HIV	   infection	   is	   characterised	   by	   rapid	   growth	   and	  spread	  of	  the	  virus	  within	  the	  host	  cell	  lymphoid	  tissues	  in	  the	  absence	  of	  host	  adaptive	  immunity,	  which	  leads	  to	  high	  titres	  of	  plasma	  viremia	  and	  substantial	  loss	  of	  CD4+	  T	  cells	  in	  the	  blood.	  At	  this	  stage,	  viral	  RNA	  can	  be	   detected	   in	   blood	   (corresponding	   to	   Fiebig	   stage	   I)	   (Figure	   1.4B).	  During	   this	   early	   stage	   of	   infection,	   HIV	   has	   infected	   lymphoid	   tissues	  and	  established	  viral	   reservoirs	   throughout	   the	  body.	  HIV	  p24	   (making	  up	   the	   viral	   capsid)	   can	   be	   detected	   in	   plasma	   at	   ~day	   7	   of	   infection	  although	   host	   immunity	   cannot	   yet	   be	   measured	   (corresponding	   to	  Fiebig	   stage	   II).	   After	   this,	   an	   expanded	   population	   of	   HIV-­‐1	   specific	  cytotoxic	   CD8+	   T	   cells	   (CTLs)	   and	   HIV-­‐specific	   binding	   antibodies	  develop	   and	   are	  measurable.	   Emergence	   of	   these	  HIV-­‐specific	   adaptive	  immune	   responses	   have	   been	   implicated	   in	   bringing	   viral	   replication	  under	  control,	  and	  lowering	  the	  viral	  load	  to	  a	  steady	  set	  point	  (Koup	  et	  al.,	  1994).	  At	  this	  stage,	  HIV	  gp120	  and	  gp41	  antibodies	  can	  be	  detected	  by	  ELISA	  (corresponding	   to	  Fiebig	  stage	   III).	  Fiebig	  stages	   IV	   (antibody	  positive	   by	   ELISA	   but	   negative	   by	   western	   blot),	   stages	   V	   (antibody	  positive	   by	   ELISA	   and	   positive	   by	   western	   blot)	   and	   stages	   VI	   (ELISA	  positive;	   western	   blot	   positive,	   p31	   antigen	   positive	   using	   ELISA	   or	  western	  blot)	  follows	  (Figure	  1.4B).	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• The	  asymptomatic	   or	   chronic	  phase	  of	  HIV	   infection	   is	   characterised	  by	  the	   establishment	   of	   viral	   “set	   point”,	   as	   a	   result	   of	   emerging	   host	  adaptive	   immune	   responses.	   Viral	   set	   point	   represents	   the	   sum	   of	  ongoing	  viral	  replication	  in	  the	  presence	  of	  this	  immunity	  and	  the	  ability	  of	   the	   host’s	   immunity	   to	   retard	   viral	   replication.	   The	   duration	   of	   this	  asymptomatic	  or	  chronic	  phase	  of	  infection	  varies	  from	  person	  to	  person	  and	   from	   country	   to	   country,	   with	   typical	   duration	   ranging	   from	   5-­‐15	  years	  (Mlisana	  et	  al.,	  2014).	  Although	  binding	  antibodies	  emerge	  earlier,	  neutralizing	  antibodies	  against	  HIV	  appear	  at	  ~3-­‐12	  weeks	  and	  broadly	  cross-­‐neutralizing	  antibodies	  typically	  emerge	  at	  ~3	  years	  post-­‐infection	  (Moore	   et	   al.,	   2008,	   2012).	   Despite	   host	   adaptive	   immune	   responses	  against	  HIV,	  a	  steady	  yet	  slow	  decrease	  in	  CD4+	  T	  cell	  numbers	  continues	  during	  chronic	  infection,	  ultimately	  resulting	  in	  exhaustion	  of	  both	  CD4+	  and	   CD8+	   T	   cells	   (Catalfamo	   et	   al.,	   2011;	   Leng	   et	   al.,	   2001;	   Ray	   et	   al.,	  2006).	   Although	   the	   typical	   duration	   of	   this	   asymptomatic	   phase	   of	  infection	  is	  <10	  years,	  some	  HIV-­‐infected	  individuals	  may	  have	  no	  AIDS-­‐defining	  symptoms	  for	  longer	  than	  10	  years	  in	  the	  absence	  of	  treatment	  (Deeks	  and	  Phillips,	  2009;	  Egger	  et	  al.,	  2002).	  
• The	   symptomatic	   phase	   (AIDS)	   is	   characterised	   by	   a	   rapid	   decrease	   of	  CD4+	  T	  cells,	  corresponding	  to	  a	  decline	  in	  HIV-­‐specific	  T	  cell	  responses	  and	  rapidly	   increasing	  viremia.	   In	   the	  absence	  of	  HAART,	  opportunistic	  infections	  usually	  appear	  leading	  to	  AIDS	  and	  death	  due	  to	  the	  collapse	  of	  host	   immunity	   (reviewed	   by	  An	   and	  Winkler,	   2010).	   In	   the	   absence	   of	  treatment,	   AIDS	   typically	   occur	   at	   CD4+	   T	   cell	   counts	   <200	   cells/ml	  blood.	  Since	  the	  introduction	  of	  anti-­‐retroviral	  therapy	  and	  then	  HAART,	  few	   HIV-­‐infected	   individuals	   still	   progress	   to	   this	   stage	   of	   infection.	  Although	  61%	  of	  individuals	  who	  need	  HAART	  are	  currently	  receiving	  it	  (UNAIDS,	  2013),	  and	  HAART	  rollout	   is	   increasing	  annually,	  most	  recent	  statistics	   report	   that	   1.6	  million	  people	  died	  of	  AIDS	   in	  2012	   (UNAIDS,	  2013).	  In	  South	  Africa,	  200	  000	  HIV-­‐infected	  individuals	  died	  of	  AIDS	  in	  2010	  (UNAIDS,	  2011).	  South	  African	  National	  Guidelines	  are	  currently	  to	  start	   treatment	   at	   350	   cells/ml	   but	   are	   scheduled	   to	   increase	   to	   500	  
	   10	  
cells/ml	  in	  2015	  (The	  South	  African	  Antiretroviral	  Treatment	  Guidelines,	  2013).	  	  
	  
Figure	  1.4.	  Typical	  clinical	  courses	  of	  HIV	  infection	  in	  humans	  and	  emergence	  of	  
host	  adaptive	  immune	  responses.	  (A)	  Clinical	  course	  has	  broadly	  been	  divided	  into	  3	  phases:	  acute,	  asymptomatic	  and	  symptomatic	  phases.	  CD4+	  T	  cell	  number	  (black	  line)	  drastically	   decreases	   during	   acute	   phase,	   rebound	   during	   the	   asymptomatic	   phase	  when	  host	  immunity	  emerges,	  achieving	  a	  relatively	  steady	  state.	  Viral	  loads	  (red	  line)	  increases	  during	  acute	  phase	   in	   the	  absence	  of	  host	   immunity,	  and	  decreases	  sharply	  when	   HIV-­‐specific	   CTLs	   (blue	   line)	   and	   antibody	   responses	   emerge	   (green	   and	  turquoise	   lines	  respectively).	  (B)	  Acute	  phase	  has	   further	  been	  divided	  into	  six	  Fiebig	  stages	  (I-­‐VI)	  based	  on	  the	  detection	  of	  HIV-­‐1	  RNA,	  viral	  antigens	  and	  emergence	  of	  host	  immunity	  (adapted	  from	  McMichael	  et	  al.,	  2010).	  
	   	  
A.#
B.#
	   11	  
1.4.	  Immune	  responses	  to	  HIV	  Both	   innate	   and	   adaptive	   host	   immune	   responses	   have	   been	   implicated	   in	  protection	   following	   HIV	   infection	   (Ackerman	   et	   al.,	   2012;	   Bergmeier	   and	  Lehner,	   2006;	   Kasturi	   et	   al.,	   2011).	   Innate	   immunity	   (including,	   neutrophils,	  natural	  killer	  (NK)	  cells,	  dendritic	  cells,	  macrophages	  and	  monocytes)	  provides	  the	  earliest	  and	   first	   line	  of	  defense	  against	  HIV	   infection	   (Altfeld	  et	  al.,	  2011;	  Kasturi	   et	   al.,	   2011;	   Sharp	   and	  Hahn,	   2011;	   Vivier	   et	   al.,	   2011).	   By	   definition,	  these	   innate	   responses	   were	   not	   thought	   to	   be	   HIV-­‐specific	   although	   some	  recent	   studies	   have	   described	   HIV-­‐specific	   responses	   directed	   by	   NK	   cells	  (Chung	  et	  al.,	  2012;	  Jost	  and	  Altfeld,	  2012;	  Parsons	  et	  al.,	  2012;	  Tiemessen	  et	  al.,	  2009).	  	  	  HIV-­‐specific	  adaptive	  immune	  responses	  are	  characterised	  by	  the	  emergence	  of	  specific	  cellular	  immunity	  (involving	  both	  CD8+	  CTLs	  and	  CD4+	  helper	  T	  cells)	  and	  humoral	  immunity	  (B	  cells	  producing	  antibodies)	  (Alter	  and	  Moody,	  2010;	  McMichael	  et	  al.,	  2010;	  Overbaugh	  and	  Morris,	  2012;	  Vivier	  et	  al.,	  2011).	  HIV-­‐specific	  antibodies	  neutralise	  or	  they	  mediate	  other	  effector	  functions	  including	  those	  that	  mediate	  antibody	  dependent	  cellular	  cytotoxicity	  (ADCC),	  those	  that	  mediate	  antibody	  dependent	  complement	  dependent	  cytotoxicity	  (ADCDC),	  and	  those	  that	  mediate	  antibody	  dependent	  cellular	  phagocytosis	  (ADCP)	  (reviewed	  by	  Ackerman	  et	  al.,	  2012).	  This	  dissertation	  will	  be	   focusing	  on	  the	  role	  of	  NK	  cells	   and	   HIV-­‐specific	   antibodies	   in	   mediating	   ADCC	   in	   the	   control	   of	   HIV	  infection.	  	  
1.5.	  HIV-­‐specific	  antibodies	  B	  cell	   responses	   to	  HIV-­‐infection	  can	  be	  detected	  as	  early	  as	  1	  week	  after	  HIV	  RNA	   is	   detectable	   in	   plasma	   (Tomaras	   et	   al.,	   2008).	   Detection	   of	   these	   HIV-­‐specific	  B	   cells	   is	   followed	  by	   emergence	  of	   circulating	   anti-­‐gp41	  antibodies	   a	  few	   days	   later	   (corresponding	   to	   Fiebig	   stage	   I;	   Figure	   1.4B),	   and	   anti-­‐gp120	  antibodies	  delayed	  a	  further	  few	  weeks	  (corresponding	  to	  Fiebig	  stage	  II;	  Figure	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1.4B).	  Although	  HIV-­‐specific	  antibodies	  that	  can	  neutralise	  HIV	  are	  an	  important	  and	  major	  focus	  of	  research,	  other	  classes	  and	  functions	  of	  antibodies	  exist	  that	  may	  play	  an	  important	  role	  in	  determining	  susceptibility	  and	  clinical	  course	  of	  HIV	  infection	  (reviewed	  by	  Overbaugh	  and	  Morris,	  2012).	  	  	  
1.5.1.	  Evolution	  of	  HIV-­‐specific	  antibody	  responses	  An	  antibody	  is	  made	  up	  of	  a	  single	  constant	  domain	  (Fc),	  which	  interacts	  with	  cells	   of	   the	   innate	   immune	   system,	   and	   two	   identical	   variable	   domains	   from	  both	   light	  and	  heavy	  chains	  (Fab)	   that	  recognise	  antigens	  bound	  on	  the	  target	  cells	   (reviewed	   by	   Woof	   and	   Burton,	   2004;	   Figure	   1.5).	   Antibodies	   or	  immunoglobulins	   (Ig)	   can	   be	   divided	   into	   five	   major	   classes	   (isotypes)	  distinguished	  by	  their	  Fc	  regions:	  IgM,	  IgD,	  IgG,	  IgA	  and	  IgE.	  In	  humans,	  IgG	  has	  been	  further	  divided	  into	  four	  subclasses:	  IgG1,	  IgG2,	  IgG3	  and	  IgG4	  (reviewed	  by	  Pan	  and	  Hammarström,	  2000).	  	  	  
	  
Figure	  1.5.	  Basic	  structure	  of	  antibody	  domains	  with	  two	  identical	  heavy	  chains	  
and	   two	   identical	   light	   chains.	   The	   antibody	   forms	   a	   Y	   shape	   linked	   together	   by	  disulfide	  bonds.	  The	  Fc	   region	   consists	   of	   carbohydrate	   glycans	   and	   two	  heavy	   chain	  constant	   (C)	   domains,	   and	   it	   mediates	   effector	   functions.	   The	   Fab	   region	   recognises	  antigens	   through	   its	   light	   and	  heavy	   chain	   variable	  domains	   (VH	   and	  VL)	   (taken	   from	  Chung	  and	  Alter,	  2014).	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During	   HIV	   infection,	   the	   first	   type	   of	   HIV-­‐specific	   antibodies	   produced	   are	  gp41-­‐specific	  IgM	  antibodies	  (Tomaras	  et	  al.,	  2008).	  At	  about	  two	  weeks,	  class	  switching	  occurs	  and	  HIV-­‐specific	  IgM	  antibodies	  are	  replaced	  by	  IgA,	  IgG	  or	  IgE	  antibodies	   (Calame,	   2001;	   Liao	   et	   al.,	   2011).	  Antibody	   class	   switching	   enables	  diversification	  of	  antibody	  effector	  functions	  by	  substituting	  the	  C	  region	  of	  IgM	  with	   that	  of	   IgG,	   IgA	  or	   IgE.	  Class	  switching	  happens	   in	   the	  germinal	  center	  of	  the	   lymph	   nodes,	   a	   specialised	   follicular	   compartment	   (He	   et	   al.,	   2006).	   After	  the	   initial	   IgM	  response	   following	  HIV	   infection,	   the	  predominant	  HIV-­‐specific	  antibody	  subtype	  circulating	  are	  IgG1	  (Doria-­‐rose	  and	  Connors,	  2010).	  	  
1.5.2.	  HIV-­‐specific	  antibodies	  that	  neutralise	  Neutralising	  antibodies	  (nAbs)	  against	  HIV	  play	  an	  important	  role	  in	  preventing	  infection	  (Alter	  and	  Moody,	  2010;	  Li	  et	  al.,	  2012;	  Srisurapanon	  et	  al.,	  2005).	  HIV	  envelope	  proteins	  mediate	  entry	  into	  the	  cells	  and	  are	  the	  main	  target	  for	  nAbs	  (Li	  et	  al.,	  2012;	  Moog	  et	  al.,	  1997;	  Pilgrim	  et	  al.,	  1996).	  HIV-­‐specific	  nAbs	  against	  the	   HIV	   variant	   to	  which	   they	  were	   raised	   (autologous	   nAbs)	   develop	  within	  weeks	  to	  months	  after	  infection	  (Mascola	  and	  Haynes,	  2013).	  These	  autologous	  nAbs	   are	   usually	   restricted	   to	   the	   V1V2	   region	   of	   the	   gp120	   protein	   of	   the	  autologous	  virus,	  are	  usually	  potent,	  HIV	  type-­‐specific	  to	  the	  infecting	  strain	  but	  not	  able	  to	  neutralise	  other	  viruses	  isolated	  from	  other	  individuals	  (Figure	  1.6;	  Mascola	   and	   Haynes,	   2013;	   Mikell	   et	   al.,	   2011).	   Autologous	   nAbs	   have	   been	  reported	  to	  drive	  HIV	  to	  escape	  neutralization	  leading	  to	  escaped	  viruses	  being	  less	  sensitive	  to	  early	  autologous	  nAbs	  overtime	  (Chung	  et	  al.,	  2011;	  Deeks	  et	  al.,	  2006).	  Mutations	  in	  N-­‐linked	  glycosylation	  sites	  on	  gp120	  (leading	  to	  changes	  in	  the	  glycan	  shield	  protecting	  HIV	  gp120),	  single	  amino	  acid	  substitutions	  within	  gp120,	  and	  insertions	  or	  deletions	  in	  gp120	  V1-­‐V4	  regions	  were	  found	  to	  be	  the	  predominant	  mechanisms	   by	  which	   HIV	   escapes	   from	   these	   autologous	   nAbs	  (Gray	  et	  al.,	  2009;	  Overbaugh	  and	  Morris,	  2012;	  Srisurapanon	  et	  al.,	  2005;	  Wei	  et	  al.,	  2003).	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While	  autologous	  nAbs	  develop	  early	  during	  HIV	   infection,	  nAbs	  that	  have	  the	  ability	  to	  broadly	  recognise	  and	  neutralise	  heterologous	  HIV-­‐1	  variants	  take	  2-­‐3	  years	   to	   develop	   (Overbaugh	   and	   Morris,	   2012).	   Only	   about	   30%	   of	   HIV-­‐infected	   individuals	   develop	   these	   broadly	   nAbs	   and	   these	   individuals	   have	  been	  important	  for	  identifying	  new	  nAbs	  and	  HIV	  epitopes	  they	  target	  (Archary	  et	   al.,	   2013;	  Moore	  et	   al.,	   2012).	   Identification	  of	  HIV-­‐specific	  nAbs	   capable	  of	  broadly	  neutralising	  HIV,	  are	  relevant	  in	  the	  development	  of	  HIV	  vaccines	  that	  can	   neutralise	   (Montefiori	   et	   al.,	   2011).	   NAbs	   are	   classified	   according	   to	   the	  epitopes	   that	   they	   recognise:	   those	   that	   recognise	   the	   CD4	   binding	   site,	   the	  V1/V2	   regions	   of	   gp120,	   the	   membrane-­‐proximal	   external	   region	   (MPER)	   of	  gp41,	   and	   the	   glycan	   V3	   region	   (reviewed	   by	   Kwong	   et	   al.,	   2013).	   NAbs	   that	  recognise	  the	  CD4	  binding	  site	  target	  the	  site	  were	  the	  host	  CD4	  receptor	  binds	  to	  the	  gp120	  envelope	  (Muster	  et	  al.,	  1993;	  Sterjovski	  et	  al.,	  2011;	  Zhang	  et	  al.,	  2012).	  NAbs	  that	  recognise	  the	  V1/V2	  target	  glycopeptides	  epitopes	  on	  the	  V1	  and	  V2	  regions	  (Sanders	  et	  al.,	  2002;	  Sterjovski	  et	  al.,	  2011;	  Wyatt	  et	  al.,	  1995).	  Nabs	   that	   recognise	   MPER	   target	   a	   site	   in	   gp41,	   proximal	   to	   the	  transmembrane-­‐spanning	   region	   (Stiegler	   et	   al.,	   2001).	   NAbs	   recognizing	   V3	  glycans	  are	  directed	  against	  epitopes	  that	  generally	  include	  residue	  Asn332	  on	  gp120	  (Su	  and	  Moog,	  2014;	  Figure	  1.6).	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1.5.3.	  Binding	  or	  non-­‐neutralising	  HIV-­‐specific	  antibodies	  HIV	  elicits	  a	  number	  of	  antibodies	  that	  bind,	  but	  do	  not	  neutralise	  HIV	  infection	  of	  new	  host	   cells	  directly	   (Brocca-­‐Cofano	  et	   al.,	   2011).	  These	  non-­‐neutralising	  HIV-­‐specific	   antibodies	   appear	  ~2	  weeks	   after	  HIV	   infection,	   around	   the	   time	  that	  HIV-­‐specific	  CTL’s	  develop	  (Figure	  1.4A).	  These	  antibodies	   form	  the	  basis	  for	  HIV	  diagnosis,	  which	  is	  based	  on	  seropositivity	  and	  can	  be	  measured	  using	  ELISA	   (HIV	   rapid	   test).	   Binding	   antibodies	   are	   thought	   to	   protect	   against	  HIV	  infection	  by	  several	  non-­‐neutralising	  mechanisms,	  including	  ADCP,	  ADCDC	  and	  ADCC.	  Each	  of	  these	  will	  be	  discussed	  in	  detail	  in	  the	  following	  sections.	  	  
1.5.3.1.	  HIV-­‐specific	  antibodies	  that	  mediate	  ADCP	  Binding	  antibodies	  have	  also	  been	  shown	  to	  enhance	  phagocytosis	  of	  antibody-­‐coated	  HIV	   particles	   by	  ADCP	   (Figure	   1.7).	   Professional	   phagocytes,	   including	  monocytes,	   macrophages	   and	   neutrophils,	   bear	   the	   Fc	   receptor.	   These	  phagocytes	  can	  directly	  phagocytose	  antibody-­‐coated	  HIV	  particles	  by	  binding	  to	   the	   antibody-­‐coated	   viral	   particle	   through	   the	   antibody	   Fc	   portion	   (Fc-­‐receptor	   mediated	   phagocytosis);	   or	   by	   engulfing	   whole	   HIV-­‐infected	   target	  cells	  which	   have	   antibodies	   coating	   their	   cell	   surface	   at	   the	   point	  where	   new	  virions	   are	   budding	   off	   (reviewed	   by	   Ackerman	   et	   al.,	   2012).	   This	   antibody-­‐mediated	  effector	  function	  is	  thought	  to	  play	  an	  important	  role	  in	  the	  rapid	  and	  early	   clearance	   of	   antibody-­‐opsonised	   viral	   particles	   during	   HIV	   infection	  (Ackerman	  et	  al.,	  2013).	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Figure	   1.7.	   Fc	   receptor-­‐mediated	   mechanism	   by	   which	   HIV-­‐specific	   antibodies	  
result	   in	   infected	   host	   cells	   being	   phagocytosed	   by	   professional	   antigen	  
presenting	  cells.	  A	  monocyte	  effector	  cell	  (purple)	  would	  interact	  with	  the	  Fc	  portion	  on	  antibodies	  (coating	  an	  HIV-­‐infected	  target	  cell	  in	  blue)	  via	  the	  FcgR2B	  receptors	  (in	  red).	  Other	  receptors	  (in	  green)	  may	  also	  be	  involved	  in	  ADCP	  (taken	  from	  Ackerman	  et	  al.,	  2012).	  	  
1.5.3.2.	  HIV-­‐specific	  antibodies	  that	  mediate	  ADCDC	  ADCDC	   is	   another	   effector	   function	   whereby	   antibodies	   recruit	   complement	  proteins	  through	  the	  classical	  or	  non-­‐classical	  complement	  cascade	  (Figure	  1.8;	  Stoermer	  and	  Morrison,	  2011).	  The	  complement	  cascade	  initiates	  the	  formation	  of	   the	  membrane	  attack	  complex	  consisting	  of	   complement	  proteins	  C1q,	  C3b,	  C4b,	   mannose	   binding	   lectin	   (MBL)	   and	   IgG	   Fc	   binding	   proteins	   (FcγBP)	  (Ackerman	  et	  al.,	  2012;	  Stoermer	  and	  Morrison,	  2011).	  This	  membrane	  attack	  complex	  forms	  pores	  in	  the	  target	  cell	  membrane	  allowing	  entrance	  of	  ions	  and	  other	  small	  molecules	  leading	  to	  osmotic	  cell	  lysis	  of	  the	  host	  cell	  and	  ultimately	  causing	  death	  (Ackerman	  et	  al.,	  2013).	  ADCDC	  is	  thought	  to	  be	   involved	  in	  the	  control	   of	   HIV	   replication	   during	   early	   infection	   (Ackerman	   et	   al.,	   2012;	  Stoermer	  and	  Morrison,	  2011).	  Furthermore,	  IgG	  antibodies	  have	  been	  reported	  to	  eliminate	  heterologous	  virus	  in	  primary	  HIV	  infection	  through	  ADCDC	  (Aasa-­‐chapman	  et	  al.,	  2005).	  	   	  
Antibody)dependent,cellular,phagocytosis,(ADCP)" Binding" antibodies" mediate"ADCP" through" monocytes,"macrophages," neutrophils"and"mast"cells,"which"act"as"professional" phagocytes"releasing" cytokines" or"oxidants" or" by" engul?ing"them" and" traf?icking" to"phagolysosomes."
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Figure	  1.8.	  Possible	  mechanism	  by	  which	  binding	  antibodies	  recruit	  complement	  
proteins	  C1q,	  C3b,	  C4b	  and	  MBL	  during	  ADCDC.	  These	  complement	  proteins	  mediate	  cytotoxicity	  by	  forming	  a	  complement	  cascade.	  HIV-­‐infected	  host	  cells	  (in	  blue)	  which	  are	  coated	  with	  HIV-­‐specific	  antibodies,	  become	  targets	  for	  these	  cytotoxic	  complexes	  (taken	  from	  Ackerman	  et	  al.,	  2012).	  	  
1.5.3.3.	  HIV-­‐specific	  antibodies	  that	  mediate	  ADCC	  ADCC	   involves	   components	   of	   both	   the	   innate	   immune	   system	   (including	   NK	  cells,	   macrophages,	   monocytes	   and	   eosonophils)	   and	   the	   acquired	   immune	  system	  (antibodies)	  (Lanier	  et	  al.	  1986;	  Jewett	  et	  al.,	  1990;	  Lopez	  et	  al.,	  1985).	  During	   ADCC,	   IgG	   antibodies	   recognise	   and	   bind	   to	   the	   HIV	   antigen	   on	   the	  surface	  of	  target	  cells	  (Chung	  et	  al.,	  2008).	  Bound	  antibody	  is	  then	  recognised	  by	  effector	  cells	  through	  the	  Fc	  region	  on	  IgGs.	  Effector	  cells	  bind	  to	  this	  Fc	  region	  using	   FcγRIIIa	   (CD16)	   receptors	   on	   their	   cell	   surface.	   The	   FcγR-­‐mediated	  binding	   between	   antibody	   coated	   HIV-­‐infected	   target	   cells	   to	   effector	   cells	  during	   ADCC	   triggers	   the	   release	   of	   cytokines,	   granzymes	   and	   perforin	   by	  effectors	  cells	  that	  enter	  the	  target	  cell	  and	  causes	  apoptosis	  (Figure	  1.9;	  Chung	  and	  Alter,	  2014;	  Cox	  et	  al.,	  1999).	  	   	  
Antibody)dependent,complement)dependent,cytotoxicity,(ADCDC),Binding& antibodies& can& initiate&the& complement& cascade& either&classical& or& non3classical& routes,&resulting& in& the& formation& of&pores& by& the& membrane& attack&complex,& as& well& as& contributing&to&increased&uptake&and&toxicities&mediated&by&other&innate&cells.&
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Figure	   1.9.	   Mechanism	   by	   which	   HIV-­‐specific	   antibodies	   bind	   to	   HIV-­‐infected	  
target	  cell,	  thereby	  recruiting	  NK	  cells,	  interacting	  with	  their	  FcγRIIIa	  (CD16)	  and	  
mediating	  ADCC.	  NK	  cell	  endosomes	  (membrane	  lined	  with	  CD107a)	  contain	  cytolytic	  granules	  (granzymes	  and	  perforin),	  which	  are	  released	  into	  the	  target	  cell.	  
	  
1.6.	  Natural	  killer	  cells	  NK	  cells	  are	   important	   components	  of	   the	   innate	   immune	  response	   to	   tumors	  and	   virally-­‐infected	   cells	   (Caligiuri,	   2008).	   NK	   cells	   can	   be	   identified	   by	   their	  expression	  of	  FcγRIIIa	  (CD16),	  CD56+	  and	  lack	  of	  expression	  of	  CD3	  (Lanier	  et	  al.,	   1986;	   Vivier	   et	   al.,	   2011).	   NK	   cells	   are	   the	   major	   effector	   cells	   for	   ADCC	  during	   HIV	   infection,	   mediated	   primarily	   through	   their	   FcγRIIIa	   (CD16)	  receptors	  that	  bind	  to	  the	  Fc	  component	  of	  IgG	  (Cooper	  et	  al.,	  2001;	  Tyler	  et	  al.,	  1989).	   Using	   these	   markers,	   distinct	   subpopulations	   of	   NK	   cells	   have	   been	  described:	  CD56Bright	  CD16-­‐	  NK	  cells	  that	  predominantly	  secrete	  cytokines	  (Poli	  et	  al.,	  2009),	  CD56Dim	  CD16+	  NK	  cells	  that	  are	  predominantly	  cytotoxic	  (Funke	  et	  al.,	   2011),	   and	  CD16+	  CD56-­‐	  NK	  cells	   that	  predominantly	   release	   chemokines,	  and	   are	  much	  more	   rare	   than	   the	  other	   two	   subsets	   (Björkström	  et	   al.,	   2010;	  Bluman	  et	  al.,	  1996;	  Walzer	  et	  al.,	  2005).	  CD56Dim	  CD16-­‐	  NK	  cells	  do	  express	  the	  CD56	   receptor	   but	   to	   a	   lesser	   extent	   than	   CD56Bright	   CD16+	   NK	   cells,	   while	  
A.#Antibody#bound#to#antigen###################B.#ADCC#
Fc#region#of#the#antibody#differ#




the# antigen# on# the# surface# of#
the#target#cell#
Effector(cell(bound(to( the(Fc(
region( of( the( antibody(
through( its( FcγR( receptor.(










the# antigen# on# the# surface# of#
the#target#cell#
Effector(cell(bound(to( the(Fc(
region( of( the( antibody(
through( its( FcγR( receptor.(














	   20	  
CD16+	  CD56-­‐	  NK	  cells	  do	  not	  express	  CD56.	  	  
Figure	   1.10.	   Distinct	   NK	   cell	   subsets	   (CD56Bright,	   CD56Dim	   and	   CD16+	   CD56-­‐)	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development,	  retention,	  relocation,	  localization	  and	  effector	  functions	  (Caligiuri,	  2008;	  Cooper	  et	  al.,	  2001).	  	  
	  
Figure	  1.11.	  Overview	  of	  NK	  cell	  surface	  receptors.	  NK	  cell	  receptors	  can	  be	  broadly	  grouped	   into	   inhibitory	   receptors	   (red),	   activating	   receptors	   (green),	   those	   that	  mediate	   adhesion	  with	   other	   host	   cells	   (blue),	   bind	   to	   cytokines	   (black),	   or	  mediate	  chemotaxis	  (purple)	  (adapted	  from	  Vivier	  et	  al.,	  2004).	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1.6.1.1.	  FAS-­‐L/FAS	  pathway	  of	  NK	  killing	  FAS	   transmembrane	   protein	   is	   a	  member	   of	   the	   tumor	   necrosis	   factor	   (TNF)	  receptor	   superfamily	   and	   is	   broadly	   distributed	   in	   tissue.	   Tumor	   cells	   do	   not	  normally	   express	   FAS,	   but	   can	  be	   induced	   to	  do	   so	   via	   IFN-­‐γ	   secretion	  by	  NK	  cells	   (Screpanti	   et	   al.,	   2001).	   Expression	   of	   FAS-­‐L	   is	   restricted	   to	   a	   highly	  selective	   cellular	   pool	   including	   activated	   T	   cells,	   NK	   T	   cells	   and	   NK	   cells	  (Kaufmann	   et	   al.,	   2012).	   Crosslinking	   of	   FcγRIIIa	   on	   NK	   cells	   can	   induce	  transcriptional	  upregulation	  of	  FAS	  ligands,	  enabling	  NK	  cells	  to	  bind	  to	  target	  cells	   expressing	  FAS	   receptors	   (Figure	  1.12;	  Rauf	   et	   al.,	   2012).	  The	  binding	  of	  FAS-­‐L	   to	   the	   FAS	   receptor	   recruits	   the	   FAS-­‐associated	   death	   domain	   (FADD),	  which	   then	   activates	   caspase-­‐8.	   Caspase-­‐8	   activates	   downstream	   effector	  caspases	  (caspase-­‐3,	  -­‐6,	  -­‐7)	  leading	  to	  target	  cell	  apoptosis	  (Figure	  1.12;	  Elmore,	  2007;	  Rauf	  et	  al.,	  2012).	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Figure	  1.12.	  FAS-­‐L/FAS	  pathway	  of	  killing	  by	  NK	  cells.	  The	  binding	  of	  FAS-­‐L	  (green)	  to	   the	   FAS	   receptor	   (red)	   on	   the	   target	   cells	   recruits	   FADD	   (purple),	   which	   then	  activates	   caspase	   activity	   (including	   caspases	   8,	   3,	   6	   and	   7)	   leading	   to	   target	   cell	  apoptosis	  (adapted	  from	  Cheema	  et	  al.,	  2004).	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constituent	  of	  NK	  cell	  granules	  (Hoves	  et	  al.,	  2010;	  Trapani	  and	  Sutton,	  2003),	  and	   it	   promotes	   apoptosis	   through	   proteolysis	   at	   aspartate	   residues	   that	  activate	  caspase	  activity	  (Figure	  1.13	  point	  1),	   including	  downstream	  caspases	  (caspase-­‐3,	  -­‐6	  and	  -­‐7),	  and	  upstream	  caspases	  (caspase-­‐2,	  -­‐8,	  -­‐9	  and	  -­‐10)	  (Figure	  1.13;	  Anthony	  et	  al.,	  2010).	  Processing	  of	  caspase-­‐3	  and	  caspase-­‐7	  by	  granzyme	  B	   promotes	   caspase-­‐mediated	   degradation	   of	   hundreds	   of	   protein	   substrates	  and	   ultimately	   leads	   to	   cell	   death	   (Afonina	   et	   al.,	   2010;	   Trapani	   and	   Sutton,	  2003).	   Granzyme	   B	   can	   also	   activate	   apoptosis	   by	   cleaving	   Bid	   (Figure	   1.13	  point	   2),	   a	   pro-­‐apoptotic	   protein	   into	   its	   truncated	   form	   (tBid)	   (Figure	   1.13	  point	  3),	  which	  activates	  two	  pro-­‐apoptotic	  proteins	  (Bak	  and	  Bax)	  (Figure	  1.13	  point	   4)	   in	   the	   outer	  mitochondrial	  membrane	   (Afonina	   et	   al.,	   2010;	   Trapani	  and	   Sutton,	   2003).	  These	  proteins	   induce	   the	   release	  of	   cytochrome	   c	   (Figure	  1.13	  point	  5),	  which	  binds	  to	  cytoplasmic	  protein	  APAF-­‐1	  (Figure	  1.13	  point	  6),	  recruiting	  caspase-­‐9	  (Figure	  1.13	  point	  7;	  Sharif-­‐Askari	  et	  al.,	  2001;	  Smyth	  et	  al.,	  2005).	   Activated	   caspase-­‐9	   can	   activate	   other	   effector	   caspases	   (Figure	   1.13	  point	   1)	   (such	   as	   caspase	   3	   and	   7)	   that	   promote	   rapid	   cell	   death	   through	  proteolysis	   of	   their	   diverse	   repertoire	   of	   substrates.	   Within	   NK	   cells,	   the	  endosomal	  membrane	  of	  these	  cytolytic	  granules	  contains	  lysosome-­‐associated	  membrane	  protein	  (LAMP	  or	  CD107a),	  which	  is	  exposed	  onto	  the	  surface	  of	  NK	  cells	   when	   granzyme	   B	   and	   other	   granules	   are	   released.	   NK	   cell	   surface	  expression	   of	   CD107a	   has	   been	   used	   as	   a	   marker	   for	   NK	   cell	   degranulation	  (Alter	   et	   al.,	   2004;	   Krzewski	   et	   al.,	   2013).	   Silencing	   LAMP	   has	   been	   shown	   to	  inhibit	  granzyme	  B	  delivery	  but	  not	  perforin	  delivery	  to	  target	  cells	  (Krzewski	  et	  al.,	  2013).	  	  In	  addition	   to	  activation	  of	  caspase	  activity,	  granzyme	  B	  had	  been	  reported	   to	  initiate	  target	  cell	  death	  via	  other	  mechanisms	  (Afonina	  et	  al.,	  2010;	  Rauf	  et	  al.,	  2012;	  Trapani	  and	  Sutton,	  2003).	  Granzyme	  B	  can	  promote	  DNA	  fragmentation	  in	   cells	   lacking	   functional	   caspases,	   which	   activates	   nucleases,	   which	   then	  mediates	   the	   internucleosomal	   degradation	   of	   DNA,	   one	   of	   the	   hallmarks	   of	  apoptosis	   induced	   by	   NK	   cells	   (Liu	   et	   al.,	   1998;	   Sharif-­‐Askari	   et	   al.,	   2001;	  Thomas	  et	  al.,	  2000).	  Furthermore,	  granzyme	  B	  may	  directly	  target	  mediators	  of	  viral	   replication	  and	   inhibit	  viral	   spread	  without	  causing	  apoptosis	  of	   infected	  cells	  (Kinchington	  and	  Hendricks,	  2008).	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Figure	   1.13.	   NK	   cells	   mediating	   ADCC	   by	   binding	   to	   HIV-­‐infected	   cells	   and	  
releasing	  preformed	  granules	  containing	  granzyme	  B	  and	  perforin,	  leading	  to	  the	  
activation	  of	  caspase	  activity.	  Secretory	  lysosomes	  are	  formed	  within	  the	  NK	  cell	  and	  travel	  to	  the	  cell	  membrane	  when	  cells	  are	  activated.	  The	  proteins	  are	  released	  at	  the	  synapse	  formed	  between	  the	  NK	  cell	  and	  target	  cell.	  Granzyme	  B	  enters	  the	  target	  cells	  by	   a	   perforin-­‐dependent	  manner	   and	   activates	   caspase	   activity	   (1).	   Granzyme	   B	   can	  also	   activate	   bid	   (2),	   which	   is	   truncated	   to	   tbid	   (3)	   to	   induce	   oligomerization	   of	  bax/bak.	  This	   facilitates	   cytochrome	  c	   release	   (5),	  which	  mediates	   the	   formation	  of	   a	  caspase-­‐activating	   complex	   between	   Apaf-­‐1	   and	   caspase-­‐9.	   Activated	   caspase-­‐9	  activates	   downstream	   effector	   caspase	   activity,	   which	   promote	   apoptosis	   (adapted	  from	  Afonina	  et	  al.,	  2010).	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1.6.2.1.	  NK	  cell	  education	  and	  cumulative	  signals	  Effector	  functions	  of	  NK	  cells	  develop	  in	  two	  stages	  (Figure	  1.14).	  The	  first	  stage	  during	  which	  an	  NK	  cell	  is	  educated,	  is	  initiated	  during	  early	  NK	  cell	  ontogeny	  in	  the	  bone	  marrow	  (	  Figure	  1.14	   left	  panel;	  Caligiuri,	  2008;	  Cooper	  et	  al.,	  2001;	  Valiante	   et	   al.,	   1997),	   and	   determines	   whether	   the	   NK	   cell	   will	   be	   directly	  cytolytic	  or	  indirect	  antibody-­‐dependent	  killers	  (Wren	  et	  al.	  2013).	  During	  this	  early	  process	  within	   the	  bone	  marrow,	   the	  activating	  and	   inhibitory	  receptors	  interact	   with	   normal	   healthy	   self-­‐environment.	   NK	   cells	   with	   inhibitory	  receptors	  for	  self-­‐ligands	  are	  stimulated	  to	  mediate	  enhanced	  effector	  functions	  including	  ADCC,	  while	  those	  that	  carry	  activating	  receptors	  for	  self-­‐ligands	  are	  less	   likely	   to	   mediate	   ADCC	   (Parsons	   et	   al.,	   2012;	   Wren	   et	   al.,	   2013).	   With	  regards	  to	  anti-­‐HIV	  ADCC,	  education	  of	  NK	  cells	  through	  the	  inhibitory	  receptor	  KIR-­‐3DL1	  (section	  1.6)	  has	  been	  demonstrated	  to	  be	  important	  (Parsons	  et	  al.,	  2012).	  There	  is	  evidence	  that	  KIR-­‐3DL1-­‐educated	  NK	  cells	  mediate	  higher	  anti-­‐HIV	  ADCC	  against	  autologous	  targets	  than	  non-­‐educated	  NK	  cells	  (Parsons	  et	  al.,	  2012;	  Ward	  et	  al.,	  2004).	  	  	  The	   second	   stage	   involves	   the	   regulation	   of	   NK	   cells	   through	   the	   cumulative	  effects	   of	   NK	   cell	   inhibitory	   and	   activating	   receptor	   interaction	   with	   cognate	  ligands	  on	  the	  surface	  of	  potential	  target	  cells	  (Figure	  1.14;	  Wren	  et	  al.,	  2013).	  Activation	  of	  NK	  cells	  to	  mediate	  effector	  functions	  requires	  cumulative	  positive	  (activating)	   signals	   to	   be	   delivered	   from	   these	   surface	   interactions	   (Lanier,	  2003).	   Moreover,	   the	   strength	   of	   the	   signal	   determines	   the	   exact	   effector	  functions.	  For	  example,	   lower	   cumulative	  activating	   signals	   induce	  NK	  cells	   to	  degranulate	   and	   secrete	   chemokines,	   while	   stronger	   cumulative	   activating	  signals	  allow	  NK	  cells	  to	  secrete	  cytokines	  such	  as	  IFN-­‐γ	  (Fauriat	  et	  al.,	  2010).	  In	  addition	   to	   CD16,	   a	   role	   for	   activating	   and	   inhibitory	   receptors	   during	   HIV-­‐specific	  ADCC	  activity	  has	  been	  observed	  during	  the	  stimulation	  of	  NK	  cells.	  For	  example,	  KIRs	   that	   interacts	  with	  HLA-­‐C	  and	  HLA-­‐E	  binding	   inhibitory	  NKG2A	  receptor	  has	  been	  reported	  to	  dramatically	  decrease	  ADCC	  (Ward	  et	  al.,	  2004).	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Figure	  1.14.	  Education	  (stage	  1)	  and	  regulation	  (stage	  2)	  of	  NK	  cell	  activity.	  (A)	  NK	  cells	   (red)	   screen	   cellular	   surface	   of	   normal	   healthy	   cells	   (brown)	   and	   if	   NK	   cell	  inhibitory	   receptors	   find	   self-­‐ligand	   (HLA-­‐I),	   the	  NK	   cell	   is	   educated	   (stage	   1)	  with	   a	  potential	   to	   mediate	   effector	   functions	   that	   results	   in	   cumulative	   activating	   signals	  (stage	  2).	   (B)	   If	  NK	  cell	   inhibitory	  receptors	   fail	   to	   recognise	  self-­‐ligand	  (stage	  1),	  NK	  cell	   remains	   uneducated	   and	   unable	   to	   stimulate	   effector	   functions	   that	   results	   in	  cumulative	  activating	  signals	  (stage	  2)	  (adapted	  from	  Wren	  et	  al.,	  2013).	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1.6.2.3.	  FcRIIIγ	  polymorphisms	  and	  ADCC	  activity	  The	  ability	  of	  NK	  cells	   to	  mediate	  ADCC	  have	  been	  shown	   to	  be	   influenced	  by	  polymorphism	  in	  the	  FcR	  receptors	  (Wren	  et	  al.,	  2013b).	  Polymorphism	  in	  CD16	  (FcγRIIIa)	   at	   amino	   acid	   position	   158	   (resulting	   in	   a	   switch	   from	   valine	   to	  phenylalanine	  in	  this	  position),	  have	  been	  shown	  to	  influence	  both	  the	  density	  of	  CD16	  expression	  on	  the	  surface	  of	  NK	  cells,	  the	  affinity	  for	  IgG	  Fc	  component,	  and	   therefore	   influences	   the	  magnitude	   of	   the	   ADCC	   responses	   in	   individuals	  with	  this	  polymorphism	  (Brown	  et	  al.,	  2012;	  Hatjiharissi	  et	  al.,	  2007;	  Naranbhai	  et	  al.,	  2013).	  	  	  
1.6.2.4.	  Role	  of	  cytokines	  in	  enhancing	  ADCC	  activity	  of	  NK	  cells	  NK	  cells	  functionality	  can	  also	  be	  altered	  by	  exogenous	  factors	  such	  as	  cytokines	  (Wren	  et	  al.,	  2013b).	  During	  viral	  infections,	  cytokines	  (such	  as	  type	  I	  IFNs,	  IL-­‐10,	   IL-­‐12,	   IL-­‐15	   and	   IL-­‐18)	   are	   responsible	   for	   early	   NK	   cell	   activation	   and	  expansion	   (Iannello	   et	   al.,	   2008).	   Exogenous	   addition	   of	   IL-­‐10	   and	   IL-­‐15	   has	  been	  shown	  to	  significantly	  increase	  NK	  cell-­‐mediated	  ADCC	  effector	  functions	  during	   HIV	   infection	   (Brenner	   et	   al.,	   1989;	   Carson	   et	   al.,	   1994;	   Wren	   et	   al.,	  2013).	  Furthermore,	  the	  effect	  of	  exogenous	  addition	  of	  IL-­‐15	  was	  more	  potent	  on	   NK	   cells	   educated	   through	   co-­‐expression	   of	   KIR3DL1	   and	   HLA-­‐Bw4,	  previously	  associated	  with	  protection	  against	  HIV	  infection	  (Boulet	  et	  al.,	  2010;	  Parsons	  et	  al.,	  2010).	  Although	   the	  exact	  mechanism	  whereby	   IL-­‐10	  and	   IL-­‐15	  enhances	   NK	   cell	   ADCC	   during	   HIV	   infection	   is	   not	   understood,	   they	   may	  increase	  NK	  cell	  sensitivity	  to	  ADCC	  antibodies	  (Wren	  et	  al.,	  2012).	  In	  contrast,	  IL-­‐4	  and	  TGF-­‐β	  have	  been	  reported	  to	  suppress	  NK	  cell	  function	  (Iannello	  et	  al.,	  2008).	  	  NK	  cell	  ability	  to	  mediate	  ADCC	  is	  therefore	  influenced	  by	  these	  characteristics	  of	   the	   Fc	   receptor	   used,	   the	   level	   of	   maturity,	   activation	   or	   inhibition,	   and	  exhaustion	  of	  these	  effector	  cells	  as	  well	  the	  cytokine	  environment	  in	  which	  NK	  cells	  are	  functioning.	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1.7.	  HIV	  epitopes	  targeted	  by	  ADCC	  During	   HIV	   infection,	   antibodies	   have	   been	   identified	   that	   target	   various	   HIV	  epitopes	  on	  free	  virus	  particles	  and	  on	  the	  host	  cell	  surface	  of	  the	  HIV-­‐infected	  cells	  (Figure	  1.15	  and	  Table	  1.2;	  reviewed	  by	  Pollara	  et	  al.,	  2011).	  HIV-­‐specific	  ADCC	   responses	   have	  been	   reported	   to	   target	   both	   linear	   and	   conformational	  epitopes	  in	  HIV	  gp120	  and	  gp41	  (Ferrari	  et	  al.,	  2011;	  Kwong	  et	  al.,	  1998;	  Lyerly	  et	   al.,	   1987).	   An	   important	   characteristic	   of	   the	   ADCC	   HIV	   epitopes	   are	   that	  these	  epitopes	  are	  exposed	  to	  antibodies	  when	  HIV	  is	  entering	  the	  host	  cell	  or	  when	  the	  HIV	  envelope	  is	  maturing	  on	  the	  host	  cell	  membrane	  of	  HIV-­‐infected	  cells,	   before	   budding	   (Briggs	   and	   Kräusslich,	   2011).	   Within	   gp120,	   epitopes	  within	  variable	   regions	  V1-­‐3	  and	   the	  CD4	  binding	  site	  have	  been	   identified	  as	  targets	   for	   ADCC	   (reviewed	   by	   Pollara	   et	   al.,	   2013).	   Within	   gp41,	   the	   MPER,	  cluster	   A,	   B	   and	   C	   regions	   were	   shown	   to	   be	   targets	   for	   ADCC	   (Figure	   1.15;	  reviewed	  by	  Pollara	  et	  al.,	  2013).	  	  
	  
Figure	   1.15.	   HIV	   gp120	   and	   gp41	   epitopes	   recognised	   by	   ADCC	   antibodies.	  The	  red	   arrows	   indicate	   the	   regions	   of	   the	   HIV-­‐envelope	   glycoprotein	   targeted	   by	   ADCC	  activity.	  The	  V1,	  V2	  are	  indicated	  in	  green	  and	  the	  V3	  region	  is	  indicated	  in	  yellow.	  The	  CD4	  binding	  site	   is	   indicated	  in	  brown.	  On	  the	  right	  panel	   is	   the	  gp41	  reactive	  face	  of	  gp120,	  showing	  the	  clusters	  (A-­‐C;	  red)	  identified	  in	  gp41	  and	  the	  V1-­‐3	  regions	  (purple)	  (adapted	  from	  Pollara	  et	  al.,	  2013).	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Table	  1.2.	  Defined	   regions	  on	   the	  HIV-­‐envelope	   targeted	  by	  human	  monoclonal	  
antibodies	  with	  ADCC	  activity	  (reviewed	  by	  Pollara	  et	  al.,	  2013).	  


















gp41 Cluster I 245-D Linear Non-neutralizing (Forthal!et!al.,!1995;!Moog!et!al.,!2014)!
 4B3 Linear Non-neutralizing (Moog!et!al.,!2014)!
 98-43 Linear Non-neutralizing (Tyler!et!al.,!1990)!
 50-69 Discontinuous Non-neutralizing (Tyler!et!al.,!1990)!
Cluster II (HR2) 98-6 Discontinuous! Non-neutralizing (Forthal!et!al.,!1995;!Tyler!et!al.,!1990)!
 126-50 Discontinuous! Non-neutralizing Tyler!et!al.,!1990)!
Not defined 31710B Not defined  (Alsmadi!et!al.,!1998)!
MPER 120-16 Linear! Non-neutralizing! (Forthal!et!al.,!1995;!Tyler!et!al.,!1990)!
 2F5 Linear! Non-neutralizing! (Moog!et!al.,!2014,!Tudor!et!al.,!2011)!
 4E10 Linear! Non-neutralizing! (Moog!et!al.,!2014)!







17B  Discontinuous! Neutralizing! (Ferrari!et!al.,!2011)!
CD4i CH08  Discontinuous! Neutralizing! (Friedman!et!al.,!2012)!
CD4i Cluster A C11, L9-i1, N5-i5, L9-i2, 
N12-i3, N26-i1  
Discontinuous! Non-neutralizing! (Guan et al., 2013)  !
CD4i Cluster B N12-i15  Discontinuous! Non-neutralizing! (Guan et al., 2013) !
CD4i Cluster C.1 L9-i3, N5-i1, N5-i3, N5-i4, 
N5-i8, N10-i1.1, N10 15.3, 
N12-i1, N12-i2, N12-i4, 
N12-i5, N12-i7, N12-i8  
Discontinuous! 9/10Neutralizing! (Guan et al., 2013) !
CD4i Cluster C.2 N12-i10, N12-i17, N12-i18, 
N12-i19  
Discontinuous! 2/6Neutralizing! (Guan et al., 2013) !
CD4 Cluster C.3 N5-i2, N5-i6, N5-i9, N5-i14, 
N5-i7, N5-i12, N10-i3.1, 
N12-i12, N12-i9, N12-i11  
Discontinuous! Non-neutralizing! (Guan et al., 2013) !
CD4 Cluster C.4 L9-i4, N5-i10.1, N5-i13, 
N10-i2, N12-i14, N12-i16  
Discontinuous! Non-neutralizing! (Guan et al., 2013) !
CD4i N10-i4, N10-i6.1  Discontinuous! Neutralizing! (Guan et al., 2013) !
CD4i C1 region CH20, CH29, CH38, CH40, 
CH49, CH51, CH52, CH53, 
CH54, CH55, CH57, CH77, 
CH78, CH80, CH81, CH90, 
CH91, CH92, CH94  
Discontinuous! Neutralizing! (Bonsignori et al., 2012)  !
C2, C3, C4, V4 
glycansites 
2G12  Discontinuous! Non-neutralizing! (Trkola et al., 1996)  !
C5 670-D 
 
Discontinuous! Non-neutralizing! (Forthal et al., 1995) !
750-D Not defined Neutralizing! (Forthal et al., 1995) !
42F, 43F Linear Non-Neutralizing! (Alsmadi et al., 1997) !
CD4 binding site 15e Discontinuous! Neutralizing! (Koup et al., 1991) !
 F105 Discontinuous! Neutralizing! (Posner et al., 1992) !
448-D Discontinuous! Neutralizing! (Forthal et al., 1995) !
1125H, 5145A Discontinuous! Neutralizing! (Alsmadi et al., 1998) !
b12 Discontinuous! Neutralizing! (Hezareh et al., 2001) !
VRC01 Discontinuous! Neutralizing! (Ferrari et al., 2011) !
V2 CH58, CH59, HG107, 
HG120  
Linear Neutralizing! (Liao et al., 2013) !
 PG9  Discontinuous! Neutralizing! (Biedma ME, 2013) !
V3 694/98D  Linear! Neutralizing! (Forthal et al., 1995) !
4117C, 41148D  Linear! Neutralizing! (Alsmadi et al., 1998) !
CH22, CH23  Linear! Neutralizing! (Bonsignori et al., 2012) !
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Many	  ADCC	  epitopes	  coincide	  with	  epitopes	  previously	  shown	  to	  be	  recognised	  by	  nAbs	  (Bonsignori	  et	  al.,	  2012;	  Pollara	  et	  al.,	  2013;	  Veillette	  et	  al.,	  2014).	  Even	  though	  the	  HIV	  envelope	  protein	  has	  been	  shown	  to	  be	  the	  major	  target	  for	  HIV-­‐specific	  ADCC,	  antibodies	  that	  recognise	  Nef,	  Vpu	  and	  Pol	  HIV	  proteins	  have	  also	  been	  described	   that	  mediate	  ADCC	   (Isitman	   et	   al.,	   2011;	  Veillette	   et	   al.,	   2014;	  Wren	   et	   al.,	   2013).	   The	   specific	   epitopes	   where	   the	   HIV-­‐specific	   ADCC	  antibodies	  bind	  on	  these	  proteins	  are	  yet	  to	  be	  identified.	  	  Although	  it	  is	  well	  established	  that	  HIV	  readily	  escapes	  from	  HIV-­‐specific	  nAbs	  and	   that	   this	   is	   the	  major	   driver	   of	   genetic	   variation	   in	   gp120	   and	   other	  HIV	  proteins	  (Deeks	  et	  al.,	  2006;	  Moore	  et	  al.,	  2012;	  Wei	  et	  al.,	  2003),	  similar	  escape	  from	   ADCC	   antibodies	   has	   only	   recently	   been	   demonstrated	   (Chung	   et	   al.,	  2011).	   It	   is	   thought	   that	  HIV-­‐specific	  ADCC	  activity	  exerts	   significant	  pressure	  on	  HIV,	   resulting	   in	  HIV	  escape	  mutations	   (Chung	  et	   al.,	   2011b;	   Isitman	  et	   al.,	  2012).	   As	   has	   been	   shown	   for	   nAbs,	   HIV-­‐specific	   ADCC	   antibodies	   have	   been	  shown	  to	  loose	  ability	  to	  recognise	  viral	  sequences	  from	  earlier	  autologous	  time	  points	   (Isitman	   et	   al.,	   2012).	   Isitman	   and	   colleagues	   (2012)	   suggested	   that	  conformational	  ADCC	  antibodies	  are	  also	  likely	  to	  elicit	  HIV	  escape	  mutants,	  but	  are	  likely	  to	  be	  more	  difficult	  to	  map	  than	  linear	  epitopes	  and	  therefore	  it	  would	  be	  difficult	  to	  detect	  immune	  escape	  (Isitman	  et	  al.,	  2012).	  	  	  
1.8.	  Protective	  role	  of	  ADCC	  in	  HIV	  infection	  Longitudinal	  studies	   in	  SIV-­‐infected	  non-­‐human	  primates	  have	  shown	  that	   the	  presence	  of	   SIV-­‐specific	  ADCC	  activity	   correlated	  with	  better	  disease	  outcome	  (Banks	   et	   al.	   2002).	   In	   humans,	   the	   presence	   of	  HIV-­‐specific	   ADCC	   antibodies	  during	  acute	  infection	  predicted	  better	  control	  of	  viremia	  by	  leading	  to	  lysis	  of	  HIV-­‐infected	  cells	  and	  reduced	  viremia	  (Forthal	  et	  al.,	  2001;	  Go´mez-­‐Roma´n	  et	  al.,	   2005;	   Baum	   et	   al.,	   1996).	   Elite	   controllers	   of	   HIV	   (individuals	   who	   are	  infected	  with	  HIV	  but	  maintain	  undetectable	  plasma	  viral	  loads	  without	  HAART)	  were	  found	  to	  have	  levels	  of	  ADCC	  activity	  (Okulicz	  et	  al.,	  2009;	  2012).	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Antibodies	   that	   mediate	   HIV-­‐specific	   ADCC	   have	   also	   been	   detected	   in	  secretions	   from	   the	   female	   genital	   tract,	   and	  women	  with	  ADCC	   antibodies	   in	  their	  genital	  secretions	  had	  lower	  genital	  viral	  loads	  compared	  to	  women	  with	  no	   genital	   ADCC	   antibodies	   (Nag	   et	   al.,	   2004).	   In	   addition,	   HIV-­‐specific	   ADCC	  antibodies	   have	   been	   found	   in	   breast	   milk	   of	   HIV-­‐infected	   women,	   and	   low	  levels	   of	   ADCC	   envelope	   specific	   IgGs	   in	   breast	  milk	   has	   been	   identified	   as	   a	  correlate	   of	   transmission	   that	   may	   impact	   infant	   infection	   risk	   to	   infants	  (Mabuka	  et	  al.,	  2012).	  	  	  
1.9.	   Properties	   of	   antibodies	   that	   influence	   the	  
magnitude	  of	  ADCC	  activity	  during	  HIV	  infection	  Properties	  of	  antibodies	  may	  influence	  the	  magnitude	  of	  ADCC	  responses	  during	  HIV	   infection	   (reviewed	   by	   Wren	   et	   al.,	   2013).	   The	   isotype,	   subclass	   or	  glycosylation	  of	  the	  Fc	  component	  (including	  the	  precise	  composition	  of	  major	  sugar	   residues)	   of	   antibodies	   may	   influence	   ADCC	   responses	   (Bruhns	   et	   al.,	  2009).	   Previous	   studies	   have	   reported	   that	   IgG1	   and	   IgG3	   antibodies	   are	   the	  most	   potent	   inducers	   of	   anti-­‐HIV	   ADCC	   (Ljunggren	   et	   al.,	   1988;	   Niwa	   et	   al.,	  2005).	   The	   removal	   of	   the	   major	   sugar	   residue	   fucose	   has	   been	   shown	   to	  increase	   ADCC	   ~100-­‐fold,	   while	   the	   addition	   of	   the	   sugar	   siliac	   acid	   during	  glycosylation	   of	   the	   Fc	   component	   has	   been	   shown	   to	   decrease	  ADCC	   activity	  (Boyd	   et	   al.,	   1996;	   Shinkawa	   et	   al.,	   2003).	   Some	   studies	   reported	   that	  galactosylation	  of	  IgG	  Fc	  enhances	  ADCC,	  while	  others	  were	  unable	  to	  replicate	  this	  enhancement	  (Boyd	  et	  al.,	  1996;	  Shinkawa	  et	  al.,	  2003;	  Wren	  et	  al.,	  2013).	  	  	  
1.10.	  ADCC	  antibodies	  mediate	  protection	  against	  HIV	  	  Recently,	   the	   “RV144”	  HIV	  vaccine	   trial	  was	  conducted	   in	  16000	  HIV-­‐negative	  Thailand	  women	  and	  men	  at	  risk	  for	  HIV	  infection	  via	  heterosexual	  exposure	  in	  Thailand	  (Rerks-­‐Ngarm	  et	  al.,	  2009).	  This	  vaccine	   trial	   included	  a	   total	  of	   four	  inoculations	  of	  a	  recombinant	  avian	  poxvirus	  live	  vector	  ALVAC-­‐HIV	  (vCP1521),	  expressing	   Gag-­‐Pro	   of	   HIV	   clade	   B	   and	   a	  membrane-­‐anchored	   clade	   E	   gp120	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and	   two	   simultaneous	   inoculations	   of	   the	   AIDSVAX	   B/E	   gp120	   proteins	  (Karnasuta	  et	  al.,	  2004;	  Rerks-­‐Ngarm	  et	  al.,	  2009).	  Thorough	  investigation	  of	  the	  immune	   correlates	   of	   protection	   in	   the	   RV144	   trial	   demonstrated	   that	  protection	   was	   associated	   with	   HIV-­‐specific	   CD4+	   T	   cells,	   binding	   (non-­‐neutralizing)	  IgG	  antibodies,	  and	  gp120	  V1V2	  antibodies	  associated	  with	  ADCC	  activity	  (Haynes	  et	  al.,	  2012).	  This	  RV144	  vaccine	  trial	  highlighted	  importantly	  that	  protection	  could	  be	  achieved	  in	  absence	  of	  nAbs	  or	  HIV-­‐specific	  CTLs.	  Also,	  this	   study	   suggested	   that	   IgA	   vaccine	   responses	  were	   not	   protective	   and	   that	  individuals	   with	   the	   highest	   titers	   of	   HIV-­‐specific	   IgA	   were	   most	   at	   risk	   of	  becoming	  infected	  (Gottardo	  et	  al.,	  2013;	  Haynes	  et	  al.,	  2012;	  Karasavvas	  et	  al.,	  2012).	  	  
1.11.	  Methods	  to	  measure	  ADCC	  Different	  approaches	  have	  been	  used	   to	   study	  NK	  cell-­‐mediated	  ADCC	  activity	  (Chung	  et	  al.,	  2009;	  Gómez-­‐Román	  et	  al.,	  2006;	  Karnasuta	  et	  al.,	  2005;	  Pollara	  et	  al.,	   2011).	   Measurement	   of	   ADCC	   activity	   of	   NK	   cells	   is	   a	   complex	   process	  because	   three	   distinct	   important	   components	   are	   involved	   in	   ADCC	   and	  therefore	   need	   to	   be	   considered	   (Chung	   et	   al.,	   2008).	   These	   3	   components	   to	  consider	   are:	   (1)	   properties	   of	   the	   target	   cells	   that	   express	   HIV	   antigens;	   (2)	  properties	  of	  the	  effectors	  cells	  (NK	  cells);	  and	  (3)	  properties	  of	  the	  HIV-­‐specific	  antibodies.	   Therefore,	   ADCC	   assays	   that	   have	   been	   widely	   used	   in	   the	   past	  measured	  either	  properties	  of	  effector	  cells;	  or	  the	  amount	  of	  killing	  of	  the	  HIV-­‐infected	  target	  cells.	  	  	  
1.11.1.	  ADCC	  assays	  measuring	  properties	  of	  the	  effector	  cells	  
1.11.1.1.	  CD107a	  flow	  cytometry	  assay	  During	  ADCC,	  NK	  cell	  effectors	  degranulate,	  releasing	  cytolytic	  granules	  into	  the	  immunological	  synapse	  between	  the	  effector	  and	  target	  cell	  to	  induce	  target	  cell	  lysis	   (section	  1.6.1).	  The	  membrane	  of	   the	   lysomal	   compartment	   that	   releases	  cytolytic	  granules	  (containing	  perforin	  and	  granzyme)	  contains	  CD107a,	  which	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can	  be	  useful	  as	  a	  cell	  surface	  marker	  to	  measure	  the	  extent	  to	  which	  NK	  cells	  have	   degranulated	   (Alter	   et	   al.,	   2004).	   Other	   markers	   such	   as	   CD16	   and	  cytokines	   (TNF-­‐α	   and	   IFN-­‐γ)	   can	   also	   be	   measured	   simultaneously	   by	   multi-­‐parameter	   flow	   cytometry	   (Alter	   et	   al.,	   2004).	   NK	   cell	   surface	   expression	   of	  CD107a	  was	  shown	  to	  correlate	  significantly	  with	  target	  cells	  lysis	  measured	  by	  Cr51-­‐release	  and	  with	  secretion	  of	  cytokines	  by	  NK	  cells	  (Alter	  et	  al.,	  2004).	  	  
1.11.1.2.	  Esterase	  release	  assay	  An	  alternative	  to	  the	  CD107a	  assay,	  Kato	  et	  al	  (1991)	  described	  measurement	  of	  esterase	  activity	  by	  the	  effector	  cells	  as	  a	  measure	  of	  effector	  cell	  degranulation.	  Effector	   cells	   release	   granules	   containing	   esterases	   (mainly	   granzyme	   A)	   that	  can	  cleave	  the	  substrate	  N-­‐α-­‐benzyloxycarbonyl-­‐ι-­‐lysine	  thiobenzyl	  ester	  (BLT),	  which	  can	  be	  used	  to	  measure	  the	  frequency	  of	  effector	  cell	  degranulation	  (Kato	  et	  al.,	  1991).	  	  
1.11.1.3.	  Perforin	  deposition	  assay	  Since	   effector	   cell	   degranulation	   results	   in	   the	   release	   of	   granules	   containing	  perforin	  and	  granzymes,	  Zaritskaya	  et	  al	   (2010)	  proposed	  measuring	  perforin	  deposition	   as	   a	   measure	   of	   effector	   cell	   function.	   Using	   this	   approach	   to	  measure	  ADCC,	  effector	  cells	  were	  stained	  with	  a	  perforin-­‐specific	  monoclonal	  antibody	   and	   perforin-­‐deposition	   within	   the	   target-­‐effector	   synapses	   can	   be	  visualised	  using	  monitored	  using	  microscopy	  (Zaritskaya	  et	  al.,	  2010).	  	  
1.11.2.	  ADCC	  assays	  measuring	  properties	  of	  the	  target	  cells	  
1.11.2.1.	  Chromium	  release	  assay	  	  Historically,	   ADCC	   assays	   have	   relied	   on	   labeling	   target	   cells	  with	   radioactive	  sodium	  chromate	  (Chromium51	  or	  Cr51;	  Brunner	  et	  al.,	  1968)	  and	  this	  approach	  has	   also	   been	   used	   to	   measure	   HIV-­‐specific	   ADCC	   (Chung	   et	   al.,	   2008).	   This	  traditional	   approach	   to	   evaluating	   target	   cell	   death	   during	   ADCC	   has	   several	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disadvantages,	  such	  as	  low	  sensitivity,	  need	  for	  potent	  radioactive	  isotopes,	  and	  that	  certain	  target	  cells	  are	  difficult	  to	  label	   in	  this	  manner	  (Go	  ́mez-­‐Roma	  ́n	  et	  al.,	  2006).	  	  
1.11.2.2.	  Rapid	  fluorometric	  ADCC	  assay	  More	   recently,	   fluorescence	   based	   assays	   have	   been	   developed	   to	   measure	  ADCC	   (Chung	   et	   al.,	   2008).	   These	   involve	   labeling	   the	   target	   cells	   with	   a	  membrane	   and	   intracellular	   fluorescent	   dyes	   and	   using	   flow	   cytometry	   to	  measure	  loss	  of	  fluorescence	  as	  a	  measure	  of	  lysis.	  These	  rapid	  and	  fluorometric	  ADCC	   assays	   rely	   on	   double	   staining	   target	   cells	   with	   a	   membrane	   marker	  (PKH-­‐26)	  and	  a	  viability	  dye	  (CSFE)	  prior	  to	  addition	  of	  effector	  cells	  (Go	  ́mez-­‐Roma	  ́n	  et	  al.,	  2006).	  	  
1.11.2.3.	  Lactate	  dehydrogenase	  (LDH)	  release	  assay	  The	  principle	  of	   this	  assay	   is	   the	  release	  of	   lactate	  dehydrogenase	  (LDH)	   from	  the	   dying	   target	   cells	  whereby	   LDH	  participates	   in	   a	   colourmetric	   reaction	   in	  which	  a	  yellow	  tetrazolium	  salt	  is	  converted	  to	  a	  red	  colour	  that	  is	  measured	  as	  a	  marker	  of	  target	  cell	  lysis	  during	  ADCC	  (Broussas	  et	  al.,	  2013).	  	  
1.11.2.4.	  ADCC-­‐GranToxilux	  and	  PanToxilux	  assays	  Recently,	   Pollara	   et	   al.	   (2011)	   described	   a	   sensitive	   high-­‐throughput	   flow	  cytometry	   based	   assay	   to	   measure	   ADCC.	   The	   GranToxilux	   assay	   measures	  granzyme	  B	  activity	  in	  target	  cells	  and	  relies	  on	  hydrolysis	  of	  a	  cell-­‐permeable	  fluorogenic	   peptide	   substrate	   containing	   a	   sequence	   recognised	   by	   the	   serine	  protease,	  granzyme	  B	  (Packard	  et	  al.,	  2007;	  Pollara	  et	  al.,	  2011).	  Granzyme	  B	  is	  delivered	   to	   target	   cells	   following	  degranulation	  of	  NK	  cells	  during	  ADCC,	  and	  this	   assay	   quantifies	   this	   delivered	   granzyme	   B	   by	   flow	   cytometry.	   The	  PanToxilux	   assay	   is	   a	   variation	   of	   the	   GranToxilux	   assay,	   with	   the	   main	  difference	  being	  the	  cell	  permeable	  fluorogenic	  substrate	  (Packard	  et	  al.,	  2007).	  
	   36	  
While	  GranToxilux	  detects	  granzyme	  B	  only,	  PanToxilux	  detects	  granzyme	  B	  as	  well	  as	  upstream	  caspase	  activity.	  	  	  
1.12.	  Aims	  and	  objectives	  The	   aim	   of	   this	   study	   was	   to	   optimise	   and	   compare	   the	   GranToxilux and	  PanToxilux assays	   to	   measure	   (1)	   direct	   killing	   and	   (2)	   HIV-­‐specific	   ADCC	  activity.	  
Objective	  1:	  To	  optimise	   the	  GranToxilux	  and	  PanToxilux	  assays	   to	  measure	  direct	  NK	  cell	  killing	  of	  the	  tumour	  cell	  line	  K562.	  	  
Hypothesis:	  
The	  PanToxilux	  assay	  will	  be	  more	  sensitive	  to	  detect	  direct	  killing	  of	  K562	  tumour	  
cells	   than	   the	   GranToxilux	   assay	   because	   it	   measures	   both	   granzyme	   B	   and	  
caspase	  activity.	  
Objective	  2:	  To	   optimise	   and	   compare	   the	   GranToxilux	   and	   PanToxilux	   assays	   for	  measurement	  of	  HIV-­‐specific	  ADCC	  activity.	  
Hypothesis:	  
The	   PanToxilux	   assay,	   which	   detects	   both	   granzyme	   B	   and	   caspase	   activity	   in	  
target	   cells,	   will	   be	   more	   sensitive	   at	   measuring	   ADCC	   activity	   in	   HIV-­‐infected	  
individuals	  than	  the	  GranToxilux	  assay,	  which	  only	  detects	  granzyme	  B.	  
	  CHAPTER	  2	  
	  




Materials	  and	  Methods	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2.1.	  NK	  target	  cell	  lines	  The	   human	   erythroleukemic	   cell	   line	   K562	   was	   used	   as	   the	   target	   cells	   for	  measuring	  direct	  killing	  of	  NK	  cells	   in	   this	   study	   (Chapter	  3).	  K562	  are	  highly	  undifferentiated	  human	  erythroleukemic	  cell	  line	  that	  do	  not	  express	  HLA	  class	  I	  molecules,	  making	  these	  cells	  sensitive	  to	  NK	  cell	  lysis	  (Naumann	  et	  al.,	  2001).	  K562	   cells	   (1	   x	   106	   cells/ml)	   were	   cultured	   in	   RPMI-­‐1640	   medium	   (Sigma-­‐Aldrich®;	   St.	   Louise,	   MO)	   containing	   10%	   FBS	   (fetal	   bovine	   serum)	   and	   1%	  penicillin-­‐streptomycin-­‐glutamine	   (R10)	   at	   37°C	   in	   a	   humidified	   5%	   CO2	  incubator.	  The	  growth	  medium	  was	  checked	  and	  replaced	  ~2	  days.	  This	  cell	  line	  was	  maintained	  in	  a	  50ml	  tissue	  culture	  flask	  in	  R10	  and	  split	  ~4	  days.	  	  CEM.NKRCCR5	   cells,	   modified	   to	   express	   CD4	   and	   CCR5	   receptor	   on	   the	   cell	  surface,	   are	   not	   directly	   sensitive	   to	   NK	   cell	   killing	   but	   become	   sensitive	   to	  killing	   following	   coating	   them	   with	   HIV	   gp120	   and	   adding	   HIV-­‐specific	  antibodies,	  making	   them	  useful	   target	   cells	   for	  measuring	  ADCC	  (Trkola	  et	  al.,	  1999).	   In	   addition,	   CEM	   cells	   which	   do	   not	   express	   CCR5	   were	   used	   as	   a	  negative	  control	  (Chapter	  4).	  CEM.NKRCCR5	  cells	  were	  cultured	  in	  a	  50ml	  plastic	  cell	   culture	   flask	   (Sigma-­‐Aldrich®)	   as	   described	   above.	   This	   cell	   line	   was	  maintained	  in	  R10	  in	  50ml	  tissue	  culture	  flask	  at	  37°C	  in	  a	  humidified	  5%	  CO2	  incubator.	  The	  growth	  medium	  was	  checked	  and	  replaced	  ~2	  days	  and	  split	  ~3	  days.	  The	  growth	  kinetics	  of	  CEM.NKRCCR5	  cells	  differed	  slightly	  from	  K562	  cells,	  growing	   faster.	   A	   sub-­‐passage	   of	   cells	   was	   done	   before	   any	   experiment	   to	  ensure	  that	  the	  cells	  were	  in	  log-­‐phase	  of	  growth.	  	  	  
2.2.	  Study	  participants	  and	  sample	  collection	  Blood	   “buffy”	   packs	   were	   obtained	   from	   8	   HIV-­‐negative	   individuals	   from	  Western	   Province	   Blood	   Transfusion	   Service	   (Pineland,	   Cape	   Town)	   and	  processed	   within	   four	   hours	   of	   collection	   for	   isolation	   of	   peripheral	   blood	  mononuclear	  cells	  (PBMCs),	  as	  a	  standardised	  source	  of	  NK	  cell	  effector	  cells	  for	  this	   study	   (used	   in	   Chapter	   3	   for	   direct	   killing	   and	   in	   Chapter	   4	   for	   ADCC-­‐
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mediated	   NK	   killing).	   In	   addition,	   whole	   blood	   (40ml)	   was	   collected	   by	  venipuncture	   from	   9	   chronically	   HIV-­‐infected	   individuals	   who	   were	   naïve	   to	  HAART.	  Plasma	  from	  these	  HIV-­‐infected	  donors	  was	  used	  as	  the	  source	  of	  HIV-­‐specific	  antibodies	  for	  the	  ADCC	  assays	  (Chapter	  4).	  Whole	  blood	  was	  collected	  into	  vacutainer	  tubes	  containing	  acid	  citrate	  dextrose	  as	  an	  anti-­‐coagulant	  (ACD;	  BD	  Bioscience,	  San	  Diego,	  CA).	  The	  University	  of	  Cape	  Town’s	  Faculty	  of	  Health	  Sciences	  Research	  Ethics	  committee	  (REC	  REF	  258/2006)	  approved	  all	  aspects	  of	   this	   study,	   and	   written	   informed	   consent	   was	   obtained	   from	   all	   the	  participants.	  	  	  
2.3.	  Processing	  of	  PBMCs	  and	  blood	  plasma	  PBMCs	   were	   isolated	   from	   HIV-­‐negative	   buffy	   packs	   using	   Ficoll-­‐Hypaque	  (Sigma-­‐Aldrich®)	  density	  gradient	  centrifugation.	  This	  method	  takes	  advantage	  of	  the	  density	  differences	  between	  mononuclear	  cells	  (such	  as	  NK	  cells,	  B	  cells,	  T	  cells,	   monocytes,	   macrophages	   and	   dendritic	   cells)	   and	   other	   blood	   elements	  and	   cells	   (red	   blood	   cells,	   platelets	   and	   neutrophils).	   Ficoll-­‐Hypaque	   is	   a	  hydrophilic	  polymer,	  which	  serves	  as	  a	  solute	  that	  produces	  a	  density	  gradient	  for	  the	  separation	  of	  cells.	  Briefly,	  15ml	  of	  Ficoll-­‐Hypaque	  was	  added	  to	  a	  50ml	  Leucosep®	  tube	  (Greiner	  Bio-­‐one;	  Frickenhausen,	  Germany)	  containing	  porous	  membrane.	  The	  porous	  membrane	  separates	  the	  Ficoll-­‐Hypaue	  from	  the	  blood	  sample	   thus	   avoiding	   their	   accidental	  mixture	   before	   centrifugation.	   This	  was	  then	   centrifuged	   at	   1258rcf	   for	   1	  min	   to	   allow	   the	   Ficoll-­‐Hypaque	   solution	   to	  descend	   below	   the	   membrane.	   Buffy	   packs	   from	   HIV-­‐negative	   blood	   donors	  were	  dispensed	  into	  the	  50ml	  Leucosep®	  tubes	  and	  centrifuged	  at	  1258rcf	  for	  15	   min.	   The	   PBMC	   layer	   was	   carefully	   removed	   using	   a	   Pasteur	   pipette	   and	  transferred	   to	   a	   15ml	   tube.	   PBMCs	   were	   washed	   with	   1%	   FBS	   in	   phosphate	  buffer	  saline	  (PBS)	  by	  centrifugation.	  The	  cell	  pellet	  was	  resuspended	  in	  6ml	  of	  RPMI	  1640	  (Gibco™)	  supplemented	  with	  10%	  FBS	  (R10)	  and	  counted	  using	  the	  automated	  Guava	  cell	  counter.	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2.4.	  Counting	  cells	  and	  viability	  assessment	  
2.4.1.	  Trypan	  blue	  exclusion	  manual	  counting	  of	  cell	  lines	  K562	   and	   CEM.NKRCCR5	   cell	   lines	   were	   manually	   counted	   using	   the	   light	  microscopy	  and	  Trypan	  blue	  exclusion	  dye	   test	   to	  differentiate	   live	   from	  dead	  cells.	   Trypan	  blue	   exclusion	  dye	  does	  not	   stain	   live	   cells	   (that	   have	   intact	   cell	  membranes	  and	  cannot	  be	  penetrated	  by	   the	  Trypan	  blue	  dye)	  but	  does	  stain	  dead	   cells	   (that	   have	   damaged	   cell	  membrane	   that	   allows	   uptake	   of	   the	   dye).	  Briefly,	   cells	  were	  stained	  with	  0.4%	  Trypan	  blue	  at	  a	  1:2	  dilution	   (10µl	  cells:	  10µl	   Trypan	   blue)	   in	   a	   96-­‐well	  microtiter	   plate	   and	   thoroughly	  mixed	  with	   a	  pipette.	   Ten	   µl	   of	   the	   cell-­‐trypan	   mixture	   was	   then	   loaded	   onto	   a	   plastic	  disposable	   Blaubrand	   Neubauer	   slide	   into	   the	   counting	  chamber/haemocytometer	   with	   a	   glass	   coverslip	   (Blaubrand®,	   Germany).	   A	  haemocytometer	  is	  a	  device	  used	  to	  determine	  the	  number	  of	  cells	  per	  defined	  unit	   volume	   of	   suspension.	   The	   haemocytometer	   was	   placed	   under	   a	   40x	  objective	  of	  a	   light	  microscope	  (Figure	  2.1).	  The	   live	  and	  dead	  cells	   in	   the	  two	  opposite	   chambers	  are	   counted	  and	   the	  absolute	   cell	   count	  and	  viability	  were	  calculated	  using	  the	  formulas	  shown	  in	  Figure	  2.1.	  After	  counting	  the	  live	  cells,	  concentration	   was	   adjusted	   to	   1x106	   cells/ml	   for	   continued	   culturing	   or	   10x	  106cells/ml	   for	   cryopreservation.	   Only	   cells	   with	   viability	   >95%	   were	  cryopreseved	  or	  used	  in	  the	  experiments.	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Figure	   2.1.	   Schematic	   of	   a	   haemocytometer	   chamber	   and	   the	   formulas	   used	   to	  
calculate	   viability	  of	   cells	   following	  Trypan	  blue	   staining.	  Cells	   in	   any	   of	   the	   two	  opposite	   squares	   are	   counted	   and	   the	   viability	   is	   calculated	   using	   the	   two	   formulas	  (taken	  from	  www.microbehunter.com).	  	  
2.4.2.	   Automated	   cell	   counting	   of	   PBMCs	   using	   the	   Guava	   cell	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2.5.	  Cryopreservation	  of	  PBMCs	  For	  long-­‐term	  storage	  of	  PBMCs,	  cells	  were	  cryopreserved	  in	  a	  media	  containing	  10%	  dimethyl	  sulfoxide	  (DMSO;	  Sigma-­‐Aldrich®)	  as	  a	  cryoprotectant,	  diluted	  in	  FBS	   as	   freezing	   medium.	   DMSO	   is	   a	   polar	   solvent	   that	   can	   penetrate	   cell	  membranes	   during	   the	   freezing	   process,	   without	   damaging	   them,	   to	   protect	  freezing	   cells	   from	  damage	   caused	   by	   ice	   crystals	   formation	   (Frackman	   et	   al.,	  1998).	  Briefly,	  PBMCs	  for	  cryopreservation	  were	  first	  resuspended	  in	  100%	  FBS	  (Invitrogen)	   at	   20x106cells/ml.	   Freezing	   media	   (20%	   DMSO	   FBS)	   was	   then	  added	   drop-­‐wise,	   with	   continual	   mixing,	   to	   obtain	   a	   final	   concentration	   of	  PBMCs	   at	   10x106cells/ml.	   The	   mixture	   was	   then	   aliquoted	   into	   pre-­‐cooled	  cryovials	   (Greiner	  Bio-­‐one)	   at	  1ml	  per	   cryovial	   (10x106	   cells)	   and	  placed	   into	  pre-­‐cooled	  controlled	  rate	  freezing	  unit,	  containing	  isopropyl	  alcohol	  to	  control	  the	   rate	   of	   freezing.	   ‘Mr	   Frosty®’	   (Nalgene;	   Rochester,	   NY)	   unit	   ensured	   that	  PBMCs	   froze	   at	   a	   rate	   of	   1˚C/min.	   ‘Mr	   Frosty®’	   units	   containing	   PBMCs	  were	  placed	   at	   -­‐80˚C	   overnight	   and	   cryovials	   containing	   PBMCs	   were	   then	  transferred	  to	  liquid	  nitrogen	  for	  long-­‐term	  storage	  within	  48	  hours.	  	  
2.6.	  Thawing	  cryopreserved	  PBMCs	  Because	  thawing	  of	  cryopreserved	  cells	  can	  be	  stressful	  to	  cells,	  working	  quickly	  and	  maintaining	  sterile	   techniques	   throughout	  ensured	   that	  a	  high	  proportion	  of	   the	   cells	   survived	   thawing.	   In	   this	   study,	   cryopreserved	   cells	  were	   thawed	  rapidly	   in	   a	   37°C	   water-­‐bath	   until	   a	   pea-­‐size	   of	   ice	   crystal	   remained.	   At	   this	  point,	   the	   cryovial	   containing	   the	   thawed	   cells	   was	   transferred	   into	   the	  biosafety	   cabinet	   and	   1ml	   of	   R1	   media	   [RPMI	   1640	   (Gibco™),	   1%	   FBS	  (Invitrogen)]	   at	   RT	   containing	   [50U	   penicillin,	   50mg/ml	   glutamine	   (Gibco™)	  and	   0.8mg/mL	   Fungin (InvivoGen)]	   was	   added	   drop-­‐wise	   while	   shaking	   the	  cryovial	   gently.	   The	   contents	   of	   the	   cryovial	   was	   then	   transferred	   to	   a	   50ml	  Falcon	  Tube	  using	  a	  sterile	  pipette	  and	  15ml	  R1	  was	  added	  and	  the	  sample	  was	  centrifuged	  at	  290rcf	  for	  10	  min.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  resuspended	   in	  500µl	   of	   0.02mg/ml	  DNAse	   I	   (Roche	  Diagnostics).	  Addition	  of	  DNAse	   to	   thawing	   cells	   prevents	   them	   from	   clumping	   by	   digesting	   the	   DNA	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released	  by	  some	  cells	  that	  lysed	  during	  cryopreservation	  or	  thawing.	  Samples	  with	  DNAse	  added	  were	   incubated	  at	  RT	  for	  2	  min	  to	   facilitate	  DNA	  digestion,	  following	  which	  they	  were	  then	  washed	  with	  30ml	  R1	  at	  290rcf	   for	  10ml.	  The	  pellet	  was	   resuspended	   in	  5ml	  R20	   for	   cell	   counting,	   adjusted	   to	   the	   required	  concentration	  with	  R20	  and	  incubated	  at	  37°C,	  5%	  CO2	  overnight.	  	  	  
2.7.	  Characterisation	  of	  NK	  cells	  by	  flow	  cytometry	  	  
2.7.1.	  Staining	  of	  NK	  cells	  The	   phenotype	   and	   function	   of	   NK	   cells	   from	   HIV-­‐negative	   PBMC	   donors	  (section	  2.3)	  used	   in	   the	  direct	  killing	  and	  ADCC	  assays	  were	  characterised	  by	  flow	   cytometry.	   Table	   2.1	   describes	   the	   antibodies	   used	   in	   this	   study,	   their	  fluorochrome,	  clone	  and	  manufacturer.	  NK	  cell	  phenotype	  was	  evaluated	  using	  antibodies	   against	   CD3	   (to	   exclude	   T	   cells),	   CD56	   and	   CD16	   (to	   differentiate	  distinct	  NK	  cell	  subsets).	  Furthermore,	  the	  functional	  ability	  of	  distinct	  NK	  cell	  subsets	   was	   evaluated	   using	   antibodies	   against	   CD107a	   (to	   measure	   NK	   cell	  degranulation,	  Alter	   et	   al.,	   2004)	  and	   intracellular	   IFN-­‐γ	   (to	  measure	   cytokine	  production).	  In	  addition,	  a	  dump	  channel	  containing	  antibodies	  directed	  against	  cells	   to	  be	  excluded	  from	  analysis	  (cells	   that	  were	  not	  of	   interest	   to	  this	  study	  including	   CD19+	   B	   cells	   and	   CD14+	  monocytes)	   and	   dead	   cells	   (ViVid	   stain	   to	  exclude	  dead	  cells)	  was	  also	  included	  in	  the	  panel	  to	  increase	  the	  specificity	  of	  staining.	  	  To	  phenotype	  and	  functionally	  characterise	  the	  universal	  HIV-­‐negative	  NK	  cell	  donor,	   PBMCs	   were	   stimulated	   with	   Phorbol	   12-­‐myristate	   13-­‐acetate	  (PMA)/ionomycin,	   Phytohaemaglutinin	   (PHA)	   (both	   positive	   controls)	   or	   left	  unstimulated	  (negative	  control).	  For	  stimulation	  with	  PHA	  and	  PMA/ionomycin,	  1x106	  cell/ml	  PBMCs	  from	  the	  HIV-­‐negative	  donor	  was	  added	  to	  the	  individual	  FACS	   tubes.	   To	   each	   of	   these	   tubes,	   10μl	   of	   Brefeldin	   A	   [(BFA;	   5mg/ml)	   to	  prevent	   the	  exocytosis	  of	   cytokine	  production	  containing	  vesicles	  allowing	   for	  the	   visualization	   of	   cytokine	   production	   following	   stimulation],	   10μl	   of	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ionomycin	   and	   12,5μl	   of	   PMA	   (2.5μg/ml)	   or	   PHA	   (2.5μg/ml)	   was	   added,	  together	  with	  5μl	  of	  CD107a.	  These	  tubes	  were	  mixed	  well	  and	  then	  placed	   in	  the	   incubator	   for	   2	   hours	   at	   37°C	   and	   5%	   CO2.	   For	   all	   experiments,	   an	  unstimulated	   control	   tube	   was	   also	   included.	   To	   these	   tubes,	   10μl	   BFA,	   10μl	  Monensin	   (10μg/ml)	   and	   5μl	   CD107a	  was	   added.	   The	   tubes	  were	  mixed	  well	  and	  placed	  in	  the	  incubator	  at	  37°C	  and	  5%	  CO2	  for	  the	  same	  length	  of	  time.	  	  	  After	   stimulating,	   the	   PBMCs	   were	   washed	   twice	   in	   PBS	   by	   centrifuging	   at	  290rcf	   for	   4	   min.	   The	   supernatant	   was	   discarded	   and	   the	   pellet	   was	  resuspended	  in	  50μl	  of	  ViVid	  dye	  (to	  stain	  dead	  cells)	  and	  transferred	  to	  a	  96-­‐well	   V-­‐bottomed	   microtiter	   plate	   (Corning;	   Tewksbury	   MA)	   for	   staining.	   The	  plate	  was	   incubated	   in	  the	  dark	  at	  RT	  for	  20	  min.	  The	  cells	  were	  then	  washed	  twice	  with	   150µl	   PBS	   by	   centrifugation	   at	   887rcf	   for	   5	  min.	   After	   the	   second	  wash,	  the	  PBMCs	  were	  resuspended	  in	  a	  volume	  of	  50μl	  containing	  the	  master-­‐mix	  of	  antibodies	   to	  stain	   for	  extracellular	  markers	   (Table	  2.1).	  The	  plate	  was	  covered	  with	   aluminium	   foil	   and	   incubated	   on	   ice	   for	   20	  min.	   The	   cells	  were	  then	   washed	   twice	   as	   previously	   described.	   To	   enable	   fixation	   and	  permeabilization,	  100µl	  of	  Cytofix/Cytoperm	  (BD	  Biosciences)	  was	  added	  to	  the	  cells	  and	  incubated	  at	  RT	  for	  20	  min.	  Cells	  were	  washed	  twice	  using	  permwash.	  The	  antibody	  cocktail	  against	  (intracellular)	  markers	  (Table	  2.1)	  was	  added	  and	  the	  plate	   incubated	   for	   20	  min	   at	  RT.	   The	  CD3	  T	   cell	  marker	  was	   included	   to	  distinguish	  NK	  cells	  (which	  lack	  expression	  of	  CD3)	  from	  T	  cells	  (which	  express	  high	   levels	   of	   CD3).	   Staining	   for	   CD3	   was	   done	   following	   permeabilisation	  (intracellularly)	  as	  stimulation	  of	  cells	  can	  sometimes	  cause	  the	  internalization	  of	   the	  CD3	  receptor,	  which	   is	  usually	  expressed	  on	  the	  surface	  of	  T-­‐cells.	  Cells	  were	  washed	  twice	  as	  previously	  described.	  Cells	  were	  resuspended	  in	  150µl	  of	  cellfix	  and	  contents	  were	   transferred	   to	   the	  FACS	   tubes	   (BD	  Biosciences).	  The	  wells	  were	  rinsed	  with	  150µl	  of	  cellfix	  and	  added	  to	  the	  tubes.	  All	  the	  samples	  were	   acquired	   within	   6	   hours	   of	   staining	   using	   the	   BD	   LSRFortessa™	   and	  approximately	  500	  000	  events	  were	  acquired	  for	  each	  tube.	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Table	  2.1.	  Antibodies	  included	  in	  the	  optimised	  flow	  cytometry	  panel	  
Fluorochrome	   Antibody	   Clone	   Function	   Manufacturer	  
Extracellular	  
PerCP-­‐Cy5.5	   CD4	  	   L200	   CD4	  T	  cell	  marker	   BD	  Bioscience	  
Qdot	  605	   CD8	   3B5	   CD8	  T	  cell	  marker	   BD	  Bioscience	  
PE	   CD16	   3G8	   Fc	   Receptor	   and	   NK	  cell	  marker	   BD	  Bioscience	  
PE-­‐Cy7	   CD56	   NCAM16.2	   NK	  cell	  marker	   BD	  Bioscience	  
FITC	   CD107a	   H4A3	   LAMP-­‐1	   and	   marker	  of	  degranulation	   BD	  Bioscience	  
PacBlue	  	   CD19	   MHCD1928	   Dump	  channel:	  B	   cell	  marker	   Invitrogen	  
PacBlue	   CD14	   M5E2	   Dump	   channel:	  Monocyte	  marker	   BD	  Bioscience	  
PacBlue	  
	  
Vivid	   	   Dump	   channel:	  Viability	  marker	   BD	  Bioscience	  
Intracellular	  
APC-­‐Cy7	   CD3	   SK7	   T	  cell	  marker	   BD	  Bioscience	  
Alexa	  Fluor	  700	   IFN-­‐γ	   B27	   Functional	  marker	   BD	  Bioscience	  All	  antibodies	  were	  first	  titrated	  to	  determine	  the	  optimal	  amount	  to	  use	  in	  the	  experiment	  (see	  Appendix	  II).	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2.7.2.	  Colour	  compensation	  tubes	  to	  correct	  for	  spectral	  overlap	  During	   multicolor	   flow	   cytometry	   (including	   multiple	   fluorochromes	   against	  distinct	   antigens)	   that	   may	   have	   overlapping	   spectral	   ranges,	   it	   is	   always	  necessary	   to	   include	   compensation	   tubes	   to	   correct	   for	   spectral	   overlap	  (Seddon	  et	  al.,	  2003).	  This	  ensures	  that	  the	  fluorescence	  detected	  by	  a	  particular	  detector	   derives	   solely	   from	   the	   fluorochrome	   conjugated	   on	   the	   specific	  antibody	  and	  not	  from	  fluorochromes	  on	  other	  emission	  spectra.	  For	  each	  of	  the	  fluorochromes	   used	   in	   the	   panel	   (Table	   2.1),	   a	   single-­‐stained	   positive	   control	  tube	  is	  prepared	  containing	  just	  the	  fluorochrome	  of	  interest.	  A	  negative	  control	  (unstained)	  is	  also	  prepared	  to	  set	  voltages	  for	  the	  fluorescence	  channels.	  	  	  For	   the	   panel	   in	   Table	   2.1,	   eight	   compensation	   tubes	   each	   having	   one	   of	   the	  different	   fluorochromes	   were	   prepared	   using	   BD	   CompBeads™.	   BD	   positive	  CompBeads™	  are	  beads	   that	  have	  been	  coupled	   to	  an	  antibody	  specific	  Kappa	  light	  chain	  of	  Ig	  from	  mouse	  or	  rats	  (Bishop	  et	  al.,	  2004).	  The	  beads	  are	  easily	  stained	   and	   have	   a	   robust	   fluorescence	   signal.	   In	   contrast,	   BD	   negative	  CompBeads™	  have	  no	  binding	  capacity.	  The	  positive	  and	  negative	  CompBeads™	  were	  vortexed	  thoroughly	  for	  1	  min	  to	  avoid	  aggregation.	  Using	  5ml	  FACs	  tubes,	  100µl	  of	  PBS	  was	  added	  to	  each	  tube	  followed	  by	  a	  drop	  of	  negative	  and	  positive	  CompBeads™.	  Tubes	  were	  singly	  stained	  with	  the	  corresponding	  volume	  of	  each	  antibody	   that	   had	   been	   used	   during	   the	   staining	   of	   samples,	   followed	   by	  incubation	  on	   ice	   for	  20	  min.	  The	  beads	  were	  washed	  by	  adding	  1ml	  PBS	  and	  centrifuging	   at	   290rcf.	   The	   supernatant	  was	   discarded	   and	   the	   pellet	  was	   re-­‐suspended	   in	   100µl	   of	   1X	   cellfix	   (BD	   Biosciences)	   and	   stored	   at	   4˚C	   until	  acquisition	   with	   the	   BD	   LSRFortessa™.	   The	   CompBeads	   were	   acquired	   along	  with	   the	   PBMCs	   stained	   with	   all	   the	   panel	   antibodies	   using	   the	   optimised	  voltages	  and	  settings.	  During	  analysis	  using	  Flowjo	  (Treestar	  Inc,	  Ashland,	  OR),	  the	   compensation	  matrix	  was	   calculated	   using	   the	   positive	   CompBeads	  while	  the	  unstained	  gated	  on	  the	  negative	  population.	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2.7.3.	  Fluorescence	  Minus	  One	  (FMO)	  controls	  In	  addition	  to	  compensation	  tubes,	  fluorescence	  minus	  one	  (FMO)	  controls	  were	  also	  used	   to	   evaluate	   spill	   over	  of	   fluorescence	   from	  other	   channels	   into	  each	  specific	  channel	  being	  evaluated.	  This	  control	  contains	  all	   fluorochrome	   in	   the	  panel	   except	   the	   one	   being	   measured.	   This	   ensures	   that	   any	   spread	   of	   the	  fluorochrome	  in	  the	  channel	  of	  interest	  is	  properly	  identified.	  One	  would	  expect	  no	   staining	   in	   the	   channel	   for	   which	   the	   antibody	   had	   been	   left	   out.	   The	  presence	   of	   staining	   in	   the	   channel	   for	   which	   the	   antibody	   had	   been	   left	   out	  would	   indicate	   that	   fluorescence	   from	   another	   channel	  was	   spilling	   over	   into	  the	   negative	   channel	   which	   would	   have	   been	   contributing	   to	   a	   false	   positive	  signal	  had	  the	  FMO	  approach	  not	  been	  implemented.	  	  Preparation	  of	  the	  FMO	  controls	  included	  staining	  1x106	  cells	  per	  well	  in	  a	  96-­‐well	  V-­‐bottomed	  plate	  with	  50µl	  of	  vivid.	  The	  plate	  was	  incubated	  at	  RT	  in	  the	  dark	  for	  20	  min.	  Cells	  were	  washed	  twice	  with	  PBS.	  Intracellular	  (CD107a,	  CD3,	  IFN-­‐γ)	  and	  extracellular	  (CD4,	  CD8,	  CD56,	  CD16	  and	  CD107a)	  antibodies	  were	  added	   as	   previously	   described;	   making	   sure	   the	   antibody	   of	   interest	   is	   not	  added.	  The	  cells	  were	  resuspended	  in	  100µl	  cellfix	  and	  transferred	  to	  5ml	  FACS	  tube.	   The	   tubes	   were	   then	   stored	   at	   4˚C	   until	   acquisition	   using	   the	   BD	  LSRFortessa™.	  	  
2.8.	   Collection	   of	   HIV-­‐positive	   plasma	   as	   source	   of	  
antibodies	  for	  ADCC	  PBMCs	  and	  plasma	  were	   isolated	   from	  ACD	  anti-­‐coagulated	  whole	  blood	   from	  HIV-­‐infected	   individuals	   using	   Ficoll-­‐Hypaque	   (Sigma	   Aldrich®)	   density	  gradient	   centrifugation,	   as	   described	   above.	   Plasma	   (5ml)	   from	   the	   top	  of	   the	  gradient	  was	  collected	  using	  a	  plastic	  disposable	  Pasteur	  pipette,	  aliquoted	  into	  1ml	   cryovials	   and	   transferred	   immediately	   into	   a	   -­‐80˚C	   freezer.	   This	   HIV-­‐positive	  plasma	  was	  used	  as	  the	  source	  of	  HIV-­‐specific	  antibodies	  for	  the	  ADCC	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assays	   (Chapter	   4).	   PBMCs	   from	   HIV-­‐positive	   individuals	   were	   collected	   and	  stored	  as	  described	  above.	  	  
2.9.	   Measurement	   of	   HIV-­‐1	   specific	   antibodies	   in	  
plasma	  
2.9.1.	   Measurement	   of	   GP120	   ELISA	   IgG	   concentration	   by	  
sandwich	  ELISA	  To	   quantify	   gp120	   IgG	   titres	   in	   the	   plasma	   from	   HIV-­‐positive	   individuals,	   a	  Corning®	  high	  binding	  ELISA	  plate	  (Sigma-­‐Aldrich®)	  was	  coated	  with	  purified	  envelope	   gp120	   consensus	   C	   (kindly	   donated	   by	   Prof	   Lynn	   Morris,	   NICD,	  Johannesburg)	   at	   a	   concentration	   of	   4µg/ml	   diluted	   in	   bicarbonate	   buffer	  (Sigma-­‐Aldrich®)	   at	   100µl	   per	   well.	   The	   plate	   was	   covered	   with	   film	   and	  incubated	  in	  the	  fridge	  at	  4˚C	  overnight.	  Next,	  the	  wells	  were	  washed	  four	  times	  with	  0.05%Tween-­‐20	   in	  PBS	   (Sigma-­‐Aldrich®).	  Wells	  were	   then	  blocked	  with	  100μl	   of	   5%	   non-­‐fat	   dry	   milk	   in	   PBS/0.05%	   Tween20	   (dilution	   buffer)	   and	  incubated	   at	   37°C	   for	   1	   hour.	   The	   contents	   from	   the	   blocking	   step	   were	  discarded.	  Next,	   a	   3-­‐fold	   serial	   dilution	  of	  HIV-­‐positive	  plasma	   starting	  with	   a	  1:10	   dilution	  was	   carried	   out	   using	   the	   dilution	   buffer.	   Diluted	   plasma	   (50µl)	  was	   then	   added	   to	   the	  wells	   and	  plate	  was	   incubated	   for	   1	   hour	   at	   37˚C.	   The	  wells	  were	  washed	  as	  previously	  with	  0.05%	  Tween	  20/PBS	  and	  50μl	  of	  anti-­‐human	  IgG-­‐HRP	  (1:1000	  dilution	  in	  dilution	  buffer;	  Sigma-­‐Aldrich®)	  was	  added	  to	   each	   well	   and	   incubated	   for	   1	   hour	   at	   37˚C.	   The	   wells	   were	   washed	   as	  previously	   and	   100μl	   of	   1-­‐Step	   Ultra	   TMB-­‐ELISA	   substrate	   (Thermo	   Fisher	  Scientific,	  Waltham,	  USA)	  was	  added	  to	  each	  well	  for	  3-­‐5	  minutes.	  Development	  of	  colour	  was	  stopped	  by	  addition	  of	  25μl	  of	  1H2SO4.	  The	  plate	  was	  read	  on	  the	  VersaMax®	   microplate	   (Molecular	   Devices)	   reader	   using	   the	   SOFTmax	   PRO	  4.3.1	  set	  at	  a	  wavelength	  of	  450nm.	  	  
	   	  
	   49	  
2.9.2.	  Profiling	  of	  HIV-­‐1	  specific	  antibodies	  by	  Western	  Blot	  Western	   blot	   analysis	   was	   carried	   out	   on	   the	   HIV-­‐positive	   samples	   using	   the	  genetic	  systems	  (GS)	  HIV-­‐1	  Western	  Blot	  kit	  (Bio-­‐Rad,	  California,	  USA).	  The	  kit	  provided	  nitrocellulose	  strips	  onto	  which	  HIV-­‐1	  proteins	  fractionated	  by	  SDS	  gel	  electrophoresis	   and	   trans-­‐blotted,	   and	   the	   proteins	  were	   resolved	   into	   bands	  according	  to	  their	  molecular	  weight.	  In	  this	  study,	  the	  nitrocellulose	  strips	  with	  immobilised	   HIV	   proteins	   were	   reacted	   with	   plasma	   from	   HIV-­‐infected	  individuals.	   If	  HIV-­‐specific	   antibodies	   are	  present	   in	   the	  plasma	   samples,	   they	  bound	  to	   their	  corresponding	  viral	  protein	  bands	  which	  were	  visualised	  using	  phosphatase-­‐labeled	  goat	  anti-­‐human	  immunoglobulin	  conjugate,	  followed	  by	  a	  substrate	  for	  the	  enzyme.	  Recognised	  HIV-­‐1	  viral	  proteins	  produce	  bands	  at	  the	  proteins	  indicated	  in	  Figure	  2.2.	  	  	  
	  
Figure	   2.2.	   Western	   blot	   strip	   showing	   the	   position	   of	   each	   HIV	   protein	   band	  
reacting	   to	  plasma	   from	  an	  HIV-­‐seropositive	   individual.	  Three	   envelope	   proteins	  (gp120,	  gp160	  and	  gp41),	  three	  reverse	  transcriptase	  proteins	  (p65,	  p51	  and	  p31)	  and	  four	  poly-­‐proteins	  (p55,	  p51,	  p40	  and	  p18)	  can	  be	  resolved	  using	  this	  kit	  (taken	  from	  www.bio-­‐rad.com).	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According	   to	   the	  manufacturer,	   the	   specimen	  diluent/wash	  buffer	  provided	   in	  the	  kit	  was	  diluted	  1:5	  with	  deionised	  water.	  Specimen/diluent	  wash	  (1ml)	  was	  added	   to	   each	   tray	   (provided	   with	   the	   kit)	   with	   one	   tray	   per	   sample	   being	  tested.	   Plasma	   samples	   (10μl)	   from	   each	   HIV-­‐infected	   individual	   were	   then	  loaded	  into	  the	  tray.	  Using	  a	  clean	  forceps,	  one	  western	  blot	  strip	  was	  put	  into	  each	  trough,	  immersed	  in	  the	  specimen/diluent	  wash,	  and	  incubated	  for	  65	  min	  at	   RT	   on	   a	   96-­‐well	   plate	   shaker	   (Labnet).	   Samples	   were	   carefully	   aspirated	  using	  a	  Pasteur	  pipette	  and	  washed	  four	  times	  with	  the	  specimen	  diluent/wash	  buffer.	   Anti-­‐human	   IgG,	   IgA	   and	   IgM	   (goat)	   alkaline	   phosphatase	   conjugate	  solution	   was	   added	   to	   the	   strips	   immediately	   after	   the	   fourth	   wash	   and	  incubated	  for	  50	  min	  at	  RT	  on	  a	  plate	  shaker.	  Next,	  samples	  were	  aspirated;	  the	  strips	  washed	  and	  soaked	  using	  deionised	  water	  for	  6	  min	  on	  a	  plate	  shaker.	  	  	  The	   deionised	   water	   was	   aspirated	   completely	   from	   each	   trough.	   Color	  development	  reagent	  (5-­‐bromo-­‐4-­‐chloro-­‐3-­‐indolyl	  phosphate)	  was	  added	  for	  4	  min	  at	  RT	  and	  the	  tray	  was	  gently	  rocked	  back	  and	  forth	  twice.	  Aspirating	  the	  color	  development	  reagent	  and	  adding	  deionised	  water	  for	  10	  min	  stopped	  the	  reaction.	   The	   strips	   were	   allowed	   to	   air	   dry	   away	   from	   direct	   light	   to	   avoid	  fading	  before	  reading	  the	  bands.	  To	  compare	  the	  band	  intensity	  of	  the	  proteins,	  the	   strips	   were	   scanned	   into	   the	   computer	   and	   analyzed	   using	   UVIband	  (UVITEC,	  Cambridge,	  UK).	  	  
2.10.	  Measurement	  of	  NK	  cell	  direct	  killing	  of	  K562	  cells	  The	   ability	   of	   NK	   cells	   to	   kill	   target	   cells	   directly	  was	   investigated	   using	   two	  high-­‐throughput	   approaches	   that	   measured	   properties	   of	   the	   target	   cells.	  GranToxilux	  assay	  is	  a	  flow	  cytometry	  based	  approach	  that	  measures	  granzyme	  B	  activity	  (Pollara	  et	  al.,	  2011).	  The	  PanToxilux	  assay,	  a	  more	  recent	  variation	  of	  the	   GranToxilux	   assay,	   measures	   both	   granzyme	   B	   and	   caspase	   activity	  (Packard	  et	  al.,	  2007).	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2.10.1.	  Preparation	  of	  NK	  effector	  cells	  Prior	   to	   the	   GranToxilux	   or	   PanToxilux	   assays,	   PBMCs	   from	   the	   HIV-­‐negative	  donors	  (section	  2.3)	  were	  thawed	  (section	  2.6),	  counted	  (section	  2.4),	  adjusted	  to	  1x106	  cells/ml,	  and	  rested	  overnight	  in	  R10	  at	  37°C	  and	  5%	  CO2.	  Immediately	  before	  the	  assay,	  PBMCs	  were	  assessed	  for	  viability	  and	  only	  those	  with	  >95%	  where	  used	  in	  the	  assay.	  	  	  
2.10.2.	  Preparation	  of	  K562	  target	  cells	  Prior	  to	  the	  assay,	  a	  sub-­‐passage	  of	  K562	  cells	  was	  made	  to	  ensure	  that	  the	  cells	  were	  >95%	  viable	  and	   in	   logarithmic	  phase	  of	  growth.	  The	  GranToxilux	  assay	  kit	  provides	  a	  TFL4	  red	  fluorescent	  probe	  used	  to	  label	  target	  cells,	  and	  NFL1	  as	  a	   viability	   marker	   (Table	   2.2;	   OncoImmunin	   Inc,	   Gaithersburg,	   MD).	   The	  manufacturer	  recommends	  that	  TFL4	  should	  be	  optimised	  for	  the	  specific	  target	  cell	   used.	   To	   determine	   the	   optimal	   amount	   of	   TFL4	   to	   use	   and	   the	   time	  required	   for	   staining,	   K562	   cells	  were	   adjusted	   to	   1x105	   cells/ml	   in	   R10	   and	  labeled	  with	  0.5μl	  or	  1μl	  TFL4	  and	  1μl	  of	  the	  viability	  stain	  NFL1.	  The	  cells	  were	  incubated	  in	  the	  dark	  for	  15	  min	  or	  30	  min	  at	  RT,	  then	  washed	  twice	  with	  wash	  buffer.	  The	  cells	  were	  resuspended	  in	  wash	  buffer	  and	  approximately	  100	  000	  events	  were	  acquired	  using	  the	  BD	  LSRFortessa™.	  	  Once	  the	  optimal	  concentration	  of	  TFL4	  and	  the	  optimal	  staining	  time	  had	  been	  determined,	  control	  tubes	  for	  the	  experiment	  were	  setup.	  Since	  the	  GranToxilux	  and	   PanToxilux	   assays	   do	   not	   require	   compensation	   because	   of	   the	   non-­‐overlapping	   spectral	   properties	   of	   the	   fluorochromes	   used	   (APC,	   PacBlue	   and	  FITC),	  these	  control	  tubes	  were	  used	  to	  set	  the	  flow	  cytometry	  channels	  and	  to	  determine	  the	  background	  activity.	  Briefly,	  1x105	  K562	  cells	  were	  labeled	  with	  TFL4,	   1μl	  NFL1	   and	   75μl	   of	   either	   the	   GranToxilux	   substrate	   (a	   substrate	   for	  granzyme	  B)	  or	  PanToxilux	  substrate	  (a	  substrate	  for	  granzyme	  B	  and	  caspase),	  which	  are	  both	  detected	   in	   the	  FITC	  channel	   (Table	  2.2).	  The	   following	  set	  up	  tubes	  were	  used	  in	  each	  experiment:	  (1)	  K562	  target	  cells	  alone;	  (2)	  K562	  cells	  with	   GranToxilux	   substrate;	   (3)	   K562	   with	   PanToxilux	   substrate;	   (4)	   PBMC	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effectors	  alone;	   (5)	  PBMC	  effectors	  with	  GranToxilux	  substrate;	  and	  (6)	  PBMC	  effectors	  with	  PanToxilux	  substrate.	  The	  cells	  were	  incubated	  at	  RT	  for	  15	  min	  and	   then	   washed	   as	   previously	   described.	   Cells	   were	   resuspended	   in	   wash	  buffer	  and	  approximately	  100	  000	  events	  acquired	  using	  the	  BD	  LSRFortessa.	  
	  
Table	   2.2.	   Markers	   and	   fluorochromes	   included	   in	   the	   GranToxilux	   and	  
PanToxilux	  kits	  
	  	  
2.10.3.	   Measurement	   of	   NK	   cell	   direct	   killing	   with	   the	  
GranToxilux	  and	  PanToxilux	  assays	  Following	  channel	  setting	  of	  APC,	  PacBlue	  and	  FITC	  on	  the	  flow	  cytometry	  using	  the	  control	  tubes,	  an	  experiment	  was	  carried	  out	  to	  measure	  direct	  K562	  target	  cell	   killing	   by	  NK	   cells	   from	  HIV-­‐negative	   donors.	  K562	   cells	   pre-­‐labeled	  with	  TFL4	   and	  NFL1	  were	   combined	  with	   PBMCs	   adjusted	   to	   an	   effector	   to	   target	  ratio	  of	  5:1.	  GranToxilux	  substrate	  (75	  μl)	  or	  PanToxilux	  substrate	  (75	  μl)	  were	  added	   to	   each	   tube.	   In	   addition	   three	   control	   tubes	   were	   included:	   (1)	   K562	  target	  cells	  alone;	  (2)	  K562	  cells	  with	  GranToxilux	  substrate;	  and	  (3)	  K562	  cells	  with	  PanToxilux	  substrate.	  The	  cells	  were	  incubated	  at	  37°C	  5%	  CO2	  for	  60	  min.	  The	   cells	  were	  washed	   twice	   using	  wash	   buffer	   and	   resuspended	   in	   200μl	   of	  wash	  buffer	   for	   acquisition.	   Approximately	   100	  000	   events	  were	   acquired	   for	  K562	   cells	   only,	   and	   the	   whole	   sample	   was	   acquired	   of	   the	   K562	   and	   PBMC	  mixture	   (~500	  000	  events)	  using	   the	  BD	  LSRFortessa.	  The	  data	  obtained	  was	  then	  analyzed	  using	  FlowJo	  software	  (version	  9.7.5;	  Treestar;	  Ashland,	  OR).	  
!
Marker& Fluorochrome& Laser& Detector&
TFL4& APC! Red! 640!nm/40!mW!




	   53	  
2.11.	   Measurement	   of	   NK	   cell	   ADCC	   killing	   of	  
CEM.NKRCCR5	  cells	  Next,	  the	  GranToxilux	  and	  PanToxilux	  assays	  were	  optimised	  to	  investigate	  HIV-­‐specific	  ADCC	  activity	  using	  CEM.NKRCCR5	  target	  cells.	  	  	  
2.11.1.	  Preparation	  of	  NK	  effector	  cells	  Cryopreserved	   PBMCs	   from	   (section	   2.5)	   were	   used	   as	   the	   source	   of	   the	   NK	  cells.	  The	  day	  before	  the	  ADCC	  assay	  was	  to	  be	  performed,	  frozen	  PBMCs	  were	  thawed	  (section	  2.6),	  counted	  (section	  2.4.2),	  adjusted	  to	  1x106/ml,	  and	  rested	  overnight	   in	   R10	   at	   37°C	   and	   5%	   CO2.	   The	   following	   day,	   the	   cells	   were	   re-­‐counted	   for	   viability	   and	   adjusted	   to	   the	   right	   concentration	   to	   obtain	   an	  effector	  to	  target	  ratio	  of	  30:1	  (E:T	  =	  30:1).	  	  
2.11.2.	  Preparation	  of	  CEM	  target	  cells	  Prior	   to	   the	   assay,	   a	   sub-­‐passage	   of	   the	   CEM.NKRCCR5	   target	   cells	   and	   CEM	  control	  cells	  was	  made	  to	  ensure	  that	  these	  cell	  lines	  were	  >95%	  viable	  and	  in	  logarithmic	  phase	  of	  growth.	  To	  confirm	  CCR5	  expression	  by	  CEM.NKRCCR5	  cells,	  they	  were	   initially	  stained	  with	  PE	  anti-­‐human	  CCR5	  antibody	  (Biolegend,	  San	  Diego,	  CA)	  and	  expression	  evaluated	  by	  flow	  cytometry.	  Three	  5ml	  FACS	  tubes	  were	   prepared	   for	   this	   confirmatory	   experiment:	   (1)	   unstained	   CEM.NKRCCR5,	  (2)	  CEM.NKRCCR5	  stained	  with	  PE-­‐conjugated	  CCR5,	  and	  (3)	  CEM	  cells	  (which	  do	  not	   express	   CCR5)	   stained	   with	   CCR5	   (as	   a	   negative	   control).	   To	   each	   tube,	  1x105	  cells	  CEM.NKRCCR5	  or	  CEM	  cells	  were	  added	  suspended	   in	  100μl	  of	  PBS.	  Pre-­‐titrated	  volume	  of	  CCR5-­‐PE	  antibody	  (5μl)	  was	  added	  and	   the	   tubes	  were	  incubated	  at	  4°C	  for	  20	  min.	  Cells	  were	  washed	  twice	  and	  resuspended	  in	  200μl	  cellfix.	  The	  samples	  were	  acquired	  immediately	  with	  the	  BD	  LSRFortessa™	  and	  analyzed	  using	  Flowjo	  (version	  9.7.5;	  Treestar;	  Ashland,	  OR).	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2.11.3.	  Coating	  of	  CEM.NKRCCR5	  target	  cells	  with	  HIV-­‐1	  gp120	  The	  recombinant	  gp120	  HIV-­‐1	  proteins	  representing	  the	  subtype	  C	  (a	  kind	  gift	  from	   Prof	   Lynn	   Morris	   from	   the	   NICD,	   Johannesburg)	   were	   used	   to	   coat	  CEM.NKRCCR5	   target	   cells	   in	   preparation	   for	   the	   ADCC	   assay.	   The	   amount	   of	  recombinant	  gp120	  used	  to	  coat	  the	  target	  cells	  was	  determined	  by	  competitive	  binding	  of	  the	  CD4-­‐FITC	  conjugated	  antibody	  (BioScience,	  San	  Jose,	  USA),	  to	  the	  CD4	  receptor	  expressed	  on	  the	  surface	  of	  the	  CEM.NKRCCR5	  cells.	  Briefly,	  1x106	  CEM.NKRCCR5	  cells	  were	  incubated	  with	  serial	  two-­‐fold	  dilutions	  of	  recombinant	  gp120	   starting	   at	   20μg/ml.	   CEM.NKRCCR5	   cells	   were	   coated	   in	   this	   way	   with	  recombinant	  gp120	   for	  90	  min	  at	  4°C	   in	  R10	  medium.	  The	  cells	  were	  washed	  twice	  and	  stained	  with	  a	  saturating	  concentration	  of	  the	  CD4-­‐FITC	  antibody	  for	  15	   min.	   After	   two	   washes,	   cells	   were	   resuspended	   in	   200μl	   of	   cellfix.	   The	  samples	   were	   acquired	   using	   the	   BD	   LSRFortessa	   and	   analyzed	   using	   Flowjo	  (version	   9.7.5;	   Treestar;	   Ashland,	   OR).	   The	   first	   concentration	   of	   gp120	   to	  reduce	   the	   mean	   fluorescence	   intensity	   (MFI)	   by	   >50%	   of	   the	   uncoated	  CEM.NKRCCR5	  cells	  was	  chosen	  to	  coat	   the	  cells	   in	   the	   final	  assay	  (described	   in	  more	  detail	  in	  Chapter	  4;	  section	  4.2.3).	  	  
2.11.4.	   Measurement	   of	   NK	   cell	   ADCC	   activity	   using	   the	  
GranToxilux	  and	  PanToxilux	  assays	  To	   determine	   the	   optimal	   amount	   of	   TFL4	   to	   use	   and	   the	   time	   required	   for	  staining,	   gp120	  coated	  CEM.NKRCCR5	   cells	  were	  adjusted	   to	  1	  x	  105	   cells/ml	   in	  R10	  and	  labeled	  with	  0.5μl	  or	  1μl	  TFL4	  and	  1μl	  of	  the	  viability	  stain	  NFL1.	  The	  cells	  were	  incubated	  in	  the	  dark	  for	  15	  min	  or	  30	  min	  at	  RT,	  and	  then	  washed	  twice	  with	  PBS.	  	  	  After	  optimising	   the	  concentration	  of	  TFL4	  and	  the	   time	  required	   for	  staining,	  control	  tubes	  to	  set	  the	  APC,	  PacBlue	  and	  FITC	  channels	  on	  the	  flow	  cytometer	  for	   both	   the	   GranToxilux	   and	   PanToxilux	   assays	   were	   setup.	   Briefly,	   1x105	  gp120	  coated	  CEM.NKRCCR5	  cells	  were	  labeled	  with	  TFL4,	  1μl	  NFL1	  and	  75μl	  of	  either	  the	  GranToxilux	  substrate	  or	  PanToxilux	  substrate,	  both	  detected	  in	  the	  
	   55	  
FITC	   channel	   (Table	   2.2).	   Approximately	   1x105	   CEM.NKRCCR5	   target	   cells	   and	  4x105	  PBMC	  effector	  cells	  were	  used	  giving	  an	  effector	  to	  target	  ratio	  of	  5:1.	  The	  following	  tubes	  were	  used	  in	  each	  experiment:	  (1)	  CEM.NKRCCR5	  cells	  alone;	  (2)	  and	  CEM.NKRCCR5	  cells	  with	  GranToxilux	  substrate;	  (3)	  CEM.NKRCCR5	  cells	  with	  PanToxilux	  substrate;	  (4)	  PBMC	  effectors	  with	  GranToxilux	  substrate;	  (5)	  PBMC	  effectors	   with	   PanToxilux	   substrate;	   and	   finally	   (6)	   PBMC	   effectors,	  CEM.NKRCCR5	  cells	  and	  GranToxilux	  substrate	  together;	  and	  (7)	  PBMC	  effectors,	  CEM.NKRCCR5	   cells	  with	   PanToxilux	   substrate	   together.	   The	   CEM.NKRCCR5	   cells	  were	  pre-­‐labeled	  with	  the	  optimal	  TFL4	  concentration	  before	  mixing	  them	  with	  target	  cells.	  The	  plate	  was	  incubated	  for	  15	  min	  in	  CO2	  at	  37°C.	  Cells	  were	  then	  washed	  twice	  in	  PBS	  by	  centrifugation	  at	  2100rp	  for	  5	  min	  and	  acquired	  using	  the	   BD	   LSRFortessa.	   The	   data	   obtained	   was	   analyzed	   using	   FlowJo	   software	  (version	  9.7.5;	  Treestar;	  Ashland,	  OR).	  	  After	   setting	   up	   the	   APC,	   PacBlue	   and	   FITC	   channels,	   the	   ADCC	   assay	   was	  carried	   out.	   Briefly,	   CEM.NKRCCR5	   cells	  were	   coated	  with	   5μg/ml	   recombinant	  gp120	   for	   90	   min	   at	   4°C	   in	   RPMI,	   and	   thereafter	   washed	   using	   R10	   by	  centrifugation	   at	   887rcf	   for	   5	   min.	   CEM.NKRCCR5	   cells	   were	   labeled	   with	   1μl	  TFL4	   and	   1μl	  NFL1	   for	   15	  min	   at	   37°C	   in	  water	   bath	   and	   then	  washed	   twice	  using	   10ml	   R10.	   For	   each	   assay,	   PBMCs	   and	   CEM.NKRCCR5	   cells	  were	   counted	  using	   a	   Guava	   PCA	   counter	   (Guava	   Technologies	   Inc,	   California,	   USA)	   and	  adjusted	  to	  a	  final	  viable	  effector	  to	  target	  ratio	  of	  30:1.	  Next,	  25μl	  of	  each	  target	  (~2x105)	  and	  effector	  (~6x106)	  cell	  suspension	  and	  75μl	  of	  the	  GranToxilux	  or	  PanToxilux	   substrate	   (OncoImmunin	   Inc,	   Gaithersburg,	   MD)	   were	   dispensed	  into	   each	   well	   of	   a	   96-­‐well	   V-­‐bottom	   plate	   according	   to	   the	   manufacturer	  instructions.	   Wells	   containing	   controls	   as	   previously	   described	   were	   also	  included	  for	  this	  experiment.	  The	  plate	  was	  incubated	  at	  RT	  for	  5	  min.	  Twenty	  five	   μl	   of	   1:1000	   dilution	   of	   each	   plasma	   sample	   was	   added	   to	   the	   cell	  suspension	  and	   incubated	   for	  15	  min	  at	  RT.	  The	  plates	  were	  centrifuged	   for	  1	  min	  290rcf,	  and	   incubated	  for	  1	  hour	  at	  37°C	  and	  5%	  CO2.	  After	  washing	  with	  wash	  buffer	   (WB),	  cells	  were	  re-­‐suspended	   in	  150μl	  of	  WB	  and	  transferred	   to	  5ml	  FACS	  tubes.	  The	  cells	  were	  acquired	  using	  the	  BD	  LSRFortessa™	  and	  at	  least	  
	   56	  
500	   000	   events	   were	   acquired.	   Analysis	   was	   performed	   using	   Flowjo	   9.7.5	  software.	  	  	  
2.12.	  Statistical	  analysis	  Statistical	   analysis	   was	   performed	   using	   GraphPad	   Prism	   (version	   6.0;	   San	  Diego).	  The	  non-­‐parametric	  Wilcoxon	  paired	  test	  was	  used	  to	  compare	  matched	  samples	  while	   the	  non-­‐parametric	  Mann-­‐Whitney	  U	   test	  was	  used	   to	  compare	  unmatched	   samples.	   The	   Bland-­‐Altman	   test	   was	   used	   to	   analyze	   agreement	  between	  GranToxilux	  and	  PanToxilux	  assays.	  A	  p-­‐value	  of	  ≤0.05	  was	  considered	  significant.	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3.1.	  Introduction	  NK	  cells	  are	  an	   important	  component	  of	   the	  host	   innate	  response	  during	  both	  viral	   infections	   including	  HIV	   and	   against	   tumor	   cells	   (Jost	   and	   Altfeld,	   2013;	  Valiante	  et	  al.,	  1997).	  NK	  cells	  can	  be	  subdivided	  into	  distinct	  populations,	  based	  on	   their	   expression	   of	   CD56,	   into	   two	  main	   subsets	   -­‐	   CD56Dim	   and	   CD56Bright.	  CD56Dim	  NK	  cells	  represent	  the	  majority	  of	  NK	  cells	  in	  blood	  (~90%),	  are	  potent	  cytotoxic	  cells,	  express	  high	  levels	  of	  perforin	  and	  granzymes	  and	  can	  mediate	  antibody	  dependent	  cytotoxicity,	  while	  CD56Bright	  NK	  cells	  represent	  the	  minor	  population	   of	   NK	   cells	   in	   blood	   (5-­‐10%)	   and	   they	   produce	   cytokines	   such	   as	  IFN-­‐γ	  upon	  stimulation	  (Cooper	  et	  al.,	  2001;	  Smyth	  et	  al.,	  2005).	  In	  addition	  to	  these	  two	  major	  subsets,	  other	  NK	  cell	  subsets	  have	  been	  describe	  which	  do	  not	  express	  CD56	  (CD56-­‐)	  but	  do	  express	  CD16	  (CD16+).	  These	  NK	  cells	  only	  have	  relatively	   weak	   expression	   of	   perforin	   and	   have	   defect	   in	   ADCC	   activity	  (Björkström	   et	   al.,	   2010).	   They	   are	   relatively	   rare	   in	   healthy	   individuals	   but	  elevated	  in	  individuals	  chronically	  infected	  with	  HIV-­‐1	  (Lopez-­‐verge	  et	  al.,	  2010;	  Mavilio	  et	  al.,	  2005;	  Williams,	  2007).	  	  	  NK	  cell	  secretory	  lysosomes,	  containing	  perforin	  and	  granzymes,	  are	  imperative	  for	   cytotoxicity	   because	   their	   release	   results	   in	   the	   induction	   of	   target	   cell	  apoptosis	  (Jiang	  et	  al.,	  2013;	  Krzewski	  et	  al.,	  2013;	  Smy,	  2002).	  When	  NK	  cells	  degranulate	   and	   release	   these	   secretory	   lysosomes	   containing	   perforin	   and	  granzymes	  during	  killing,	  the	  lysosomal	  membranes	  surrounding	  these	  cytolytic	  proteins	   contains	   CD107a,	   which	   is	   expressed	   on	   the	   cell	   surface	   and	   can	   be	  used	  as	  a	  marker	  of	  degranulation	  (Krzewski	  et	  al.,	  2013;	  Penack	  et	  al.,	  2005).	  CD107a	   is	   upregulated	   on	   the	   surface	   of	   activated	   NK	   cells	   and	   assays	   to	  measure	   degranulation,	   based	   on	   CD107a	   expression,	   have	   been	   shown	   to	  correlate	   with	   both	   NK	   cell-­‐mediated	   lysis	   of	   target	   cells	   (measured	   by	   Cr51-­‐release)	  and	  cytokine	  secretion	  (Mata	  et	  al.,	  2014;	  Wren	  et	  al.,	  2012).	  	  	  Different	   approaches	   have	   been	   used	   to	   evaluate	   NK	   cell	   cytotoxicity,	   either	  directly	   or	   indirectly,	   allowing	   a	   comprehensive	   evaluation	   of	   the	   NK	   cell	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function	  (He	  et	  al.,	  2013;	  Mata	  et	  al.,	  2014;	  Morice,	  2007).	  The	  Cr51-­‐release	  assay	  is	  the	  gold	  standard	  in	  evaluating	  cytolytic	  effector	  function	  for	  NK	  cells	  (Chung	  et	   al.,	   2008;	  Mata	  et	   al.,	   2014;	  Richard	  et	   al.,	   2014).	  Recently,	   the	  GranToxilux	  and	   PanToxilux	   flow	   cytometry	   based	   high-­‐throughput	   assays	   have	   been	  developed	   that	   measures	   cytotoxicity	   against	   fluorescent	   labeled	   targets,	  granzyme	  B	  and	  caspase	  loss	  or	  degranulation	  (Alter	  et	  al.,	  2004;	  Pollara	  et	  al.,	  2011).	  When	  evaluating	  direct	  NK	   cell-­‐mediated	   cytotoxicity,	   the	  NK-­‐sensitive	  HLA	  class	  I	  deficient	  K562	  cells	  are	  traditionally	  used	  as	  target	  cells	  (Geiger	  et	  al.,	  2012;	  Koeffler	  and	  Golde,	  1980).	  	  The	   aim	   of	   this	   Chapter	   was	   to	   optimise	   and	   compare	   the	   GranToxilux	   and	  PanToxilux	  assays	  for	  measuring	  NK	  cell	  direct	  killing	  of	  K562	  cells.	  In	  addition	  to	  optimising	  these	  assays	  for	  measurement	  of	  direct	  tumour	  cell	  killing,	  an	  aim	  of	  this	  Chapter	  was	  the	  selection	  of	  a	  suitable	  NK	  cell	  donor	  for	  the	  HIV-­‐specific	  ADCC	  assays	  described	  in	  Chapter	  4.	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3.2.	  Results	  
3.2.1.	  Optimising	  growth	  of	  K562	  target	  cells	  and	  staining	  with	  
the	  nuclear	  marker	  TFL4	  To	  ensure	  that	  the	  K562	  target	  cells	  that	  will	  be	  used	  to	  measure	  NK	  cell	  direct	  killing	  in	  this	  study	  were	  viable	  and	  in	  logorithmic	  phase	  of	  growth	  during	  the	  assay,	   the	   growth	   kinetics	   of	   K562	   cells	   were	   initially	   monitored	   for	   a	   few	  growth	  cycles	  prior	  (Figure	  3.1).	  For	  this	  study,	  K562	  cells	  were	  considered	  to	  be	  in	  log	  phase	  between	  day	  11	  and	  15,	  with	  a	  viability	  of	  >95%	  determined	  by	  Trypan	  blue.	  	  
	  
Figure	  3.1.	  K562	  cells	  growth	  kinetics.	  Cell	  numbers	  and	  viability	  in	  this	  experiment	  were	  counted	  by	  Trypan	  blue	  staining	  and	  manual	  counting.	  Counting	  was	  performed	  every	   day	   from	   days	   1-­‐17.	   The	   experiment	  was	   repeated	   twice,	   and	   the	   dotted	   lines	  indicate	   the	  days	  during	  which	  K562	  cells	  were	   in	   log	  phase	  of	  growth,	  with	  viability	  >95%.	  	  The	   TFL4	   cellular	   fluorophore	   is	   used	   to	   label	   all	   target	   cells	   in	   both	   the	  GranToxilux	  and	  PanToxilux	  assays	   (Packard	  et	  al.,	  2007;	  Pollara	  et	  al.,	  2011).	  To	   optimise	   the	   concentration	   of	   TFL4	   dye	   needed	   to	   label	   K562	   target	   cells,	  cells	  were	  labeled	  with	  either	  0.5μl	  or	  1	  μl	  TFL4	  for	  15	  or	  30	  min	  (Figure	  3.2).	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Labeling	  K562	  cells	  with	  0.5μl	  TFL4	  for	  15	  min	  was	  chosen	  as	  the	  optimal	  target	  cell	   staining	   conditions	   for	   further	   assays.	   The	   volume	  of	   the	   viability	  marker	  NFL1,	   GranToxilux	   fluorogenic	   substrate	   (GzB)	   and	   PanToxilux	   fluorogenic	  substrate	   (PS)	   are	   standard	   for	   any	   target	   cells	   used	   in	   the	   high-­‐throughput	  assays.	  	  
	  
Figure	   3.2.	   Representative	   flow	   cytometry	   plots	   showing	   optimisation	   of	   K562	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To	  set	  the	  gates	  for	  the	  GranToxilux	  and	  PanToxilux	  assays,	  a	  panel	  of	  controls	  were	   used:	   TFL4-­‐K562	   cells	   alone;	   TFL4-­‐K562	  with	   GzB	   substrate	   alone;	   and	  TFL4-­‐K562	  with	  PS	  substrate	  alone;	  PBMCs	  (source	  of	  NK	  effector	  cells)	  alone;	  PBMCs	   with	   GzB	   substrate	   alone;	   and	   PBMCs	   with	   PS	   substrate	   alone.	   The	  gating	   strategy	   used	   for	   the	   GranToxilux	   and	   PanToxilux	   assay	   is	   shown	   in	  Figure	  3.3.	  	  
	  
Figure	   3.3.	   Overview	   of	   the	   gating	   strategy	   used	   for	   the	   GranToxilux	   and	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3.2.2.	   Screening	   of	   NK	   cell	   donors	   for	   direct	   killing	   using	   the	  
GranToxilux	  and	  PanToxilux	  assays	  	  To	   select	   a	   universal	   ADCC	   effector	   NK	   cell	   donor	   for	   this	   study,	   eight	   HIV-­‐negative	  samples	  were	  evaluated	  for	  NK	  cell	  activity	  against	  K562	  targets.	  HIV-­‐negative	  donors	  were	  screened	  as	  universal	  donors	   for	  NK	  cells	   since	   they	  do	  not	   have	   antibodies	   against	   HIV	   that	   could	   confound	   measurement	   of	   ADCC	  activity	  in	  the	  subsequent	  Chapter.	  Briefly,	  PBMCs	  (as	  a	  source	  of	  NK	  cells)	  were	  incubated	  with	  K562	  target	  cells	   in	  presence	  of	   the	  granzyme	  B	  substrate	  (for	  the	   GranToxilux	   assay)	   or	   granzyme	   B	   and	   caspase	   substrate	   (for	   the	  PanToxilux	   assay)	   for	   60	  min	   at	   an	   effector	   to	   target	   ratio	   of	   5:1.	   Figure	   3.4	  summarises	   the	   gating	   strategy	   used	   to	  measure	   direct	   killing	   of	   K562	   target	  cells	   by	   NK	   cells	   in	   the	   GranToxilux	   and	   PanToxilux	   assays.	   The	   results	   are	  expressed	   as	   percentage	   of	   viable	   target	   cells	   staining	   positive	   for	   the	  proteolytically	   active	   form	   of	   granzyme	   B	   (for	   the	   GranToxilux),	   or	   for	  granzyme	   B	   and	   upstream	   caspase	   activity	   (for	   the	   PanToxilux	   assay;	   Figure	  3.4C).	   In	   the	   GranToxilux	   assay,	   granzyme	   B	   activity	   in	   the	   8	   donors	   ranged	  from	  2.0-­‐8.4%.	  The	  highest	  frequency	  of	  direct	  NK	  cell	  activity	  was	  detected	  in	  PBMC	   donor	   F	   (8.4%).	   In	   the	   PanToxilux	   assay,	   the	   frequency	   of	   granzyme	  B	  and	   caspase	   activity	   detected	   in	  K562	   target	   cells	   ranged	  between	  6.9-­‐35.2%,	  with	   the	   highest	   frequencies	   of	   killing	   also	   being	   detected	   in	   PBMC	   donor	   F	  (Figure	  3.4C).	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Figure	  3.4.	  Screening	  for	  NK	  cell	  activity	  for	  direct	  killing	  of	  K562	  target	  cells	  in	  
the	  GranToxilux	   and	  PanToxilux	   assays	   from	  8	  HIV	   seronegative	  PBMC	  donors.	  (A)	   Representative	   flow	   cytometry	   plots	   showing	   gating	   strategy	   to	   identify	   viable	  K562	   cells	   using	   TFL4,	   NFL1	   and	   FITC	   markers.	   (B)	   Representative	   flow	   cytometry	  plots	   showing	   the	   gating	   strategy	   used	   for	   the	   GranToxilux	   (top	   row	   plots)	   and	  PanToxilux	  assays	  (bottom	  row	  plots).	  (C)	  NK	  cell	  frequencies	  of	  granzyme	  B	  (blue	  bar)	  and	   frequencies	   of	   dual	   granzyme	   B	   and	   caspase	   activity	   (red	   bar)	   across	   the	   eight	  donors	   screened.	   This	   experiment	   was	   performed	   only	   once	   so	   no	   error	   bars	   are	  shown.	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Since	   the	   PanToxilux	   assay	   (measuring	   granzyme	   B	   and	   caspase	   activity)	   has	  been	  developed	  by	   the	   same	  manufacturer	   and	  marketed	  as	   a	  modification	  of	  the	   GranToxilux	   assay	   (which	   measure	   granzyme	   B	   activity	   alone),	   the	   two	  assays	  were	   compared	   in	   their	   ability	   to	  measure	   direct	   killing	   of	   K562	   cells	  (Figure	  3.5).	  All	  of	  the	  8	  PBMC	  donors	  showed	  higher	  direct	  cytolytic	  activity	  in	  the	  PanToxilux	  assay	   than	   the	  GranToxilux	  assay	  against	  K562	  cells	   (p=0.007;	  Figure	  3.5A).	  	  A	   Bland-­‐Altman	   statistical	   test	   was	   performed	   to	   evaluate	   whether	   the	   two	  assays	  were	  in	  agreement	  (Figure	  3.5B).	  This	  test	  calculates	  the	  mean	  difference	  between	  two	  assays	  of	  measurement	  (the	  “bias’’)	  and	  95%	  limits	  of	  agreement	  as	  the	  mean	  difference,	  which	  is	  for	  visual	  judgement	  (Bland	  and	  Altman,	  1999).	  If	   the	   bias	   is	   close	   to	   zero,	   then	   the	   assays	   are	   in	   agreement.	   This	   analysis	  showed	  that	  the	  two	  assays	  were	  not	  in	  agreement,	  with	  a	  bias	  of	  –11	  and	  95%	  limits	  of	  agreement	  from	  -­‐29.82	  to	  6.69.	  	  	  
	  
Figure	   3.5.	   Comparison	   between	   the	   GranToxilux	   and	   PanToxilux	   assays	   for	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3.2.3.	  Phenotypic	  and	  functional	  characteristics	  of	  NK	  cells	  from	  
donor	  F	  To	  phenotype	  NK	  cells	   from	  3	  of	  the	  8	  donors	  with	  the	  highest	   levels	  of	  direct	  killing	  against	  K562	  cells,	  PBMCs	  from	  donor	  F,	  E	  and	  H	  were	  stained	  for	  the	  NK	  cell	  markers	  CD56	  and	  CD16	  and	  NK	  cell	  subsets	  evaluated	  by	  flow	  cytometry	  (Figure	  3.6).	  CD56Bright	  CD16-­‐	  NK	  cells	  have	  previously	  been	  reported	  to	  be	  the	  minor	  subset,	  and	   less	  cytotoxic	  NK	  cell	   subsets	   than	  CD56Dim	  CD16+	  NK	  cells	  (Cooper	  et	  al.,	  2001).	  CD56Dim	  CD16+	  NK	  cells	  are	  predominantly	  cytotoxic	  and	  comprise	  ~90%	  of	  human	  NK	  cells	   (Cooper	  et	  al.,	  2001).	   In	  all	  3	  healthy	  HIV-­‐negative	  NK	  cell	  donors,	  CD56Dim	  CD16+	  NK	  cells	  were	  the	  major	  NK	  cell	  subset,	  whereas	  CD56Bright	  CD16-­‐	  NK	  cells	   and	  CD56-­‐	  CD16+	  NK	  cells	  were	   the	  minor	  subsets	  (Figure	  3.6B).	  This	  is	  similar	  to	  previous	  studies	  showing	  that	  ~90%	  of	  NK	   cells	   in	   blood	   were	   CD56Dim	   CD16+	   NK	   cells	   whereas	   only	   ~10%	   were	  CD56Bright	   CD16-­‐	   (Bayigga	   et	   al.,	   2014;	   Björkström	   et	   al.,	   2010;	   Cooper	   et	   al.,	  2001).	  NK	  cells	  expressing	  the	  CD16	  receptor	  (FcγRIIIa)	  are	  the	  major	  effector	  cells	  for	  ADCC	  activity	  (Chapter	  4,	  Cooper	  et	  al.,	  2001),	  thus	  the	  CD56Dim	  CD16+	  NK	  cells	  are	  the	  predominant	  NK	  cell	  subset	  mediating	  ADCC	  activity.	  Since	  the	  CD16	  (FcIIIRγ)	  is	  the	  receptor	  that	  binds	  to	  antibody-­‐coated	  target	  cells	  during	  ADCC,	   its	   high	   level	   of	   expression	   is	   positively	   associated	   with	   ADCC	   activity	  (Hatjiharissi	   et	   al.,	   2007;	   Jia	   et	   al.,	   2013),	   and	   its	   low	   level	   of	   expression	   has	  functional	   consequences	   for	  ADCC	   (Bayigga	  et	   al.,	   2014;	  Lichtfuss	  et	   al.,	   2011;	  Mandelboim	  et	  al.,	  1999).	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Figure	   3.6.	   Flow	   cytometry	   analysis	   of	   CD56Bright,	   CD56Dim	   and	   CD16+	  CD56-­‐	  NK	  
subsets	  in	  PBMCs	  from	  HIV-­‐negative	  individuals.	  (A)	  Representative	  flow	  cytometry	  plot	  showing	  the	  gating	  strategy	  used	  to	  evaluate	  NK	  cell	  phenotypes.	  A	  time	  gate	  was	  set	   to	  exclude	  acquisition	  artefacts,	   followed	  by	  a	  singlets	  gate	  and	  then	   lymphocytes.	  Viable	   CD3-­‐	   NK	   cells	   were	   gated	   on	   and	   these	   CD3-­‐	   viable	   lymphocytes	   were	   then	  assessed	  for	  expression	  of	  CD56	  or	  CD16.	  (B)	  Frequency	  distribution	  of	  NK	  cell	  subsets.	  This	  experiment	  was	  only	  conducted	  once	  so	  no	  error	  bars	  are	  shown.	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To	   further	   characterise	   the	   functional	   ability	   of	   NK	   cell	   subsets,	   PBMCs	   from	  donor	   F	   were	   stimulated	   with	   the	   mitogen	   PHA	   and	   PMA/Ionomycin	   and	  assessed	   for	   their	   ability	   to	   degranulate	   (measured	  by	   expression	   of	   CD107a)	  and	   produce	   cytokines	   (measured	   by	   intracellular	   IFN-­‐γ;	   Figure	   3.7).	   The	  frequency	  of	  NK	  cells	  from	  donor	  F	  that	  have	  degranulated	  (expressed	  CD107a)	  following	   PHA-­‐stimulation	   ranged	   from	   6.0-­‐14.0%	   compared	   to	   2.0-­‐14.0%	  following	  PMA/ionomycin	   stimulation.	   CD56Dim	  CD16+	  NK	   cells	   expressed	   the	  highest	  frequencies	  of	  CD107a+	  cells	  compared	  to	  CD56Bright	  and	  CD16+	  CD56-­‐	  NK	   cells	   (Figure	   3.7B).	   The	   frequency	   of	   NK	   cells	   expressing	   IFN-­‐γ following	  PHA	   stimulation	   ranged	   from	   7.1-­‐31.0%,	   compared	   to	   1.0-­‐4.0%	   following	  stimulation	   with	   PMA/ionomycin.	   CD56Dim	   NK	   cells	   were	   the	   subset	   most	  frequently	   producing	   IFN-­‐γ	   following	   stimulation	   with	   PHA	   (31.0%),	   while	  CD56Bright	   NK	   cells	   were	   the	   subset	   most	   frequently	   producing	   IFN-­‐γ (4.0%)	  when	   stimulated	   with	   PMA/ionomycin.	   It	   was	   interesting	   that	   more	   NK	   cells	  produced	  IFN-­‐γ	  following	  PHA	  stimulation	  than	  PMA/ionomycin	  stimulation.	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Figure	  3.7.	  Functional	  analysis	  of	  NK	  cell	  subsets.	  (A)	  Degranulation	  was	  measured	  by	   the	   expression	   of	   CD107a	   on	   the	   surface	   of	   NK	   cell	   subsets,	   while	   cytokine	  production	  was	  measured	  by	  the	   intracellular	  expression	  of	   IFN-­‐γ.	  This	  repesentative	  plot	  shows	  CD56Dim	  CD16+	  NK	  cell	  subset	  expression	  of	  CD107a	  and	  IFN-­‐γ	  before	  and	  after	  stimulation	  with	  PHA.	  Approximately	  500	  000	  events	  were	  captured	  and	  analyzed	  using	   Flowjo.	   (B)	   NK	   cell	   subsets	   expression	   of	   CD107a	   or	   production	   of	   IFN-­‐γ	  following	   stimulation	   with	   PHA	   or	   PMA/ionomycin.	   Results	   have	   been	   corrected	   for	  background	   measured	   in	   the	   unstimulated	   controls.	   CD56Bright	   CD16-­‐	   NK	   cells	   are	  shown	  as	  green	  bars,	  CD56Dim	  CD16+	  NK	  cells	  are	  shown	  as	  pink	  bars	  and	  CD16+	  CD56-­‐	  NK	  cells	   are	   shown	  as	  orange	  bars.	  This	   experiment	  was	  performed	  only	  once,	   so	  no	  error	  bars	  are	  shown.	  	  	   	  
A.# unstimulated+ stimulated+
0 103 104 105
























0 103 104 105





















































































































































CD107a+PHA+stimulation PMA+stimulationCD107a+ IFN8γ+ IFN8γ+PHA+stimulation PMA+stimulation
B.#
	   69	  
3.3.	  Discussion	  Flow	   cytometry	   based	   assessment	   of	   immune	   cell	   cytotoxicity	   allow	   sensitive	  and	  reliable	  measurement	  of	  in	  vitro	  cytotoxicity.	  Several	  high-­‐throughput	  flow	  cytometry-­‐based	  methods	  have	  been	  used	  for	  detection	  of	  NK	  cell	  activity	  (Alter	  et	  al.,	  2004;	  Chung	  et	  al.,	  2009;	  Gómez-­‐Román	  et	  al.,	  2006;	  Hwang	  et	  al.,	  2012;	  Parsons	  et	  al.,	  2012;	  Thobakgale	  et	  al.,	  2012;	  Wren	  et	  al.,	  2012).	  These	  include	  the	  GranToxilux	  and	  PanToxilux	  assays	   that	  measure	  delivery	  of	   the	   cytotoxic	  granules	   and	   enzymes	   to	   NK	   target	   cells	   (Packard	   et	   al.,	   2007;	   Pollara	   et	   al.,	  2011).	  The	  aim	  of	   this	  Chapter	  was	   to	  optimise	  and	  compare	   the	  GranToxilux	  and	  PanToxilux	  assays	  to	  measure	  direct	  NK	  cell	  killing	  of	  K562	  tumour	  target	  cells.	  	  	  The	  K562	  cell	  line	  has	  been	  widely	  used	  as	  targets	  in	  assays	  to	  measure	  direct	  NK	  cell	  killing	  (Alter	  et	  al.,	  2004;	  Fauriat	  et	  al.,	  2010;	  Garcia-­‐Iglesias	  et	  al.,	  2009;	  Lichtfuss	  et	  al.,	  2011;	  Romee	  et	  al.,	  2013),	  because	  of	  their	  sensitivity	  to	  NK	  cell	  killing.	   NK	   cells	   kill	   by	   releasing	   cytolytic	   granules	   containing	   perforin	   and	  granzymes,	  which	  activates	  caspase	  activity	  during	  interaction	  with	  target	  cells,	  resulting	   in	  granzymes	  and	  caspases	  being	  detectable	   in	  the	  cytoplasms	  of	   the	  target	   cells	   (Caligiuri,	   2008;	   Jost	   and	   Altfeld,	   2013).	   While	   the	   GranToxilux	  substrate	  detects	  granzyme	  B	  activity	   in	   target	  cells,	   the	  PanToxilux substrate	  detects	  granzyme	  B	  and	  caspase	  activity.	  	  	  HIV-­‐negative	  PBMC	  donors	  were	  screened	   for	  selection	  of	  a	  suitable	  universal	  NK	  cell	  donor	  for	  optimisation	  of	  the	  GranToxilux	  and	  PanToxilux	  assays	  in	  this	  Chapter	  and	  for	  use	  in	  ADCC	  assays	  in	  Chapter	  4.	  All	  of	  the	  8	  HIV-­‐negative	  NK	  cell	   donors	   screened	   had	   detectable	   granzyme	   B	   activity	   in	   the	   GranToxilux	  assay	   and	   granzyme	   B	   and	   caspase	   activity	   in	   the	   PanToxilux	   assay	   against	  K562	   cells.	   However,	   the	   PanToxilux assay	   was	   more	   sensitive	   than	   the	  GranToxilux	   assay	   at	   detecting	   direct	   killing	   of	   K562	   cells	   in	   all	   donors,	   with	  significantly	  higher	  levels	  of	  cytotoxicity	  detected	  than	  against	  the	  GranToxilux	  assay.	   This	   is	   likely	   because	   the	   PanToxilux	   detects	   both	   granzyme	   B	   and	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upstream	  caspase	  activity,	  while	  the	  GranToxilux	  assay	  detects	  only	  granzyme	  B	  activity	  (Packard	  and	  Komoriya,	  2008).	  Of	  the	  8	  donors	  screened,	  PBMCs	  from	  donor	   F	   exhibited	   the	   highest	   frequency	   of	   killing	   against	   K562	   target	   cells	  using	  both	  assays	  and	  was	  therefore	  chosen	  as	  a	  universal	  NK	  cell	  donor	  for	  the	  rest	  of	  this	  study.	  	  Expression	   of	   NK	   cells	   phenotypic	   markers	   CD56	   and	   CD16	   and	   functional	  markers	  of	  degranulation	  (CD107a)	  and	  cytokine	  production	  (IFN-­‐γ)	  by	  NK	  cells	  from	   donor	   F	   were	   investigated	   using	   flow	   cytometry	   following	   stimulation	  with	   mitogenic	   PHA	   and	   PMA/ionomycin.	   Like	   previous	   studies	   (Hubert	   and	  Amigorena,	   2012;	   Sansoni	   et	   al.,	   1993;	   Timmons	   and	   Cieslak,	   2008),	   CD56Dim	  were	   found	   to	  be	   the	  major	  NK	  cell	   subsets	   in	  PBMCs	   identified	   in	   this	   study,	  and	   this	   NK	   cell	   subset	   exhibited	   high	   levels	   of	   CD107a	   expression	   following	  stimulation.	  This	  NK	  cell	   subset	  has	  been	  shown	   to	  be	   responsible	   for	  natural	  cytotoxicity	   against	   tumor	   target	   cells	   (Penack	   et	   al.,	   2005).	   Interestingly,	  CD56Dim	   NK	   cells	   also	   expressed	   high	   levels	   of	   IFN-­‐γ following	   PHA	   but	   not	  PMA/ionomycin	  stimulation, compared	  to	  CD56Bright	  NK	  cells,	  which	  are	  known	  to	  be	  the	  most	  potent	  producers	  of	  IFN-­‐γ (Caligiuri,	  2008;	  Cooper	  et	  al.,	  2001).	  In	  T	  cells,	  previous	  studies	  have	  reported	  that	  PHA	  stimulates	  a	  wider	  range	  of	  intracellular	  cytokine	  production	  than	  PMA/ionomycin	  (Baran	  et	  al.,	  2001).	  The	  differences	  observed	  in	  the	  expression	  of	  CD107a	  and	  IFN-­‐γ	  by	  CD16+	  NK	  cells	  following	   stimulation	   with	   either	   PHA	   or	   PMA-­‐/ionomycin	   might	   also	   be	  attributed	   to	   the	   fact	   that	  PMA	  causes	   shedding	  or	   cleavage	  of	  CD16	   from	   the	  cell	   surface,	  which	  would	   result	   in	   failure	   to	   detect	   NK	   cells	   using	   CD16	   as	   a	  marker	  (Huth	  et	  al.,	  2014;	  Romee	  et	  al.,	  2013).	  While	  these	  CD56Dim	  CD16+	  NK	  cells	  are	  the	  subset	  of	  most	  interest	  to	  this	  study	  due	  to	  their	  ability	  to	  mediate	  ADCC	  activity	  via	  their	  FcγIIIa	  receptor	  (CD16),	  it	  is	  notable	  that	  other	  subsets	  (CD56Bright	  and	  CD56-­‐	  CD16+)	  evaluated	  expressed	  CD107a	  and	  IFN-­‐γ.	  	  Direct	  NK	  cell	  cytotoxicty	  against	  tumour	  or	  virally-­‐infected	  cells	   is	  dependent	  on	   both	   phenotypic	   and	   functional	   characteristics	   of	   the	   cell	   (Biron,	   2012;	  Cooper	  et	  al.,	  2001;	  Mandelboim	  et	  al.,	  1999;	  Morice,	  2007).	  NK	  cells	  employ	  a	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variety	   of	   activating	   receptors	   to	   kill	   virally	   infected	   and	   tumour	   cells.	  Prominent	   among	   these	   receptors	   are	   the	   natural	   cytotoxicity	   receptors	  (NKp30,	   NKp44,	   NKp46;De	   Maria	   et	   al.,	   2003;	   Garcia-­‐Iglesias	   et	   al.,	   2009;	  Mavilio	  et	  al.,	  2003).	  NK	  cells	  expressing	  NKp46	  were	  shown	  to	  be	  important	  in	  mediating	   direct	   killing	   of	   tumour	   cells	   (Glasner	   et	   al.,	   2012;	   Hwang	   et	   al.,	  2012).	  	  	  A	  limitation	  of	  this	  study	  was	  that	  the	  PBMCs	  screened	  for	  NK	  cell	  activity	  using	  the	  GranToxilux	  and	  PanToxilux	  assays	  were	  all	  cryopreserved	  prior	  to	  testing.	  Previous	   studies	  have	   shown	   that	   cryopreserved	  PBMCs	  which	  are	  not	   rested	  overnight	   after	   thawing	   have	   decreased	   cytotoxic	   function	   compared	   to	   fresh	  PBMCs	  or	   those	   that	  have	  been	   rested	  appropriately	   after	   thawing	   (Callery	   et	  al.,	  1980,	  Strong	  et	  al.,	  1982,	  Hirsen	  et	  al.,	  1983).	  However,	  PBMCs	  for	  this	  study	  were	   thawed	   the	   day	   before	   the	   GranToxilux	   and	   PanToxilux	   assays	   were	  performed	   and	   allowed	   to	   rest	   overnight	   to	   allow	   cells	   to	   recover	   cytolytic	  functions	  and	   for	  cells	  destined	   for	  apoptosis	   to	  die.	  More	  recent	  studies	  have	  demonstrated	  that	  cryopreservation	  of	  PBMCs	  do	  not	  affect	  cytotoxicity	  if	  they	  are	  allowed	  to	  rest	  in	  media	  for	  more	  than	  5	  hours	  to	  recover	  cytotoxic	  function	  (Gómez-­‐Román	  et	  al.,	  2006;	  Mata	  et	  al.,	  2014;	  Pollara	  et	  al.,	  2011).	  In	  these	  more	  recent	   studies,	   NK	   cells	   obtained	   from	   cryopreserved	   PBMCs	   were	   found	   to	  mediate	  significantly	  higher	  cytolytic	  activity	  compared	  to	  those	  obtained	  from	  fresh	   PBMCs	   (Mata	   et	   al.,	   2014).	   Although	   the	   focus	   of	   this	   Chapter	   was	  selection	  of	  a	  universal	  NK	  cell	  donor	   to	  use	   in	   subsequent	  HIV-­‐specific	  ADCC	  assays	  (Chapter	  4),	  another	  possible	  limitation	  was	  that	  universal	  NK	  cell	  donor	  selection	   was	   based	   on	   measuring	   direct	   NK	   cell	   killing	   which	   may	   not	  completely	  reflect	  their	  cytolytic	  function	  in	  ADCC	  assay.	  	  In	  summary,	  two	  high-­‐throughput	  assays	  for	  measuring	  NK	  cell-­‐mediated	  direct	  cytotoxicity	   against	   a	   tumour	   cell	   line	  K562	  were	   optimised	   and	   compared	   in	  this	   study.	   The	  GranToxilux	   and	   PanToxilux assays	   differed	   in	   their	   ability	   to	  detect	   NK	   cell	   direct	   killing	   of	   K562	   target	   cells,	   with	   the	   PanToxilux	   assay	  (measuring	  granzyme	  B	  and	  caspase	  activity)	  proving	  to	  be	  more	  sensitive	  than	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4.1.	  Introduction	  Although	   several	   different	   assays	   have	   been	   used	   over	   the	   years	   to	   measure	  ADCC	  activity,	   these	  have	   traditionally	  made	  use	  of	   radioactivity	   (Chung	  et	  al.,	  2008;	  Gómez-­‐Román	  et	  al.,	  2006;	  Karnasuta	  et	  al.,	  2005)	  and	   the	  majority	  are	  labour	   intensive	   and	   not	   suited	   to	   high-­‐throughput	   screening	   of	   ADCC	  applicable	   such	   as	   in	   large	   HIV	   trials	   (Alpert	   et	   al.,	   2012;	   Chung	   et	   al.,	   2008;	  Larson	   et	   al.,	   2011).	   High-­‐throughput	   non-­‐radioactive	   assays	   have	   been	  developed	   recently	   that	   are	   less	   labour	   intensive,	   and	   these	   include	   the	  GranToxilux	   and	   PanToxilux	   assays	   .	   The	   GranToxilux assay	   measures	   the	  number	  of	  target	  cells	  into	  which	  granzyme	  B	  has	  been	  delivered	  (Pollara	  et	  al.,	  2011),	   while	   the	   PanToxilux	   assay	   measures	   both	   granzyme	   B	   and	   caspase	  activity	   within	   target	   cells	   (Kute	   et	   al.,	   2012).	   The	   GranToxilux	   assay	   was	  intended	  as	  an	  assay	  which	  detects	  cytotoxicity	  (Packard	  et	  al.,	  2007).	  Pollara	  et	  al.	   (2011)	   subsequently	   modified	   and	   optimised	   it	   to	   detect	   cytotoxicity	  mediated	  by	  HIV-­‐specific	  antibodies.	  To	  my	  knowledge,	   there	  are	  currently	  no	  published	   studies	   using	   the	   PanToxilux	   assay	   to	   measure	   HIV-­‐specific	   ADCC	  responses.	  Therefore,	  the	  same	  modifications	  applied	  to	  the	  GranToxilux	  assay	  by	   Pollara	   et	   al.	   (2011)	   were	   used	   to	   optimise	   the	   PanToxilux	   assay	   in	   this	  study.	  	  	  
One	   of	   the	   challenges	   of	   studying	  ADCC	   during	  HIV	   infection	   has	   always	   been	  choosing	   the	  most	   appropriate	  way	   to	   express	  HIV	   antigens	   on	   the	   surface	   of	  target	   cells	   and	   the	   best	   target	   cells	   to	   use	   (Stratov	   et	   al.,	   2008;	  Wren	   et	   al.,	  2013).	  Several	  studies	  have	  used	  HIV-­‐infected	  CD4	  T	  cells	  as	  targets	  in	  the	  ADCC	  assay	  (Davis	  et	  al.,	  2011;	  Isitman	  et	  al.,	  2011;	  Pegu	  et	  al.,	  2013;	  Smalls-­‐Mantey	  et	  al.,	  2012;	  Tomaras	  et	  al.,	  2013),	  while	  others	  have	  used	  immortalised	  cell	   lines	  coated	  with	  recombinant	  HIV	  proteins	  (Ahmad	  et	  al.,	  2001;	  Chung	  et	  al.,	  2008;	  Pollara	   et	   al.,	   2011;	   Trkola	   et	   al.,	   1999).	   Choice	   of	   ADCC	   target	   cells	   and	   HIV	  antigens	  are	   likely	  to	   influence	  what	   is	  being	  measured,	  as	  target	  cells	  need	  to	  be	   coated	   with	   the	   right	   HIV	   epitopes	   to	   be	   recognised	   by	   ADCC	   antibodies.	  Most	  HIV-­‐specific	  antibodies	  that	  mediate	  ADCC	  that	  have	  been	  identified	  thus	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far	  have	  been	  directed	  against	  specific	  epitopes	  within	  HIV-­‐1	  envelope	  proteins	  gp120	  and	  gp41	  (Table	  1.2;	  Pollara	  et	  al.,	  2013;	  Srisurapanon	  et	  al.,	  2005).	  	  
	  
In	   this	   Chapter,	   the	   immortalised	   cell	   line	   CEM,	   stably	   transfected	  with	   CCR5	  (CEM.NKRCCR5	   cells),	   were	   used	   as	   target	   cells	   as	   they	   can	   be	   either	   infected	  directly	  with	  HIV	  or	  coated	  with	  recombinant	  gp120	  to	  measure	  ADCC.	  The	  aim	  of	   this	  Chapter	  was	   to	  optimise	  and	  compare	   the	  GranToxilux	  and	  PanToxilux	  assays	  for	  measuring	  ADCC	  activity	  to	  HIV.	  
	   	  
	   76	  
4.2.	  Results	  
4.2.1.	   Clinical	   characteristics	   of	   HIV-­‐infected	   individuals	   used	  
for	  antibodies	  Nine	   HIV-­‐positive	   women	   were	   included	   in	   this	   study	   as	   the	   source	   of	   HIV-­‐specific	   antibodies.	   These	   chronically	   infected	   women	   were	   healthy	   despite	  having	   been	   infected	   with	   HIV	   for	   >5	   years,	   maintaining	   CD4+	   T	   cell	   counts	  >300cells/μl	   in	   absence	   of	  HAART.	   Two	   of	   the	  women	  maintained	   viral	   loads	  <50	  RNA	  copies	  per	  ml	  and	  were	  likely	  to	  be	  considered	  to	  be	  HIV	  controllers.	  In	  addition,	   plasma	   from	   6	   HIV-­‐negative	   women	   were	   included	   as	   a	   negative	  controls.	   Table	   4.1	   summarises	   the	   clinical	   characteristics	   of	   the	   HIV-­‐positive	  women	  in	  this	  study.	  	  	  
Table	  4.1.	  Clinical	  descriptions	  of	  the	  HIV-­‐positive	  women	  
	  





!PID! (Years)! (Months)! (RNA!copies/ml)! (cells/µl)!
NY010! 41! 60! <50! 334!
NY040! 41! 78! 7200! 322!
NY064! 27! 84! 930! 383!
NY094! 38! 72! 1700! 465!
NY099! 26! 66! 10000! 525!
NY100! 33! 78! 53000! 778!
NY219! 33! 78! 16000! 551!
NY234! 35! 72! 2600! 680!
NY292! 42! 108! <50! 529!
Median!
[CI]!
35![33:41]! 78![72:78]! 2600![930:10,000]! 525![383:551]!
a!PID!(Participant!Identification);!CI!(Confidence!Intervals)!
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4.2.2.	  Measurement	  of	  HIV-­‐1	  specific	  antibody	  titres	  The	   titre	   of	   HIV-­‐specific	   antibodies	   against	   gp120	   were	   measured	   in	   plasma	  from	  9	  HIV-­‐infected	  and	  6	  HIV-­‐negative	  women	  by	  ELISA	  (Figure	  4.1).	  Plasma	  from	  HIV-­‐negative	  women	  were	  included	  as	  negative	  controls.	  The	  HIV-­‐positive	  individuals	   had	   significantly	   higher	   HIV	   gp120-­‐specific	   antibodies	   than	   HIV-­‐negative	   individuals	   (at	   1:100	   plasma	   dilution,	   p=0.0004;	   at	   1:1000	   plasma	  dilution,	  p=0.0007).	  All	  HIV-­‐infected	  individuals	  had	  detectable	  IgG	  responses	  to	  HIV	   gp120	   and	   were	   therefore	   suitable	   for	   testing	   the	   ability	   of	   this	   sera	   to	  mediate	  ADCC	  activity	  against	  CEM.NKRCCR5	  target	  cells.	  	  
Figure	   4.1.	   Measurement	   of	   gp120	   specific	   IgG	   titres	   by	   ELISA	   in	   plasma	   from	  
HIV-­‐positive	   and	   HIV-­‐negative	   individuals.	   The	   different	   colour	   curves	   represent	  plasma	   IgG	   titres	   for	   the	   HIV-­‐positive	   individuals	   while	   the	   black	   curves	   represent	  plasma	   titres	   for	   the	  HIV-­‐negative	   samples.	  Plasma	  was	  diluted	  using	  a	  10-­‐fold	   serial	  dilutions.	  The	  OD	  wavelength	  used	  was	  450nm.	  Titers	  in	  HIV-­‐positive	  plasma	  differed	  significantly	  from	  HIV-­‐negative	  plasma	  at	  1:100	  and	  1:1000	  dilutions,	   indicated	  in	  the	  figure	  by	  the	  dotted	  lines.	  	  To	   further	   characterise	   the	   breadth	   of	   HIV-­‐specific	   antibodies	   in	   the	   HIV-­‐positive	  women	  plasma	  samples,	  HIV-­‐specific	  western	  blot	  analysis	  was	  carried	  out	   (Figure	   4.2).	   In	   addition	   to	   gp120-­‐specific	   antibodies,	   the	   western	   blots	  show	  that	  all	  9	  HIV-­‐positive	  plasma	  samples	  had	  antibodies	  binding	   to	  gp160,	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p65,	  p55/51,	  p41,	  p40,	  p31,	  p24	  and	  p18	   (Figure	  4.2),	  while	  plasma	   from	   the	  HIV	  negative	  individual	  tested	  did	  not	  bind.	  By	  western	  blot,	  the	  most	  strongly	  recognised	   protein	   in	   all	   HIV-­‐positive	   plasma	   samples	   was	   gp160	   and	   gp41	  followed	   by	   p24	   and	   p55/51.	   Densitometry	   values	   of	   the	   protein	   band	  intensities	   was	   measured	   using	   Uviband	   software	   (UVItec,	   UK),	   and	   relative	  density	  of	  recognition	  of	  each	  HIV	  protein	  was	  expressed	  as	  a	  ratio	  to	  the	  most	  abundent	   protein	   recognised,	   gp160	   (Figure	   4.2B).	   The	   ratio	   of	   gp120:gp160	  was	   a	   median	   of	   0,90	   (1,05-­‐0,80)	   in	   the	   HIV-­‐positive	   samples	   screened.	   This	  analysis	  confirmed	  that	  the	  HIV-­‐positive	  plasma	  samples	  chosen	  to	  optimise	  the	  GranToxilux	  and	  PanToxilux	  assays	  had	  binding	  antibodies	  to	  gp120	  as	  well	  as	  other	  HIV	  antigens.	  	  	  
Figure	  4.2.	  Western	  blot	  profiling	  of	  HIV	  proteins	  recognised	  by	  plasma	  from	  HIV-­‐
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4.2.3.	  Preparation	  of	  target	  and	  effector	  cells	  for	  ADCC	  assays	  	  
4.2.3.1.	  Optimisation	  of	  gp120-­‐	  coating	  of	  CEM.NKRCCR5	  cells	  	  To	  ensure	   that	   the	  CEM.NKRCCR5	   cells	  used	   in	   the	  GranToxilux	  and	  PanToxilux	  ADCC	   assays	   were	   viable	   and	   in	   the	   logarithmic	   phase	   of	   growth,	   growth	  kinetics	  of	  the	  cells	  were	  monitored	  for	  a	  few	  growth	  cycles	  prior	  to	  setting	  up	  the	  experiments	  (Figure	  4.3).	  CEM.NKRCCR5	  cells	  grew	  more	  rapidly	   than	  K562	  cells	  (Chapter	  3),	  used	  to	  measure	  direct	  killing	  by	  NK	  cells.	  CEM.NKRCCR5	  cells	  were	  considered	  to	  be	  in	  the	  log	  phase	  at	  around	  day	  6	  of	  culture	  and	  showed	  good	   viability	   (>95%)	   and	   were	   used	   in	   all	   subsequent	   experiments	   in	   this	  phase.	  	  	  
	  
Figure	  4.3.	  Measurement	  of	   CEM.NKRCCR5	   cells	   growth	  kinetics.	  Cell	   numbers	   and	  viability	  in	  this	  experiment	  were	  counted	  by	  Trypan	  blue	  staining	  and	  manual	  counting.	  Counting	  was	  performed	  at	  days	  1	  until	  9.	  Two	  independent	  experiments	  were	  carried	  out,	  indicated	  by	  the	  different	  colour	  lines.	  The	  dotted	  box	  indicates	  the	  days	  of	  culture	  considered	  to	  represent	  CEM.NKRCCR5	  cells	  in	  log	  phase	  when	  viability	  was	  >95%.	  The	  black	  line	  is	  the	  first	  experiment	  of	  labeling	  CEM.NKRCCR5	  cells,	  while	  the	  blue	  line	  is	  the	  growth	  of	  cells	  used	  for	  the	  ADCC	  experiments.	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CEM.NKRCCR5	  cells	  have	  been	  transfected	  to	  stably	  express	  the	  HIV-­‐1	  co-­‐receptor	  CCR5	   on	   their	   cell	   surface	   (Trkola	   et	   al.,	   1999).	   To	   confirm	   that	   the	   CCR5	  receptor	   was	   expressed	   by	   the	   CEM.NKRCCR5	   cells	   used	   in	   these	   experiments,	  cells	  were	  initially	  stained	  with	  PE	  anti-­‐human	  CCR5	  antibody	  (Figure	  4.4).	  The	  majority	  of	  CEM.NKRCCR5	  cells	  (99.3%)	  expressed	  CCR5	  on	  their	  cell	  surface.	  In	  addition	   to	   CEM.NKRCCR5	   cells,	   CEM	   cells	   were	   also	   included	   as	   a	   negative	  control	  target	  cell	  line.	  CEM	  cells	  do	  not	  express	  CCR5	  (Gervaix	  et	  al.,	  1997)	  and	  this	  was	  confirmed	  by	  flow	  cytometry	  (Figure	  4.4).	  	  	  
	  Figure	  4.4.	  Measurement	  of	  cell	  surface	  expression	  of	  CCR5	  by	  CEM.NKRCCR5	  and	  
CEM	  cells.	  The	  cell	  lines	  were	  examined	  for	  stable	  surface	  expression	  of	  CCR5	  by	  flow	  cytometry.	   Approximately	   100	   000	   events	   were	   captured	   and	   CCR5	   expression	   by	  these	  cells	  was	  assessed	  using	  Flowjo.	  The	  negative	  and	  positive	  gates	  were	  set	  using	  the	  unstained	  control.	  	  After	   determining	   the	   expression	   of	   CCR5	   on	   CEM.NKRCCR5	   cells,	   the	   optimal	  amount	  of	  recombinant	  gp120	  to	  coat	  the	  CEM.NKRCCR5	  cells	  was	  determined	  by	  competitive	  staining	  of	  CD4	  on	  the	  cell	  surface	  of	  CEM.NKRCCR5	  cells	  (according	  to	  the	  method	  described	  by	  Pollara	  et	  al.,	  2011).	  CEM.NKRCCR5.cells	  were	  coated	  with	   varying	   amounts	   of	   gp120	   to	   block	   the	   CD4	   receptor,	   and	   then	  subsequently	   labeled	   with	   a	   standard	   saturating	   concentration	   of	   CD4-­‐FITC	  (Figure	   4.5).	   The	   concentration	   of	   gp120	   that	   reduced	   the	   CD4	   median	  fluorescence	   intensity	   (MFI)	   of	   unstained	   CEM.NKRCCR5	   cells	   by	   ~50%	   was	  chosen	   as	   the	   optimal	   concentration	   to	   coat	   CEM.NKRCCR5	   cells.	   This	   was	  determined	   to	   be	   5μg	   HIV	   subtype	   C	   gp120.	   From	   this	   point	   forward,	   all	   the	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CEM.NKRCCR5	  cells	  used	  in	  all	  experiments	  were	  coated	  with	  5μg	  gp120	  for	  use	  in	  the	  ADCC	  assays.	  	  
	  
Figure	  4.5.	  Titration	  of	  recombinant	  gp120	  for	  coating	  CEM.NKRCCR5	  cells	  in	  order	  
to	  block	  CD4	  antibody	  binding	  in	  the	  ADCC	  assay.	  (A)	  Impact	  of	  recombinant	  gp120	  coating	  at	  varying	  concentrations	  (20,	  10,	  5,	  2.5,	  1.25,	  0.625	  and	  0.3125	  μg)	  on	  changes	  in	   CD4-­‐FITC	   staining,	  measured	   by	   changes	   in	  MFI	   relative	   to	   uncoated	  CEM.NKRCCR5	  cells.	   Five	  μg	   (at	   the	  dotted	   red	   line)	   reduced	   the	  CD4-­‐FITC	   (100%)	  MFI	  by	  54%.	   (B)	  Histogram	  overlay	  of	  uncoated	  and	  gp120	  coated	  (5μg/ml)	  CEM.NKRCCR5	  cells.	  
	  
4.2.3.2.	  Optimisation	  of	  TFL4	  target	  cell	  fluorescent	  marker	  For	  CEM.NKRCCR5	  cells,	  the	  amount	  of	  TFL4	  needed	  to	  stain	  target	  cells	  with	  was	  initially	  optimised.	  TFL4	  is	  a	  red	  fluorescent	  marker	  which	  labels	  the	  target	  cells	  before	   co-­‐incubating	   them	   with	   the	   NK	   effector	   cells.	   Although	   TFL4	  concentrations	  were	  optimised	  for	  K562	  cells	  (Chapter	  3),	  the	  amount	  of	  TFL4	  needed	  to	  be	  optimised	  for	  CEM.NKRCCR5	  cells	  because	  each	  cell	  line	  has	  slightly	  differing	   growth	   kinetics,	   metabolism	   and	   morphology,	   and	   hence	   dye	  permeability	   might	   differ.	   Optimisation	   of	   the	   TFL4	   marker	   was	   carried	   out	  similarly	  to	  the	  K562	  cells.	  Briefly,	  1x106	  gp120	  coated	  CEM.NKRCCR5	  cells	  were	  put	  into	  wells	  with	  either	  0.5μl	  or	  1μl	  TFL4	  for	  15	  min	  or	  30	  min	  (Figure	  4.6).	  The	  optimal	  condition	  of	  TFL4	  chosen	  was	  labelling	  CEM.NKRCCR5	  cells	  with	  1μl	  TFL4	  for	  15	  min.	  At	  this	  concentration,	  CEM.NKRCCR5	  cells	  appeared	  as	  a	  single	  population	   and	   there	   was	   no	   cell	   spread	   compared	   to	   the	   other	   incubation	  conditions.	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Figure	   4.6.	   Optimisation	   of	   TFL4	   staining	   of	   gp120-­‐coated	   CEM.NKRCCR5	   cells.	  A	  time	  gate	  was	  set	  to	  exclude	  any	  technical	  irregularities,	  followed	  by	  a	  singlets	  gate	  to	  exclude	  doublet	   cells.	   Viable	  CEM.NKRCCR5	   cells	  were	   gated	  by	   combining	   staining	   for	  TFL4	   and	   NFL1	   (viability)	   marker	   signals.	   A	   total	   of	   100	   000	   events	   was	   captured.	  Gating	  and	  analysis	  was	  performed	  using	  Flowjo.	  
	  
4.2.3.3.	  Optimisation	  of	  effector	  to	  target	  ratios	  It	   was	   necessary	   to	   optimise	   the	   effector	   to	   target	   ratio	   to	   ensure	   acceptable	  background	   and	   noise	   signal	   ratios	   for	   the	   differing	   substrates	   used	   in	   the	  GranToxilux	   and	   PanToxilux	   assays.	   To	   do	   this,	   the	   ratio	   of	   effectors:targets	  ranging	  from	  5:1	  to	  30:1	  were	  investigated	  (Figure	  4.7).	  In	  both	  the	  GranToxilux	  and	   PanToxilux	   assays,	   30:1	   effector:target	   ratio	   gave	   the	   lowest	   background	  fluorescence	   of	   0.96%	   and	   1.59%	   respectively,	   compared	   to	   the	   other	   ratios	  tested	   (Figure	   4.7B).	  Morever,	   this	   ratio	   has	   been	   reported	   to	   allow	   sensitive	  detection	  of	  ADCC	   responses	   in	  HIV-­‐1	   infected	   individuals	   in	  previous	   studies	  (Pollara	  et	  al.,	  2011).	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Figure	   4.7.	   Optimisation	   of	   effector:target	   ratios	   of	   the	   GranToxilux	   and	  
PanToxilux	   assays.	  Approximately	  500	  000	  events	  were	   captured	  and	  analyzed	  
using	  Flowjo.	   (A)	  From	   the	   combined	  effector	  and	   target	   cell	  population	   in	  plot	  one,	  viable	  target	  cells	  were	  gated	  out	  in	  plot	  two,	  using	  TFL4	  and	  NFL1	  signals.	  Plot	  three	  is	  gating	  on	   the	   target	   cells	  by	   combining	  TFL4	  and	  FITC	   signals	   to	   look	  at	   granzyme	  B	  and	  caspase	  activity.	  (B)	  The	  first	  row	  is	  the	  GranToxilux	  assay	  using	  different	  effector	  to	  target	  ratios	  (5:1-­‐30:1)	  in	  addition	  to	  the	  granzyme	  B	  substrate.	  The	  second	  row	  is	  the	  PanToxilux	  assay	  using	  different	  effector	  to	  target	  ratios	  (5:1-­‐30:1),	   in	  addition	  to	  the	  granzyme	  B	  and	  caspases	  substrate.	  	  
4.2.3.4.	  Optimisation	  of	  HIV-­‐positive	  plasma	  dilutions	  To	  optimise	  the	  concentration	  of	  HIV-­‐positive	  plasma	  to	  use	  as	  a	  source	  of	  HIV-­‐specific	   antibodies,	   plasma	   from	   two	   chronically	  HIV-­‐infected	  women	   (NY040	  and	   NY094;	   Table	   4.1)	   were	   used.	   A	   series	   of	   10-­‐fold	   HIV-­‐positive	   plasma	  dilutions	  was	  carried	  out	  using	  the	  same	  HIV-­‐negative	  NK	  cell	  donor	  (donor	  F,	  section	   3.3.3;	   Chapter	   3)	   to	   determine	   the	   optimum	  plasma	  dilution	   to	   use	   in	  these	   assays.	   Titratable	   granzyme	   B	   activity	   in	   the	   GranToxilux	   assay	   was	  observed	  across	  the	  different	  dilutions	  for	  both	  the	  HIV-­‐positive	  samples	  NY010	  (ranging	  from	  1.77-­‐14%)	  and	  NY094	  (ranging	  from	  3.49-­‐16.50%)	  (Figure	  4.8).	  The	  maximum	  granzyme	  B	  activity	  was	  observed	  at	  a	  1:1000	  plasma	  dilution	  in	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both	   donors	   (Figure	   4.8B).	   HIV-­‐negative	   plasma	   was	   included	   as	   a	   negative	  control	  and	  there	  was	  a	  low	  background	  granzyme	  B.	  All	  samples	  were	  used	  at	  a	  1:1000	  plasma	  dilution	  in	  the	  final	  assays.	  	  
	  
Figure	   4.8.	   Optimisation	   of	   HIV-­‐positive	   plasma	   dilutions	   for	   use	   in	   the	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4.2.4.	  Final	  protocol	   for	   the	  GranToxilux	  and	  PanToxilux	  ADCC	  
assay	  Following	   this	   series	   of	   optimisations	   and	   titrations,	   the	   following	   protocol	  yielded	  the	  most	  optimal	  conditions	  for	  the	  GranToxilux	  and	  PanToxilux	  assays.	  Figure	   4.9	   summarises	   the	   major	   steps	   and	   optimisations.	   For	   all	   further	  experiments,	   CEM.NKRCCR5	   cells	  were	   coated	  with	   5μg/ml	   recombinant	   gp120	  (optimised	   in	   section	  4.2.3.1)	  and	  stained	  with	  TFL4	   for	  15	  min	   (optimised	   in	  section	  4.2.3.2).	  The	  CEM.	  NKRCCR5	  cells	  were	  incubated	  with	  donor	  F	  PBMCs	  (as	  a	   source	   of	   NK	   cells),	   at	   an	   effector:target	   ratio	   of	   30:1	   (optimised	   in	   section	  section	  4.2.3.3),	  in	  the	  presence	  of.1:1000	  dilution	  of	  plasma	  from	  HIV-­‐infected	  individuals	  (optimised	  in	  section	  4.2.3.4).	  	  















Figure	  4.9.	  Overview	  of	  the	  GranToxilux	  and	  PanToxilux	  assays	  indicating	  all	  the	  steps	  optimised	  in	  this	  study.	  The	  CEM.NKRCCR5	  cells	  were	  first	  coated	  with	  the	  optimised	  amount	  of	  gp120	  on	  the	  day	  of	  the	  assay	  before	  being	  used	  in	  both	  the	  GranToxilux	  and	  PanToxilux	  assays.	  The	  first	  step	  was	  optimising	  gp120	  to	  coat	  the	  cells,	  followed	  by	  optimisation	  of	  the	  cell	  markers	  including	  substrates	  for	  GranToxilux	  (GzB)	  and	  PanToxilux	  (PS)	  assays,	  thirdly	  optimisation	  of	  the	  effector:target	  ratio	  and	  lastly	  optimisation	  of	  plasma	  dilutions.	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Figure	  4.10	  shows	  a	  representative	  figure	  of	  the	  GranToxilux	  assay	  showing	  the	  gating	  strategy	  used.	  CEM.NKRCCR5	  cells	  (target	  cells	  alone)	  labeled	  with	  TFL4	  and	  NFL1	  were	  used	  to	  identify	  the	  viable	  cells	  which	  were	  TFL4	  positive	  but	  NFL1	  negative.	  Out	  of	  the	  viable	   CEM.NKRCCR5	   cells,	   granzyme	   B	   positive	   cells	   were	   identified.	   The	   results	   are	  expressed	   as	   %	   granzyme	   B	   (percentage	   of	   CEM.NKRCCR5	   cells	   positive	   for	  proteolytically	  active	  granzyme	  B)	  for	  the	  rest	  of	  the	  study.	  	  
	  
Figure	  4.10.	  Representative	  plots	   showing	   the	  gating	   strategy	  used	   for	   the	  GranToxilux	  
assay.	   (A)	  Target	   cells	  were	  gated	  on	  using	  SSC	  and	  FSC	  plots.	  Next,	   the	  background	  noise	  of	  GzB	   substrate	   (FITC)	   was	   evaluated	   using	   viable	   CEM.NKRCCR5	   (TFL4+NFL1-­‐)	   and	   PBMCs	  without	  plasma	  (B).	  A	  seronegative	  plasma	  sample	  at	  a	  1:1000	  dilution	  (C)	  was	  used	  to	  set	  the	  final	  background	  noise	  with	  plasma	  (NY094).	  (D)	  A	  representative	  HIV-­‐positive	  plasma	  sample	  at	  a	  1:1000	  dilution.	  Approximately	  500	  000	  events	  were	  captured	   for	  each	  assay.	  Gating	  and	  analysis	  was	  performed	  using	  Flowjo.	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Figure	  4.11	  shows	  a	   representative	   figure	  of	   the	  PanToxilux	  assay	  showing	   the	  gating	  strategy	  used.	  Similarly	  to	  the	  GranToxilux	  assay,	  the	  first	  gate	  was	  set	  on	  CEM.NKRCCR5	  cells	   using	   the	   forward	   and	   side	   scatter	   plot.	   Secondly,	   combining	   TFL4	   and	   NFL1	  signals	  gated	  out	  the	  viable	  CEM.NKRCCR5	  cells.	  Thirdly,	  granzyme	  B	  and	  caspase	  activity	  was	  measured	  in	  the	  viable	  CEM.NKRCCR5	  cells	  by	  combining	  TFL4	  and	  FITC	  signals.	  	  	  
	  
Figure	   4.11.	   Representative	   plot	   showing	   the	   gating	   strategy	   used	   for	   the	   PanToxilux	  
assay.	  (A)	  Target	  cells	  were	  gated	  on	  using	  SSC	  and	  FSC	  plots.	  Next	  the	  background	  noise	  of	  PS	  substrate	   (FITC)	   was	   evaluated	   using	   viable	   CEM.NKRCCR5	   (TFL4+NFL1-­‐)	   and	   PBMCs	   without	  plasma	   (B).	   A	   seronegative	   plasma	   sample	   at	   a	   1:1000	   dilution	   (C)	  was	   used	   to	   set	   the	   final	  background	  noise	  with	  plasma.	  (D)	  A	  representative	  HIV-­‐positive	  plasma	  sample	  (NY094)	  at	  a	  1:1000	   dilution.	   Approximately	   500	   000	   events	   were	   captured.	   Gating	   and	   analysis	   was	  performed	  using	  Flowjo.	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4.2.5.	   Comparison	   between	   GranToxilux	   and	   PanToxilux	   assays	   for	  
measuring	  ADCC	  The	  ability	  of	  plasma	  from	  the	  HIV-­‐positive	  donors	  (Table	  4.1)	  to	  mediate	  ADCC	  against	  CEM.NKRCCR5	  target	  cells	  was	  compared	  to	  plasma	  from	  HIV-­‐negative	  donors	  using	  both	  the	  GranToxilux	   and	  PanToxilux	   assays	   (Figure	   4.12).	  Using	   the	  GranToxilux	   assay	   to	  measure	  NK-­‐cell	  mediated	  ADCC	  from	  the	  9	  HIV-­‐positive	  plasma	  donors,	  the	  frequency	  of	   granzyme	   B+	   target	   cells	   ranged	   from	   3.53	   to	   42%.	   In	   contrast,	   the	   frequency	   of	  granzyme	  B+	  target	  cells	  resulting	  from	  HIV-­‐negative	  plasma	  samples	  ranged	  from	  0.10	  to	  1.38%.	  Plasma	  from	  HIV-­‐positive	  donors	  mediated	  significantly	  higher	  ADCC	  killing	  in	   the	   GranToxilux	   assay	   than	   the	   HIV-­‐negative	   donors	   (p=0.0028).	   Using	   the	  PanToxilux	  assay	   to	  measure	  NK-­‐cell	  mediated	  ADCC	   from	   the	  9	  HIV-­‐positive	  donors,	  the	   frequency	   of	   target	   cells	   staining	   positive	   for	   granzyme	   B	   and	   caspase	   activity	  ranged	  from	  7.5	  to	  66.5%	  (Figure	  4.12).	  The	  amount	  of	  granzyme	  B	  and	  caspase	  activity	  induced	   by	   plasma	   from	  HIV-­‐negative	   individuals	   ranged	   from	  1	   to	   6%.	   Plasma	   from	  HIV-­‐positive	   individuals	  mediated	   significantly	   higher	  ADCC	   killing	   than	  HIV-­‐negative	  controls	   (p=0.0004)	   in	   the	   PanToxilux	   assay.	   While	   the	   magnitude	   of	   ADCC	   activity	  measured	   in	   plasma	   from	   HIV-­‐infected	   individuals	   was	   largely	   similar	   between	   the	  GranToxilux	  and	  PanToxilux	  assays,	   the	  background	   level	  of	  ADCC	  detected	   in	  plasma	  from	   HIV-­‐negative	   individuals	   was	   significantly	   higher	   in	   the	   PanToxilux	   than	   the	  GranToxilux	  assay	  (p=0.0043;	  Figure	  4.12A),	  suggesting	  that	  the	  GranToxilux	  assay	  was	  superior	  to	  the	  PanToxilux	  assay	  by	  virtue	  of	  low	  background.	  	  	  The	   Bland-­‐Altman	   test	   was	   used	   to	   compare	   HIV-­‐specific	   ADCC	   activity	  measured	   in	  matched	  plasma	  samples	  using	  the	  GranToxilux	  and	  PanToxilux	  assays	  (Figure	  4.12C).	  The	  average	  bias	  between	  the	  two	  assays	  was	  -­‐2,	  indicating	  that	  these	  two	  assays	  were	  largely	   in	   agreement	   and	   that	   there	   was	   no	   significant	   differences	   between	   these	  methods	   in	   measuring	   ADCC	   in	   the	   HIV-­‐infected	   individuals.	   Of	   the	   9	   HIV-­‐positive	  plasma	  samples	  used	   in	   this	   study,	  2/9	  showed	  noticable	  differences	   in	  ADCC	  activity	  measured	  using	  the	  two	  assays.	  Plasma	  from	  donor	  NY094	  (dark	  blue	  dot;	  Figure	  4.12C)	  resulted	   in	   16%	   granzyme	   B	   activity	   in	   the	   GranToxilux	   assay	   compared	   to	   66%	  granzyme	   B	   and	   caspase	   activity	   detected	   using	   the	   PanToxilux	   assay.	   Plasma	   from	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donor	   NY234	   (lime	   dot;	   Figure	   4.12C)	   resulted	   in	   42%	   granzyme	   B	   activity	   in	   the	  GranToxilux	  assay	  compared	  to	  12%	  detected	  by	  the	  PanToxilux	  assay.	  	  
	  
Figure	  4.12.	   Comparison	  between	   the	  GranToxilux	  and	  PanToxilux	  assays	   for	  detecting	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4.2.6.	   Relationship	   between	   ADCC	   activity,	   antibody	   titres	   and	   HIV	  
clinical	  status	  Previously,	   studies	  have	   reported	   that	  HIV-­‐specific	  ADCC	  activity	  was	  associated	  with	  clinical	  status	  of	  HIV-­‐infected	   individuals,	   including	  a	  positive	  association	  with	  CD4+	  T	  cell	   counts	   and	   a	   negative	   association	   with	   plasma	   viral	   loads	   (Ahmad	   et	   al.,	   2001;	  Johansson	   et	   al.,	   2011;	   Smalls-­‐Mantey	   et	   al.,	   2012).	   In	   this	   study,	   HIV-­‐specific	   ADCC	  activity	  measured	  by	  the	  GranToxilux	  and	  PanToxilux	  assays	  were	  compared	  with	  CD4+	  T	  cell	  counts	  and	  plasma	  viral	  loads	  in	  the	  9	  HIV-­‐positive	  individuals.	  ADCC	  activity	  did	  not	  correlate	  with	  either	  CD4+	  T	  cell	   counts	   (Rho=0.28	  p=0.46	   for	  GranToxilux	  assay;	  Rho=0.20	   p=0.6	   for	   PanToxilux	   assay)	   or	   plasma	   viral	   loads	   (Rho=0.08	   p=0.8	   for	  GranToxilux	  assay;	  Rho=0.16	  p=0.66	  for	  PanToxilux	  assay).	  	  High	   antibody	   titres	   have	   been	   reported	   in	   long-­‐term	   non-­‐progressors	   during	   HIV	  infection	  (Okulicz,	  2012;	  Wren	  et	  al.,	  2013).	  Despite	  the	  HIV-­‐infected	  individuals	  in	  this	  study	  being	  healthy	  despite	  being	   infected	   for	  >5	  years	  with	  broad	   reactivity	   to	  most	  HIV	   proteins	   (measured	   by	   western	   blot),	   no	   correlation	   was	   found	   between	   ADCC	  activity	  and	  titres	  of	  gp120	  antibodies	  (Rho=0.08	  p=0.8	  for	  GranToxilux	  and	  Rho=0.15	  p=0.7	  for	  PanToxilux	  assay).	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4.3.	  Discussion	  In	   this	  Chapter,	   two	  high-­‐throughput	   commercial	   assays	   for	  measuring	  ADCC	  activity,	  the	  GranToxilux	  and	  PanToxilux	  assays	  were	  optimised	  and	  compared.	  The	  GranToxilux	  assay	  detects	  intracellular	  granzyme	  B	  activity	  (Packard	  and	  Komoriya,	  2008;	  Pollara	  et	  al.,	  2011)	  while	   the	  PanToxilux	  assay	  detects	  both	  granzyme	  B	  and	  upstream	  caspase	  activity	   delivered	   by	   NK	   cells	   into	   the	   target	   cells	   (Packard	   and	   Komoriya,	   2008;	  Packard	   et	   al.,	   2007).	  While	   both	   the	   GranToxilux	   and	   PanToxilux	   ADCC	   assays	  were	  useful	   in	  detecting	  HIV-­‐specific	  ADCC	  activity	   in	  plasma	   from	  chronically	  HIV-­‐infected	  individuals,	   the	  higher	  background	  ADCC	  activity	  detected	  by	   the	  PanToxilux	  assay	   in	  the	   HIV-­‐negative	   plasma	   samples	   suggests	   that	   the	   GranToxilux	   assay	   may	   be	   more	  useful	  for	  the	  purposes	  of	  measuring	  HIV-­‐specific	  activity.	  	  The	  pro-­‐apoptotic	  protease	  granzyme	  B	   is	  a	  potent	   inducer	  of	  caspase-­‐dependent	  and	  caspase	   independent	   forms	   of	   target	   cell	   apoptosis	   (Anthony	   et	   al.,	   2010).	   Adding	  caspase	  detection	  could	  increase	  the	  PanToxilux	  assays	  sensitivity,	  since	  it	  detects	  both	  NK	   cell	   released	   granzyme	   B	   and	   target	   cell	   activated	   caspase	   activity.	   While	   both	  upstream	  and	  downstream	  caspases	  are	  activated	  by	  granzyme	  B	  to	   initiate	  apoptosis	  (Afonina	  et	  al.,	  2010;	  Anthony	  et	  al.,	  2010),	  the	  PanToxilux	  assay	  only	  detects	  upstream	  caspase	   activity.	   Interestingly,	   using	   the	   PanToxilux	   assay	   in	   this	   Chapter	   to	   detect	  ADCC	   activity	   (which	   measures	   both	   caspase	   and	   granzyme	   B	   activity)	   was	   not	  significantly	  different	   from	  measuring	  granzyme	  B	  alone	  using	   the	  GranToxilux	  assay.	  Since	  the	  PanToxilux	  assay	  detects	  only	  upstream	  but	  not	  downstream	  caspase	  activity,	  it	   might	   be	   that	   more	   downstream	   caspases	   were	   activated	   to	   initiate	   target	   cell	  apoptosis	   during	   ADCC,	   or	   that	   a	   caspase-­‐independent	   pathway	  might	   have	   been	   the	  major	  pathway	  activated	  during	  ADCC	  activity	  in	  this	  study.	  	  	  HIV-­‐positive	  plasma	  donors	  in	  this	  study	  recognised	  all	  of	  the	  HIV	  proteins	  included	  on	  the	  western	  blot	  strip.	  HIV	  gp160,	  a	  precursor	  glycoprotein	  later	  processed	  into	  gp120	  and	  gp41,	  was	  the	  most	  dominant	  antigen	  recognised	  in	  all	  donors,	  while	  gp120	  was	  the	  least	  dominant	  antigen	  recognised.	  Furthermore,	  the	  HIV-­‐positive	  plasma	  donors	  used	  had	  binding	  IgG	  antibodies	  against	  HIV	  envelope	  gp120	  (assessed	  by	  ELISA).	  Most	  HIV	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epitopes	   targeted	   by	   ADCC	   antibodies	   are	   within	   gp120	   and	   gp41	   (Bonsignori	   et	   al.,	  2012;	   Ferrari	   et	   al.,	   2011;	   Madhavi	   et	   al.,	   2013),	   and	   ADCC	   is	   mediated	   by	   IgG	  antibodies,	  particularly	  IgG1	  and	  IgG3	  (Bruhns	  et	  al.,	  2009;	  Haynes	  et	  al.,	  2011;	  Wren	  et	  al.,	  2013).	  The	  CD16	  receptor	  on	  the	  surface	  of	  NK	  cells	  recognise	  the	  Fc	  region	  of	  these	  antibodies	   bound	   on	   the	   surface	   of	   a	   target	   cell	   expressing	   HIV	   antigens	   (Cox	   et	   al.,	  1999;	  Seidel	  et	  al.,	  2013).	  The	  antibody	  effector	   functions	  can	  be	  affected	  by	  different	  factors	   including	   Fc	   glycosylation.	   The	   exact	   subclass	  within	   the	   IgG	   isotype	  was	   not	  assessed	  further,	  which	  is	  one	  of	  the	  limitations	  of	  this	  study.	  Furthermore,	  antibody	  Fc	  glycosylation,	  which	   influences	   the	   ability	  of	   the	   antibodies	   to	  mediate	  ADCC	  was	  not	  investigated.	  	  HIV-­‐specific	  ADCC	  activity	  measured	  using	  the	  GranToxilux	  and	  PanToxilux	  assays	  did	  not	  correlate	  with	  clinical	  status	  (CD4	  T	  cell	   counts	  or	  viral	   loads)	  of	   the	  HIV-­‐positive	  plasma	   donors	   used	   in	   this	   study.	   However,	   the	   number	   of	   donors	   evaluated	   in	   this	  study	  was	   very	   small	   and	   these	   convenient	   donors	  would	  most	   likely	   be	   classified	   as	  long-­‐term	  non-­‐progressors	  or	  HIV	  controllers.	  Similar	  to	  this	  study,	  Smalls-­‐Mantey	  et	  al.	  (2012),	   using	   the	   GranToxilux	   assay,	   did	   not	   observe	   any	   association	   between	   HIV	  plasma	   viral	   load	   and	   ADCC	   activity	   in	   sera	   from	   HIV-­‐positive	   individuals.	   However,	  ADCC	  activity	  has	  been	  associated	  with	  total	  IgG	  binding	  during	  HIV	  infection	  (Smalls-­‐Mantey	   et	   al.,	   2012).	   This	   is	   in	   contrast	   to	   a	   prior	   study	   which	   found	   a	   positive	  association	   between	   HIV-­‐specific	   ADCC	   activity	   and	   viral	   load	   in	   long	   term	   non-­‐progressors,	  and	  that	  long-­‐term	  non-­‐progressors	  had	  significantly	  lower	  ADCC	  activity	  compared	   to	   viremic	   individuals	   (Ahmad	   et	   al.,	   2001).	   However,	   this	   study	   used	   the	  chromium	   release	   assay	   and	   not	   the	   GranToxilux	   assay.	   A	   study	   by	   Sun	   et	   al.	   (2011)	  reported	  a	  positive	  correlation	  between	  NK	  cell	  mediated	  ADCC	  activity	  and	  SIV-­‐specific	  antibody	  titers	  in	  non-­‐human	  primates.	  	  Choice	  of	   target	   cell	   for	   the	  ADCC	  assay	   is	   an	   important	   consideration	  because	   target	  selection	   provides	   useful	   information	   to	   determine	   immunogenecity	   and	   protective	  quality	  of	  antigens	  detected	  by	  the	  immune	  system.	  The	  target	  cells	  used	  in	  this	  Chapter	  were	   CEM.NKRCCR5	   cells,	   a	   CD4+	   T	   cell	   line	   resistant	   to	   NK	   cell	   killing	   mediated	  cytotoxicity	  receptors	  (Trkola	  et	  al.,	  1999).	  Pollara	  et	  al.	  (2011)	  compared	  gp120-­‐coated	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CEM.NKRCCR5	   cells,	  CEM.NKRCCR5	   cells	   infected	  with	  A1953	  strain	  of	  HIV,	  CEM.NKRCCR5	  cells	  infected	  with	  infectious	  molecular	  clones	  encoding	  HIV	  subtype	  B,	  or	  HIV-­‐infected	  CD4+	  T	  cells	  for	  GranToxilux	  assay.	  They	  concluded	  that	  CEM.NKRCCR5	  cells	  coated	  with	  gp120	   or	   infected	   with	   A1953	   virus	   were	   the	   most	   reliable	   target	   cell	   platforms	   to	  detect	   ADCC	   responses.	   In	   this	   study,	   HIV	   subtype	   C	   (predominant	   in	   Sub-­‐Saharan	  Africa)	  recombinant	  gp120	  was	  chosen	  to	  coat	  the	  CEM.NKRCCR5	  cells	  because	  most	  HIV-­‐specific	  ADCC	  antibodies	  described	  in	  literature	  are	  against	  the	  gp120	  protein	  (Ahmad	  et	   al.,	   2001;	   Ferrari	   et	   al.,	   2011;	   Pegu	   et	   al.,	   2013;	   Trkola	   et	   al.,	   1996).	   Although	   not	  reflecting	  a	  natural	  HIV	  infection	  in	  which	  HIV-­‐infected	  CD4+	  T	  cells	  are	  used	  as	  targets,	  this	  system	  using	  gp120-­‐coating	  CEM.NKRCCR5	  cells	  as	  targets	  provides	  a	  robust	  system	  to	  compare	  the	  GranToxilux	  and	  PanToxilux	  assays.	  Using	  CEM.NKRCCR5	  cells	  as	  targets	  instead	   of	   donor	   CD4+	   T	   cells	   as	   targets	   avoids	   issues	   around	   CD4+	   T	   cell	   donor	  variability	  and	  using	  gp120-­‐coating	  ensured	  a	  more	  even	  spread	  of	  HIV	  antigen	  to	  bind	  with	  HIV-­‐specific	   antibodies	   than	  HIV	   infection,	  where	   not	   all	   of	   the	   target	   cells	  may	  become	  infected	  or	  express	  HIV	  antigens	  on	  their	  cell	  surface	  simultaneously	  (Pollara	  et	  al.,	   2011).	   Therefore,	   this	   Chapter	   focused	   on	   optimisation	   of	   gp120	   coated	  CEM.NKRCCR5	  cells	  to	  measure	  HIV-­‐specific	  ADCC	  activity.	  	  In	   this	   study,	   the	  PanToxilux	   assay	  yielded	  higher	   levels	  of	  background	  ADCC	  activity	  from	   HIV-­‐negative	   plasma	   donors	   than	   the	   GranToxilux	   assay,	   although	   the	   level	   of	  specific	   activity	   was	   similar.	   This	   higher	   level	   of	   background	   ADCC	   activity	   from	   the	  PanToxilux	  assay	  might	  be	  due	  to	  this	  assay	  detecting	  both	  granzyme	  B	  and	  upstream	  caspase	  activity	  compared	  to	   the	  GranToxilux	  assay	  which	  measures	  only	  granzyme	  B	  activity	  (Packard	  and	  Komoriya,	  2008).	  Other	  studies	  have	  reported	  background	  noise	  of	   ~20%	   in	   some	   rapid	   and	   fluorometric	   antibody-­‐dependent	   cellular	   cytotoxicity	  assays	  (Gómez-­‐Román	  et	  al.,	  2006;	  Richard	  et	  al.,	  2014).	  Background	  noise	  of	  ~8%	  has	  been	   reported	   in	   HIV-­‐negative	   samples	   using	   the	   GranToxilux	   assay	   (Pollara	   et	   al.,	  2011),	  which	  is	  in	  line	  with	  or	  slightly	  lower	  than	  the	  levels	  reported	  in	  this	  study.	  To	  my	  knowledge,	   there	   is	   currently	  no	   study	  published	  measuring	  ADCC	  activity	  during	  HIV	  infection	  using	  the	  PanToxilux	  assay,	  so	  the	  PanToxilux	  assay	  background	  can	  only	  be	   compared	   to	   studies	  which	   used	   the	   GranToxilux	   assay	   to	  measure	   ADCC	   activity	  during	  HIV	  infection.	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In	  conclusion,	  I	  have	  optimised	  two	  high-­‐throughput	  assays	  and	  compared	  their	  ability	  to	  measure	  HIV-­‐specific	  ADCC	  activity.	  The	  GranToxilux	   assay	  was	   found	   to	  be	  better	  because	  it	  had	  similar	  specificity	  to	  the	  PanToxilux	  assay	  in	  detecting	  HIV-­‐specific	  ADCC	  activity,	  but	  yielded	  significantly	  lower	  background	  or	  non-­‐specific	  ADCC	  activity.	  
	  Chapter	  5.	  D	  CHAPTER	  5	  
	  
Discussion	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5.1.	  Discussion	  The	   ability	   to	   define	   the	   effectiveness	   of	   ADCC	   responses	   has	   been	   hampered	   by	  traditional	   methods	   which	   are	   labour	   intensive	   and	   time	   consuming,	   make	   use	   of	  radioactive	  labelling	  and	  are	  not	  easily	  used	  for	  high	  throughput	  screening	  (Chung	  et	  al.,	  2008).	  There	  is	  no	  clear	  consensus	  on	  the	  best	  ADCC	  assay	  to	  use	  that	  correlates	  most	  closely	   with	   improved	   outcomes	   for	   HIV	   infection,	   since	   different	   assays	   measure	  overlapping	   functions	   of	   ADCC	   antibodies.	   More	   recent	   high-­‐throughput	   methods	   to	  measure	   ADCC	   activity	   during	   HIV	   infection	   have	   either	   focused	   on	   measuring	  properties	   of	   the	   effector	   NK	   cell	   population	   (Alter	   et	   al.,	   2004;	   Gómez-­‐Román	   et	   al.,	  2006)	  or	  the	  target	  cell	  populations	  (Ferrari	  et	  al.,	  2011;	  Lambotte	  et	  al.,	  2013;	  Pollara	  et	  al.,	  2011;	  Tomaras	  et	  al.,	  2013).	  This	  study	  optimised	  two	  high-­‐throughput	  assays,	  the	  GranToxilux	  and	  PanToxilux,	  to	  measure	  NK	  cell	  direct	  killing	  and	  ADCC	  activity	  during	  HIV	   infection.	   The	  GranToxilux	   assay	   has	   been	  utilised	   before	  measuring	  HIV-­‐specific	  ADCC	   (Ferrari	   et	   al.,	   2011;	   Lambotte	   et	   al.,	   2013;	   Pollara	   et	   al.,	   2011;	   Tomaras	   et	   al.,	  2013),	   however,	   to	  my	   knowledge,	   there	   is	   no	   published	   study	   using	   the	   PanToxilux	  assay	  to	  measure	  HIV-­‐specific	  ADCC.	  	  	  Chapter	   3	   focused	   on	   selection	   of	   an	  HIV-­‐negative	   NK	   cell	   donor	   for	  measuring	   both	  direct	   killing	   and	   ADCC	   activity;	   and	   subsequent	   optimisation	   and	   comparison	   of	   the	  GranToxilux	  and	  PanToxilux	  assays	  to	  measure	  direct	  NK	  killing	  of	  the	  tumour	  cell	  line	  K562.	  NK	  cells	  from	  the	  selected	  universal	  donor	  were	  phenotypically	  and	  functionally	  characterised	   and	   shown	   to	   be	   predominantly	   CD56Dim	   NK	   cells,	   with	   only	   a	   minor	  population	  of	  CD56Bright	  and	  CD16+	  CD56-­‐	  NK	  cells.	  The	  CD56Dim	  NK	  cells	  were	  shown	  to	  degranulate	   (CD107a+)	   more	   than	   the	   other	   two	   subsets	   and	   produce	   more	   IFN-­‐γ	  following	   polyclonal	   stimulation.	   Using	   this	   NK	   cell	   donor,	   findings	   from	   Chapter	   3	  suggest	  that	  the	  PanToxilux	  assay	  was	  more	  sensitive	  at	  detecting	  NK-­‐cell	  direct	  killing	  than	  the	  GranToxilux	  assay,	  yielding	  direct	  killing	  activity	  that	  was	  significantly	  higher;	  and	   that	   there	  was	   poor	   agreement	   between	   the	   assays	   for	  measuring	  NK-­‐cell	   direct	  killing.	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Chapter	   4	   focused	   on	   measurement	   of	   ADCC	   activity,	   using	   the	   GranToxilux	   and	  PanToxilux	   assays,	  mediated	   by	   plasma	   from	  HIV-­‐positive	   individuals	   against	   gp120-­‐coated	   CEM.NKRCCR5	   target	   cells.	   Both	   the	   GranToxilux	   and	   PanToxilux	   assays	   had	  similar	  sensitivity	  in	  detecting	  ADCC	  activity	  using	  HIV-­‐positive	  plasma.	  However,	  lower	  background	  ADCC	  activity	  was	  measured	  from	  HIV-­‐negative	  plasma	  samples	  using	  the	  GranToxilux	  assay	  compared	  to	  the	  Pantoxilux	  assay.	  Despite	  differences	  between	  these	  assays	  in	  background,	  both	  performed	  quiet	  similarly	  at	  detecting	  HIV-­‐specific	  NK-­‐cell	  mediated	  ADCC	  killing	  in	  this	  study	  and	  were	  shown	  to	  be	  in	  agreement.	  	  
5.2.	   Proposed	   model	   for	   the	   differences	   in	   performance	   of	  
these	  assays	  NK	   cells	   can	  mediate	   cytotoxicity	   through	  different	   receptors	   and	  different	   pathways.	  NCRs	  on	  NK	  cells	  have	  been	  reported	  to	  play	  a	  major	  role	   in	  NK	  cell	  direct	  killing	  (De	  Maria	   et	   al.,	   2003;	   Garcia-­‐Iglesias	   et	   al.,	   2009;	   Mavilio	   et	   al.,	   2003),	   while	   the	   CD16	  receptor	  mediate	  ADCC	  by	  binding	   to	   the	  Fc	   region	  of	   the	  antibodies	   (He	  et	  al.,	  2013;	  Johansson	  et	  al.,	  2011;	  Mandelboim	  et	  al.,	  1999).	  This	  study	  found	  that	  the	  GranToxilux	  and	  PanToxilux	  assays	  differed	   in	  sensitivity	  to	  measure	  NK	  cell	  direct	  killing	  of	  K562	  cells,	   but	  were	   largely	   similar	   at	  measuring	  HIV-­‐specific	  ADCC	  activity	   against	   gp120-­‐coated	  CEM.NKCCR5	  target	  cells.	  The	  disparate	  finding	  in	  sensitivity	  might	  be	  because	  of	  the	  differences	  in	  NK	  cell	  direct	  killing	  of	  tumor	  cell	  compared	  to	  NK	  cell	  ADCC	  killing	  mechanism.	  	  	  During	  direct	  killing,	  granzyme	  B	  released	  by	  degranulating	  NK	  cells	  might	  activate	  the	  caspase-­‐dependent	   pathway	   to	   induce	   tumour	   target	   cell	   apoptosis.	   Therefore,	   the	  detectation	  of	  both	  granzyme	  B	  and	  upstream	  caspases	  by	  the	  PanToxilux	  assay	  might	  make	  it	  more	  sensitive	  compared	  to	  the	  GranToxilux	  assay	  which	  only	  detects	  granzyme	  B.	   In	   contrast,	   during	   ADCC,	   the	   released	   granzyme	   B	   might	   alternatively	   activate	  apoptosis	   through	   a	   caspase-­‐dependent	   pathway	   or	   a	   caspase-­‐independent	   manner	  which	   preferentially	   activates	   more	   downstream	   caspases	   not	   detected	   by	   the	  PanToxilux	  assay	  (which	  measures	  only	  upstream	  caspase	  activity).	  Since	  direct	  NK-­‐cell	  killing	   does	   not	   require	   activation	   through	   antibodies,	   caspases	   may	   be	   activated	  
	   98	  
quickly	   and	   detected	   by	   the	   PanToxilux	   compared	   to	   ADCC.	   Furthermore,	   the	  interaction	  of	  K562	  cells	  with	  the	  NK	  cells	  inhibitory	  and	  activating	  receptors	  may	  lead	  to	  a	  stronger	  cumulative	  activating	  signal	  that	  may	  stimulate	  the	  release	  of	  IFN-­‐γ	  by	  NK	  cells.	  This	  may	  induce	  surface	  expression	  of	  the	  FAS-­‐L	  receptors	  on	  K562	  cells	  leading	  to	   elevated	   caspase	   production	   and	   therefore	   enhanced	   sensitivity	   of	   the	   PanToxilux	  assay.	   Alternatively,	   the	   differences	   in	   performance	   between	   the	   GranToxilux	   and	  PanToxilux	  assay	  may	  reflect	  differences	  in	  the	  target	  cells	  used.	  CEM	  target	  cells	  used	  in	   the	  ADCC	  assay	  may	  not	  activate	  upstream	  caspases	  as	  efficiently	  or	  with	   the	  same	  kinetics	   as	   K562	   cells	   used	   in	   the	   direct	   killing	   assay.	   This	   proposed	   model	   is	  summarised	  in	  Figure	  5.1.	  	  	  
	  
Figure	   5.1.	   Proposed	  model	   to	   explain	   differences	   in	   the	   sensitivity	   of	   the	  GranToxilux	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5.3.	  Potential	  limitations	  of	  this	  study	  PBMCs	  were	  used	  as	  the	  source	  of	  effector	  NK	  cells	  and	  not	  purified	  NK	  cells.	  In	  addition	  to	   having	   about	   15%	   NK	   cells,	   PBMCs	   could	   also	   contain	   20%	   neutrophils	   and	   15%	  monocytes	   which	   have	   also	   been	   reported	   to	   mediate	   ADCC	   during	   HIV	   infection	  (Smalls-­‐Mantey	  et	  al.,	  2013),	  and	  might	  have	  contributed	  to	  the	  ADCC	  activity	  measured	  in	  this	  study.	  Selection	  of	  the	  universal	  NK	  cell	  donor	  was	  based	  on	  NK	  cell	  direct	  killing	  of	   K562	   following	   polyclonal	   stimulation	   with	   PMA/ionomycin	   or	   PHA,	   but	   the	  mechanism	  by	  which	  NK	  cells	  kill	  K562	  cells	  may	  differ	   from	  the	  mechanism	  they	  use	  for	  ADCC.	   Inhibitory	   receptors	  on	  NK	   cells	   recognise	   tumour	   cells	   lacking	  HLA	   class	   I	  (missing	   self;	   Long	   2002),	   which	   then	   interacts	   with	   activating	   receptors	   to	   activate	  granzyme	  B	  and	  caspase	  activity,	  while	  during	  ADCC,	  granzyme	  B	  and	  caspase	  activity	  is	  activated	  by	  the	  cross-­‐linking	  of	  the	  FcγRIIIa activating receptor. So	  it	  is	  possible	  that	  the	  ability	  of	  NK	  cells	  to	  directly	  kill	  K562	  tumour	  cells	  does	  not	  reflect	  their	  potency	  to	  kill	  antigen-­‐coated	  target	  cells	  in	  an	  ADCC	  assay.	  It	  may	  have	  been	  better	  to	  use	  a	  broader	  evaluation	  of	  NK	  cell	  activity	  in	  selection	  of	  the	  universal	  donor,	  such	  as	  evaluating	  NK	  cell	   performance	   against	   HIV-­‐coated	   CEM.NKRCCR5	   target	   cells	   or	   their	   ability	   to	  degranulate	  in	  response	  to	  HIV	  antigens.	  In	  addition,	  antibodies	  with	  known	  good	  ADCC	  activity	  such	  as	  the	  well-­‐characterized	  A32	  monoclonal	  antibody	  should	  have	  been	  used	  to	  screen	  the	  panel	  of	  NK	  cell	  donors	  for	  ADCC	  activity.	  Donor	  to	  donor	  variation	  in	  NK	  cell	  activity	  are	  likely	  to	  influence	  the	  results,	  as	  the	  amount	  of	  granzyme	  B	  and	  caspase	  produced	   by	   a	   chosen	   NK	   cell	   donor	   is	   dependent	   on	   the	   ability	   of	   NK	   cells	   to	   be	  activated,	   inhibited,	   to	   bind	   antibodies	   and	   to	   effeciently	   release	   cytolytic	   granules	   to	  kill	  target	  cells	  (Alpert	  et	  al.,	  2012;	  Davis	  et	  al.,	  2011).	  These	  donor	  NK	  cells	  studied	  in	  this	  dissertation	  were	  not	  phenotyped	   for	   the	  activating	  and	   inhibiting	   receptors,	   and	  the	   net	   result	   of	   activating	   and	   inhibitory	   receptor	   engagement	   are	   likely	   to	   also	  influence	  NK	  cell	  ability	  to	  mediate	  ADCC.	  Moreover,	  the	  frequency	  of	  NK	  cells	  was	  not	  assessed	   and	   the	   FcγRIIIa	   receptor	  was	   not	   genotyped	   for	   polymorphisms	   that	   could	  influence	  ADCC	  activity	  (Wren	  et	  al.,	  2013b).	  
	  Although	   gp120-­‐coated	   CEM.NKRCCR5	   target	   cells	   have	   been	   reported	   to	   be	   reliable	  target	  cells	  for	  measuring	  ADCC	  activity	  (Pollara	  et	  al.,	  2011),	  use	  of	  gp120	  alone	  instead	  of	  virally-­‐infected	  cells	  or	  coating	  with	  other	  HIV	  antigens	  was	  a	  possible	   limitation	  in	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this	   study.	   Some	  ADCC	   epitopes	   are	   found	   on	   gp41	   as	  well	   as	   on	   other	  HIV	   proteins,	  therefore	  antibodies	  that	  target	  epitopes	  other	  than	  the	  ones	  on	  gp120	  may	  have	  been	  missed.	  HIV-­‐specific	  antibodies	  from	  plasma	  of	  HIV-­‐positive	  individuals	  were	  quantified	  using	  gp120	  ELISA	  and	  western	  blot	  analysis,	  both	  of	  which	  measured	  IgG	  titres.	   IgG1	  and	   IgG3	  have	   been	  described	   as	   the	  most	   common	   IgG	   isotype	   to	  mediate	  ADCC	   via	  strong	   CD16	   interactions	   (Chung	   et	   al.,	   2008).	   During	   HIV	   infection,	   anti-­‐Env	   plasma	  antibodies	  are	  predominantly	  IgG1	  subclass,	  whereas	  anti-­‐Env	  IgG3	  is	  the	  second	  most	  predominant	   IgG	  subclass	  and	  had	  been	  shown	  to	  decline	   in	   individuals	   infected	  with	  HIV	  for	  more	  than	  five	  years	  (Yates	  et	  al.,	  2011).	  The	  amount	  of	  IgG	  subclasses	  was	  not	  quantified	   in	   this	   study.	   Furthermore,	   antibody	   functions	   can	   be	   affected	   by	   other	  factors,	  such	  as	  polymorphisms	  which	  increases	  IgG	  affinity	  to	  the	  CD16	  receptor,	  which	  were	  not	  evaluated	  in	  this	  study	  (Bruhns	  et	  al.,	  2009;	  Boyd	  et	  al.,	  1996;	  Shinkawa	  et	  al.,	  2003).	   In	  previous	  studies	  using	   the	  GranToxilux	  assay	   to	  measure	  HIV-­‐specific	  ADCC	  activity,	   HIVIG	   immunoglobulin	   has	   been	   used	   as	   a	   positive	   HIV-­‐specific	   antibody	  control	   (Bonsignori	   et	   al.,	   2012;	   Ferrari	   et	   al.,	   2011;	   Lambotte	   et	   al.,	   2013).	  Alternatively,	   the	   HIV	   monoclonal	   antibody	   A32	   has	   also	   been	   reported	   to	   mediate	  potent	  ADCC	  activity	  and	  has	  been	  used	  as	  a	  positive	  control	  (Ferrari	  et	  al.,	  2011).	  There	  was	  no	  positive	  HIV-­‐specific	  antibody	  control	  used	  in	  this	  study	  with	  known	  properties	  or	  performance	  in	  ADCC	  assays.	  	  
5.4.	  Conclusion	  The	  GranToxilux	   and	   PanToxilux	   high-­‐throughput	   flow	   cytometry	   based	  ADCC	   assays	  were	  optimised	  and	  compared	  to	  measure	  direct	  NK	  cell	  killing	  and	  HIV-­‐specific	  ADCC	  activity.	  While	  the	  PanToxilux	  assay	  was	  more	  sensitive	  at	  measuring	  direct	  killing	  than	  the	  GranToxilux	  assay,	  both	  assays	  were	  similar	  in	  detecting	  ADCC	  activity	  in	  plasma	  of	  HIV-­‐infected	   individuals.	   However,	   lower	   background	   activity	   was	   measured	   by	   the	  GranToxilux	   assay	  using	  HIV-­‐negative	   control	  plasma	   than	   the	  PanToxilux	  assay.	  This	  study	  suggests	  that	  both	  the	  GranToxilux	  and	  PanToxilux	  assays	  represent	  simple,	  rapid	  and	  reliable	  flow	  cytometry	  based	  high-­‐throughput	  assays	  to	  study	  HIV-­‐1	  gp120	  specific	  ADCC	  responses	  using	  gp120-­‐coated	  CEM.NKRCCR5	  cells,	  although	  the	  GranToxilux	  assay	  out-­‐performed	  the	  PanToxilux	  assay	  in	  its	  ability	  to	  measure	  HIV-­‐specific	  ADCC	  activity.	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In	  conclusion,	  ADCC	  in	  vivo	  is	  enormously	  complex	  and	  very	  few	  assays	  can	  provide	  an	  accurate	   reflection	   of	   the	   combined	   features	   of	   an	   individual’s	   unique	   target	   cell,	  antibody	   and	   effector	   cell	   interactions	   that	   give	   an	   overall	   snapshot	   of	   their	   all-­‐encompassing	  ADCC	  capability.	  	  
	   i	  
REFERENCES	  
	  
Aasa-­‐chapman,	  M.M.I.,	  Holuigue,	  S.,	  Aubin,	  K.,	  Wong,	  M.,	  Jones,	  N.A.,	  Cornforth,	  D.,	  Newton,	  P.,	  Williams,	  I.,	  Aasa-­‐chapman,	  M.I.,	  Pellegrino,	  P.,	  Borrow,	  P.,	  2005.	  Detection	  of	  Antibody-­‐Dependent	  Complement-­‐Mediated	  Inactivation	  of	  both	  Autologous	  and	  Heterologous	  Virus	  in	  Primary	  Human	  Immunodeficiency	  Virus	  Type	  1	  Infection	  Detection	  of	  Antibody-­‐Dependent	  Complement-­‐Mediated	  Inactivation	  of	  both	  Autologous	  and	  Het.	  J.	  Virol.	  75,	  2823–2830.	  	  Ackerman,	  M.E.,	  Dugast,	  A.-­‐S.,	  Alter,	  G.,	  2012.	  Emerging	  concepts	  on	  the	  role	  of	  innate	  immunity	  in	  the	  prevention	  and	  control	  of	  HIV	  infection.	  Annu.	  Rev.	  Med.	  63,	  113–130.	  	  Ackerman,	  M.E.,	  Dugast,	  A.-­‐S.,	  McAndrew,	  E.G.,	  Tsoukas,	  S.,	  Licht,	  A.F.,	  Irvine,	  D.J.,	  Alter,	  G.,	  2013.	  Enhanced	  phagocytic	  activity	  of	  HIV-­‐specific	  antibodies	  correlates	  with	  natural	  production	  of	  immunoglobulins	  with	  skewed	  affinity	  for	  FcγR2a	  and	  FcγR2b.	  J.	  Virol.	  87,	  5468–5476.	  	  Afonina,	  I.S.,	  Cullen,	  S.P.,	  Martin,	  S.J.,	  2010.	  Cytotoxic	  and	  non-­‐cytotoxic	  roles	  of	  the	  CTL/NK	  protease	  granzyme	  B.	  Immunol.	  Rev.	  235,	  105–116.	  	  Ahmad,	  R.,	  Sindhu,	  S.T.,	  Toma,	  E.,	  Morisset,	  R.,	  Vincelette,	  J.,	  Menezes,	  J.,	  Ahmad,	  A.,	  2001.	  Evidence	  for	  a	  correlation	  between	  antibody-­‐dependent	  cellular	  cytotoxicity-­‐mediating	  anti-­‐HIV-­‐1	  antibodies	  and	  prognostic	  predictors	  of	  HIV	  infection.	  J.	  Clin.	  Immunol.	  21,	  227–233.	  Alpert,	  M.D.,	  Heyer,	  L.N.,	  Williams,	  D.E.J.,	  Harvey,	  J.D.,	  Greenough,	  T.,	  Allhorn,	  M.,	  Evans,	  D.T.,	  2012.	  A	  novel	  assay	  for	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity	  against	  HIV-­‐1-­‐	  or	  SIV-­‐infected	  cells	  reveals	  incomplete	  overlap	  with	  antibodies	  measured	  by	  neutralization	  and	  binding	  assays.	  J.	  Virol.	  86,	  12039–12052.	  	  Alter,	  G.,	  Malenfant,	  J.M.,	  Altfeld,	  M.,	  2004.	  CD107a	  as	  a	  functional	  marker	  for	  the	  identification	  of	  natural	  killer	  cell	  activity.	  J.	  Immunol.	  Methods	  294,	  15–22.	  	  Alter,	  G.,	  Moody,	  M.A.,	  2010.	  The	  humoral	  response	  to	  HIV-­‐1:	  new	  insights,	  renewed	  focus.	  J.	  Infect.	  Dis.	  202,	  315–322.	  	  Altfeld,	  M.,	  Fadda,	  L.,	  Frleta,	  D.,	  Bhardwaj,	  N.,	  2011.	  DCs	  and	  NK	  cells:	  critical	  effectors	  in	  the	  immune	  response	  to	  HIV-­‐1.	  Nat.	  Rev.	  Immunol.	  11,	  176–186.	  	  Anthony,	  D.	  a,	  Andrews,	  D.M.,	  Watt,	  S.	  V,	  Trapani,	  J.	  a,	  Smyth,	  M.J.,	  2010.	  Functional	  dissection	  of	  the	  granzyme	  family:	  cell	  death	  and	  inflammation.	  Immunol.	  Rev.	  235,	  73–92.	  	  	  
	   ii	  
Archary,	  D.,	  Rong,	  R.,	  Gordon,	  M.L.,	  Boliar,	  S.,	  Madiga,	  M.,	  Gray,	  E.S.,	  Dugast,	  A.,	  Hermanus,	  T.,	  Goulder,	  P.J.R.,	  Hoosen,	  M.,	  2013.	  Characterization	  of	  anti-­‐HIV-­‐1	  neutralizing	  and	  binding	  antibodies	  in	  chronic	  HIV-­‐1	  subtype	  C	  infection.	  Virology.	  433,	  410–420.	  	  Baba,	  M.,	  Miyake,	  H.,	  Okamoto,	  M.,	  Iizawa,	  Y.,	  Okonogi,	  K.,	  2000.	  Establishment	  of	  a	  CCR5-­‐expressing	  T-­‐lymphoblastoid	  cell	  line	  highly	  susceptible	  to	  R5	  HIV	  type	  1.	  AIDS	  Res.	  Hum.	  Retroviruses	  16,	  935–941.	  	  Baran,	  J.,	  Kowalczyk,	  D.,	  Oz,	  M.,	  Zembala,	  M.,	  2001.	  Three-­‐Color	  Flow	  Cytometry	  Detection	  of	  Intracellular	  Cytokines	  in	  Peripheral	  Blood	  Mononuclear	  Cells :	  Comparative	  Analysis	  of	  Phorbol	  Myristate	  Acetate-­‐Ionomycin	  and	  Phytohemagglutinin	  Stimulation	  Three-­‐Color	  Flow	  Cytometry	  Detection	  of	  Intracellular	  Cy.	  Clin.	  Vaccine	  Immunol.	  7,	  303–313.	  	  Bayigga,	  L.,	  Nabatanzi,	  R.,	  Sekiziyivu,	  P.N.,	  Mayanja-­‐Kizza,	  H.,	  Kamya,	  M.R.,	  Kambugu,	  A.,	  Olobo,	  J.,	  Kiragga,	  A.,	  Kirimunda,	  S.,	  Joloba,	  M.,	  Nakanjako,	  D.,	  2014.	  High	  CD56++CD16-­‐	  natural	  killer	  (NK)	  cells	  among	  suboptimal	  immune	  responders	  after	  four	  years	  of	  suppressive	  antiretroviral	  therapy	  in	  an	  African	  adult	  HIV	  treatment	  cohort.	  BMC	  Immunol.	  15,	  2.	  	  Bergmeier,	  L.	  a.,	  Lehner,	  T.,	  2006.	  Innate	  and	  Adaptive	  Mucosal	  Immunity	  in	  Protection	  against	  HIV	  Infection.	  Adv.	  Dent.	  Res.	  19,	  21–28.	  	  Biron,	  C.	  a,	  2012.	  Yet	  another	  role	  for	  natural	  killer	  cells:	  cytotoxicity	  in	  immune	  regulation	  and	  viral	  persistence.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  109,	  1814–1815.	  	  Björkström,	  N.K.,	  Ljunggren,	  H.-­‐G.,	  Sandberg,	  J.K.,	  2010.	  CD56	  negative	  NK	  cells:	  origin,	  function,	  and	  role	  in	  chronic	  viral	  disease.	  Trends	  Immunol.	  31,	  401–406.	  	  Bland,	  J.M.,	  Altman,	  D.G.,	  1999.	  Statistical	  Methods	  in	  Medical	  Research.	  Stat.	  Methods	  Med.	  Res.	  8,	  135.	  Bluman,	  E.M.,	  Bartynski,	  K.J.,	  Avalos,	  B.R.,	  Caligiuri,	  M.	  a,	  1996.	  Human	  natural	  killer	  cells	  produce	  abundant	  macrophage	  inflammatory	  protein-­‐1	  alpha	  in	  response	  to	  monocyte-­‐derived	  cytokines.	  J.	  Clin.	  Invest.	  97,	  2722–2727.	  	  Bonsignori,	  M.,	  Pollara,	  J.,	  Moody,	  M.A.,	  Alpert,	  M.D.,	  Chen,	  X.,	  Hwang,	  K.-­‐K.,	  Gilbert,	  P.B.,	  Huang,	  Y.,	  Gurley,	  T.C.,	  Kozink,	  D.M.,	  Marshall,	  D.J.,	  Whitesides,	  J.F.,	  Tsao,	  C.-­‐Y.,	  Kaewkungwal,	  J.,	  Nitayaphan,	  S.,	  Pitisuttithum,	  P.,	  Rerks-­‐Ngarm,	  S.,	  Kim,	  J.H.,	  Michael,	  N.L.,	  Tomaras,	  G.D.,	  Montefiori,	  D.C.,	  Lewis,	  G.K.,	  DeVico,	  A.,	  Evans,	  D.T.,	  Ferrari,	  G.,	  Liao,	  H.-­‐X.,	  Haynes,	  B.F.,	  2012.	  Antibody-­‐dependent	  cellular	  cytotoxicity-­‐mediating	  antibodies	  from	  an	  HIV-­‐1	  vaccine	  efficacy	  trial	  target	  multiple	  epitopes	  and	  preferentially	  use	  the	  VH1	  gene	  family.	  J.	  Virol.	  86,	  11521–11532.	  	  Bots,	  M.,	  Medema,	  J.P.,	  2006.	  Granzymes	  at	  a	  glance.	  J.	  Cell	  Sci.	  119,	  5011–5014.	  	  	  
	   iii	  
Boulet,	  S.,	  Song,	  R.,	  Kamya,	  P.,	  Bruneau,	  J.,	  Shoukry,	  N.H.,	  Tsoukas,	  C.M.,	  Bernard,	  N.F.,	  2010.	  HIV	  Protective	  KIR3DL1	  and	  HLA-­‐B	  Genotypes	  Influence	  NK	  Cell	  Function	  Following	  Stimulation	  with	  HLA-­‐Devoid	  Cells.	  J.	  Immunol.	  184,	  2057–2064.	  	  Boyd,	  P.N.,	  Lines,	  A.C.,	  Patel,	  A.K.,	  1996.	  The	  effect	  of	  the	  removal	  of	  siliac	  acid,	  galactose	  and	  total	  carbohydrate	  and	  the	  functional	  activity	  of	  Campath-­‐1H.	  Mol.	  Immunol.	  32,	  1311–1318.	  Brenner,	  B.G.,	  Dascal,	  a,	  Margolese,	  R.G.,	  Wainberg,	  M.	  a,	  1989.	  Natural	  killer	  cell	  function	  in	  patients	  with	  acquired	  immunodeficiency	  syndrome	  and	  related	  diseases.	  J.	  Leukoc.	  Biol.	  46,	  75–83.	  Briggs,	  J.	  a	  G.,	  Kräusslich,	  H.-­‐G.,	  2011.	  The	  molecular	  architecture	  of	  HIV.	  J.	  Mol.	  Biol.	  410,	  491–500.	  	  Briggs,	  J.	  a	  G.,	  Wilk,	  T.,	  Welker,	  R.,	  Kräusslich,	  H.-­‐G.,	  Fuller,	  S.D.,	  2003.	  Structural	  organization	  of	  authentic,	  mature	  HIV-­‐1	  virions	  and	  cores.	  EMBO	  J.	  22,	  1707–1715.	  	  Broussas,	  M.,	  Broyer,	  L.,	  Goetsch,	  L.,	  2013.	  Glycosylation	  Engineering	  of	  Biopharmaceuticals.	  Methods	  in	  Molecular	  Biology.	  988,	  305–317.	  	  Brown,	  B.K.,	  Wieczorek,	  L.,	  Kijak,	  G.,	  Lombardi,	  K.,	  Currier,	  J.,	  Wesberry,	  M.,	  Kappes,	  J.C.,	  Ngauy,	  V.,	  Marovich,	  M.,	  Michael,	  N.,	  Ochsenbauer,	  C.,	  Montefiori,	  D.C.,	  Polonis,	  V.R.,	  2012.	  The	  role	  of	  natural	  killer	  (NK)	  cells	  and	  NK	  cell	  receptor	  polymorphisms	  in	  the	  assessment	  of	  HIV-­‐1	  neutralization.	  PLoS	  One	  7,	  e29454.	  	  Bruhns,	  P.,	  Iannascoli,	  B.,	  England,	  P.,	  Mancardi,	  D.A.,	  Fernandez,	  N.,	  Jorieux,	  S.,	  2009.	  Specificity	  and	  affinity	  of	  human	  Fc	   	  receptors	  and	  their	  polymorphic	  variants	  for	  human	  IgG	  subclasses.	  Blood	  113,	  3716–3725.	  	  Bryceson,	  Y.T.,	  Chiang,	  S.C.C.,	  Darmanin,	  S.,	  Fauriat,	  C.,	  Schlums,	  H.,	  Theorell,	  J.,	  Wood,	  S.M.,	  2011.	  Molecular	  mechanisms	  of	  natural	  killer	  cell	  activation.	  J.	  Innate	  Immun.	  3,	  216–226.	  Calame,	  K.L.,	  2001.	  Plasma	  cells:	  finding	  new	  light	  at	  the	  end	  of	  B	  cell	  development.	  Nat.	  Immunol.	  2,	  1103–1108.	  Caligiuri,	  M.	  a,	  2008.	  Human	  natural	  killer	  cells.	  Blood	  112,	  461–469.	  	  Campbell-­‐yesufu,	  O.T.,	  Gandhi,	  R.T.,	  2011.	  Update	  on	  Human	  Immunodeficiency	  Virus	  (	  HIV	  )	  -­‐2	  Infection.	  Clin.	  Infect.	  Dis.	  52,	  780–787.	  	  Carlson,	  L.-­‐A.,	  Briggs,	  J.	  a	  G.,	  Glass,	  B.,	  Riches,	  J.D.,	  Simon,	  M.N.,	  Johnson,	  M.C.,	  Müller,	  B.,	  Grünewald,	  K.,	  Kräusslich,	  H.-­‐G.,	  2008.	  Three-­‐dimensional	  analysis	  of	  budding	  sites	  and	  released	  virus	  suggests	  a	  revised	  model	  for	  HIV-­‐1	  morphogenesis.	  Cell	  Host	  Microbe	  4,	  592–599.	  Carson,	  B.W.E.,	  Giri,	  J.G.,	  Lindemann,	  M.J.,	  Linett,	  M.L.,	  Ahdieh,	  M.,	  Paxton,	  R.,	  Anderson,	  D.,	  Eisenmann,	  J.,	  Grabstein,	  K.,	  Caligiuri,	  M.A.,	  1994.	  Interleukln	  (IL)	  15	  Is	  a	  Novel	  
	   iv	  
Cytokine	  That	  Activates	  Human	  Natural	  Killer	  Cells	  via	  Components	  of	  the	  IL-­‐2	  Receptor.	  J.	  Exp.	  Methods.	  180,	  1395-­‐1403.	  Catalfamo,	  M.,	  Wilhelm,	  C.,	  Tcheung,	  L.,	  Proschan,	  M.,	  Friesen,	  T.,	  Park,	  J.-­‐H.,	  Adelsberger,	  J.,	  Baseler,	  M.,	  Maldarelli,	  F.,	  Davey,	  R.,	  Roby,	  G.,	  Rehm,	  C.,	  Lane,	  C.,	  2011.	  CD4	  and	  CD8	  T	  cell	  immune	  activation	  during	  chronic	  HIV	  infection:	  roles	  of	  homeostasis,	  HIV,	  type	  I	  IFN,	  and	  IL-­‐7.	  J.	  Immunol.	  186,	  2106–2116.	  	  Cheema,	  Z.F.,	  Santillano,	  D.R.,	  Wade,	  S.B.,	  Newman,	  J.M.,	  Miranda,	  R.C.,	  2004.	  cell-­‐surface	  Fas	  /	  Apo-­‐1	  suicide	  receptor	  expression	  in	  proliferating	  modifies	  estrogen	  control	  of	  cell-­‐cycle	  proteins.	  BMC	  Neurosci.	  21,	  1–21.	  Chung,	  A.,	  Rollman,	  E.,	  Johansson,	  S.,	  Kent,	  S.J.,	  Stratov,	  I.,	  2008.	  The	  utility	  of	  ADCC	  responses	  in	  HIV	  infection.	  Curr.	  HIV	  Res.	  6,	  515–519.	  Chung,	  A.W.,	  Alter,	  G.,	  2014.	  Dissecting	  the	  antibody	  constant	  region	  protective	  immune	  parameters	  in	  HIV	  infection.	  Future	  Virol.	  9,	  397–414.	  Chung,	  A.W.,	  Isitman,	  G.,	  Navis,	  M.,	  Kramski,	  M.,	  Center,	  R.J.,	  Kent,	  S.J.,	  Stratov,	  I.,	  2011.	  Immune	  escape	  from	  HIV-­‐specific	  antibody-­‐dependent	  cellular	  cytotoxicity	  (ADCC)	  pressure.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  108,	  7505–7510.	  	  Chung,	  A.W.,	  Rollman,	  E.,	  Center,	  R.J.,	  Kent,	  S.J.,	  Stratov,	  I.,	  Stephen,	  J.,	  2009.	  Rapid	  degranulation	  of	  NK	  cells	  following	  activation	  by	  HIV-­‐specific	  antibodies.	  J.	  Immunol.	  182,	  1202–1210.	  Cohen,	  M.S.,	  Gay,	  C.L.,	  Busch,	  M.P.,	  Hecht,	  F.M.,	  2010.	  The	  detection	  of	  acute	  HIV	  infection.	  J.	  Infect.	  Dis.	  202	  Suppl	  ,	  S270–277.	  Cooper,	  M.	  a,	  Fehniger,	  T.	  a,	  Caligiuri,	  M.	  a,	  2001.	  The	  biology	  of	  human	  natural	  killer-­‐cell	  subsets.	  Trends	  Immunol.	  22,	  633–640.	  Cox,	  J.H.,	  Garner,	  R.P.,	  Redfield,	  R.R.,	  Aronson,	  N.E.,	  Davis,	  C.,	  Ruiz,	  N.,	  Birx,	  D.L.,	  1999.	  Antibody-­‐dependent	  cellular	  cytotoxicity	  in	  HIV	  type	  1-­‐infected	  patients	  receiving	  VaxSyn,	  a	  recombinant	  gp160	  envelope	  vaccine.	  AIDS	  Res.	  Hum.	  Retroviruses	  15,	  847–854.	  	  Davis,	  Z.B.,	  Ward,	  J.P.,	  Barker,	  E.,	  2011.	  Preparation	  and	  use	  of	  HIV-­‐1	  infected	  primary	  CD4+	  T-­‐cells	  as	  target	  cells	  in	  natural	  killer	  cell	  cytotoxic	  assays.	  J.	  Vis.	  Exp.	  1–7.	  	  De	  Maria,	  A.,	  Fogli,	  M.,	  Costa,	  P.,	  Murdaca,	  G.,	  Puppo,	  F.,	  Mavilio,	  D.,	  Moretta,	  A.,	  Moretta,	  L.,	  2003.	  The	  impaired	  NK	  cell	  cytolytic	  function	  in	  viremic	  HIV-­‐1	  infection	  is	  associated	  with	  a	  reduced	  surface	  expression	  of	  natural	  cytotoxicity	  receptors	  (NKp46,	  NKp30	  and	  NKp44).	  Eur.	  J.	  Immunol.	  33,	  2410–2418.	  	  Deeks,	  S.G.,	  Phillips,	  A.N.,	  2009.	  HIV	  infection,	  antiretroviral	  treatment,	  ageing,	  and	  non-­‐AIDS	  related	  morbidity.	  BMJ.	  338,	  288-­‐292.	  	  
	   v	  
Deeks,	  S.G.,	  Schweighardt,	  B.,	  Wrin,	  T.,	  Galovich,	  J.,	  Hoh,	  R.,	  Sinclair,	  E.,	  Hunt,	  P.,	  McCune,	  J.M.,	  Martin,	  J.N.,	  Petropoulos,	  C.J.,	  Hecht,	  F.M.,	  2006.	  Neutralizing	  antibody	  responses	  against	  autologous	  and	  heterologous	  viruses	  in	  acute	  versus	  chronic	  human	  immunodeficiency	  virus	  (HIV)	  infection:	  evidence	  for	  a	  constraint	  on	  the	  ability	  of	  HIV	  to	  completely	  evade	  neutralizing	  antibody	  responses.	  J.	  Virol.	  80,	  6155–6164.	  Doria-­‐rose,	  N.A.,	  Connors,	  M.,	  2010.	  Antibody	  Secreting	  B-­‐cells	  in	  HIV	  Infection.	  Curr.	  Opin.	  HIV	  AIDS	  4,	  426–430.	  	  Egger,	  M.,	  May,	  M.,	  Chêne,	  G.,	  Phillips,	  A.N.,	  Ledergerber,	  B.,	  Dabis,	  F.,	  Costagliola,	  D.,	  D’Arminio	  Monforte,	  A.,	  de	  Wolf,	  F.,	  Reiss,	  P.,	  Lundgren,	  J.D.,	  Justice,	  A.C.,	  Staszewski,	  S.,	  Leport,	  C.,	  Hogg,	  R.S.,	  Sabin,	  C.	  a,	  Gill,	  M.J.,	  Salzberger,	  B.,	  Sterne,	  J.	  a	  C.,	  2002.	  Prognosis	  of	  HIV-­‐1-­‐infected	  patients	  starting	  highly	  active	  antiretroviral	  therapy:	  a	  collaborative	  analysis	  of	  prospective	  studies.	  Lancet	  360,	  119–129.	  Elmore,	  S.,	  2007.	  Apoptosis:	  a	  review	  of	  programmed	  cell	  death.	  Toxicol.	  Pathol.	  35,	  495–516.	  	  F.	  Okulicz,	  J.,	  2012.	  Elite	  Controllers	  and	  Long-­‐term	  Nonprogressors:	  Models	  for	  HIV	  Vaccine	  Development?	  J.	  AIDS	  Clin.	  Res.	  03,	  1–4.	  	  Fauriat,	  C.,	  Long,	  E.O.,	  Ljunggren,	  H.-­‐G.,	  Bryceson,	  Y.T.,	  2010.	  Regulation	  of	  human	  NK-­‐cell	  cytokine	  and	  chemokine	  production	  by	  target	  cell	  recognition.	  Blood	  115,	  2167–2176.	  	  Ferrari,	  G.,	  Pollara,	  J.,	  Kozink,	  D.,	  Harms,	  T.,	  Drinker,	  M.,	  Freel,	  S.,	  Moody,	  M.A.,	  Alam,	  S.M.,	  Tomaras,	  G.D.,	  Ochsenbauer,	  C.,	  Kappes,	  J.C.,	  Shaw,	  G.M.,	  Hoxie,	  J.	  a,	  Robinson,	  J.E.,	  Haynes,	  B.F.,	  Munir,	  S.,	  John,	  C.,	  James,	  E.,	  2011.	  An	  HIV-­‐1	  gp120	  envelope	  human	  monoclonal	  antibody	  that	  recognizes	  a	  C1	  conformational	  epitope	  mediates	  potent	  antibody-­‐dependent	  cellular	  cytotoxicity	  (ADCC)	  activity	  and	  defines	  a	  common	  ADCC	  epitope	  in	  human	  HIV-­‐1	  serum.	  J.	  Virol.	  85,	  7029–7036.	  	  Fiebig,	  E.W.,	  Wright,	  D.J.,	  Rawal,	  B.D.,	  Garrett,	  P.E.,	  Schumacher,	  R.T.,	  Peddada,	  L.,	  Heldebrant,	  C.,	  Smith,	  R.,	  Conrad,	  A.,	  Kleinman,	  S.H.,	  Busch,	  M.P.,	  2003.	  Dynamics	  of	  HIV	  viremia	  and	  antibody	  seroconversion	  in	  plasma	  donors:	  implications	  for	  diagnosis	  and	  staging	  of	  primary	  HIV	  infection.	  AIDS	  17,	  1871–1879.	  	  Frackman,	  B.S.,	  Kobs,	  G.,	  Simpson,	  D.,	  Storts,	  D.,	  Corporation,	  P.,	  1998.	  Betaine	  and	  DMSO :	  Enhancing	  Agents	  for	  PCR.	  65,	  27.	  Frankel,	  a	  D.,	  Young,	  J.	  a,	  1998.	  HIV-­‐1:	  fifteen	  proteins	  and	  an	  RNA.	  Annu.	  Rev.	  Biochem.	  67,	  1–25.	  	  Friedrich,	  B.M.,	  Dziuba,	  N.,	  Li,	  G.,	  Endsley,	  M.	  a,	  Murray,	  J.L.,	  Ferguson,	  M.R.,	  2011.	  Host	  factors	  mediating	  HIV-­‐1	  replication.	  Virus	  Res.	  161,	  101–114.	  	  Forthal,	  D.	  N.,	  Landucci,	  G.,	  Gorny,	  M.	  K.,	  Zolla-­‐Pazner,	  S.,	  &	  Robinson,	  W.	  E.,1995.	  Functional	  activities	  of	  20	  human	  immunodeficiency	  virus	  type	  1	  (HIV-­‐1)-­‐specific	  
	   vi	  
human	  monoclonal	  antibodies.	  AIDS	  Research	  and	  Human	  Retroviruses,	  11(9),	  1095–1099.	  Funke,	  J.,	  Dürr,	  R.,	  Dietrich,	  U.,	  Koch,	  J.,	  2011.	  Natural	  Killer	  Cells	  in	  HIV-­‐1	  Infection :	  A	  Double-­‐Edged	  Sword.	  AIDS	  Rev.	  13,	  67–76.	  Gallo,	  R.C.,	  Montagnier,	  L.,	  2003.	  The	  discovery	  of	  HIV	  as	  the	  cause	  of	  AIDS.	  N.	  Engl.	  J.	  Med.	  349,	  2283–2285.	  	  Garcia-­‐Iglesias,	  T.,	  Del	  Toro-­‐Arreola,	  A.,	  Albarran-­‐Somoza,	  B.,	  Del	  Toro-­‐Arreola,	  S.,	  Sanchez-­‐Hernandez,	  P.E.,	  Ramirez-­‐Dueñas,	  M.G.,	  Balderas-­‐Peña,	  L.M.A.,	  Bravo-­‐Cuellar,	  A.,	  Ortiz-­‐Lazareno,	  P.C.,	  Daneri-­‐Navarro,	  A.,	  2009.	  Low	  NKp30,	  NKp46	  and	  NKG2D	  expression	  and	  reduced	  cytotoxic	  activity	  on	  NK	  cells	  in	  cervical	  cancer	  and	  precursor	  lesions.	  BMC	  Cancer	  9,	  186.	  	  Garoff,	  H.,	  Hewson,	  R.,	  Opstelten,	  D.E.,	  1998.	  Virus	  Maturation	  by	  Budding	  Virus	  Maturation	  by	  Budding.	  Microbiol.	  Mol.	  Biol.	  Rev.	  62,	  1171-­‐1190.	  Geiger,	  T.,	  Wehner,	  A.,	  Schaab,	  C.,	  Cox,	  J.,	  Mann,	  M.,	  2012.	  Comparative	  proteomic	  analysis	  of	  eleven	  common	  cell	  lines	  reveals	  ubiquitous	  but	  varying	  expression	  of	  most	  proteins.	  Mol.	  Cell.	  Proteomics	  11,	  M111.014050.	  	  Gervaix,	  a,	  West,	  D.,	  Leoni,	  L.M.,	  Richman,	  D.D.,	  Wong-­‐Staal,	  F.,	  Corbeil,	  J.,	  1997.	  A	  new	  reporter	  cell	  line	  to	  monitor	  HIV	  infection	  and	  drug	  susceptibility	  in	  vitro.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  94,	  4653–4658.	  Glasner,	  A.,	  Ghadially,	  H.,	  Gur,	  C.,	  Stanietsky,	  N.,	  Tsukerman,	  P.,	  Enk,	  J.,	  Mandelboim,	  O.,	  2012.	  Recognition	  and	  prevention	  of	  tumor	  metastasis	  by	  the	  NK	  receptor	  NKp46/NCR1.	  J.	  Immunol.	  188,	  2509–2515.	  	  Gómez-­‐Román,	  V.R.,	  Florese,	  R.H.,	  Patterson,	  L.J.,	  Peng,	  B.,	  Venzon,	  D.,	  Aldrich,	  K.,	  Robert-­‐Guroff,	  M.,	  2006.	  A	  simplified	  method	  for	  the	  rapid	  fluorometric	  assessment	  of	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity.	  J.	  Immunol.	  Methods	  308,	  53–67.	  	  Gottardo,	  R.,	  Bailer,	  R.T.,	  Korber,	  B.T.,	  Gnanakaran,	  S.,	  Phillips,	  J.,	  Shen,	  X.,	  Tomaras,	  G.D.,	  Turk,	  E.,	  Imholte,	  G.,	  Eckler,	  L.,	  Wenschuh,	  H.,	  Zerweck,	  J.,	  Greene,	  K.,	  Gao,	  H.,	  Berman,	  P.W.,	  Francis,	  D.,	  Sinangil,	  F.,	  Lee,	  C.,	  Nitayaphan,	  S.,	  Rerks-­‐Ngarm,	  S.,	  Kaewkungwal,	  J.,	  Pitisuttithum,	  P.,	  Tartaglia,	  J.,	  Robb,	  M.L.,	  Michael,	  N.L.,	  Kim,	  J.H.,	  Zolla-­‐Pazner,	  S.,	  Haynes,	  B.F.,	  Mascola,	  J.R.,	  Self,	  S.,	  Gilbert,	  P.,	  Montefiori,	  D.C.,	  2013.	  Plasma	  IgG	  to	  linear	  epitopes	  in	  the	  V2	  and	  V3	  regions	  of	  HIV-­‐1	  gp120	  correlate	  with	  a	  reduced	  risk	  of	  infection	  in	  the	  RV144	  vaccine	  efficacy	  trial.	  PLoS	  One	  8,	  e75665.	  	  Gray,	  E.S.,	  Taylor,	  N.,	  Wycuff,	  D.,	  Moore,	  P.L.,	  Tomaras,	  G.D.,	  Wibmer,	  C.K.,	  Puren,	  A.,	  DeCamp,	  A.,	  Gilbert,	  P.B.,	  Wood,	  B.,	  Montefiori,	  D.C.,	  Binley,	  J.M.,	  Shaw,	  G.M.,	  Haynes,	  B.F.,	  Mascola,	  J.R.,	  Morris,	  L.,	  2009.	  Antibody	  specificities	  associated	  with	  neutralization	  breadth	  in	  plasma	  from	  human	  immunodeficiency	  virus	  type	  1	  subtype	  C-­‐infected	  blood	  donors.	  J.	  Virol.	  83,	  8925–8937.	  	  
	   vii	  
Guan,	  Y.,	  Pazgier,	  M.,	  Sajadi,	  M.	  M.,	  Kamin-­‐Lewis,	  R.,	  Al-­‐Darmarki,	  S.,	  Flinko,	  R.,	  Lewis,	  G.	  K.	  (2013).	  Diverse	  specificity	  and	  effector	  function	  among	  human	  antibodies	  to	  HIV-­‐1	  envelope	  glycoprotein	  epitopes	  exposed	  by	  CD4	  binding.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.,	  110(1),	  E69–78.	  Greene,	  W.C.,	  2007.	  A	  history	  of	  AIDS:	  looking	  back	  to	  see	  ahead.	  Eur.	  J.	  Immunol.	  37	  Suppl	  1,	  S94–102.	  	  Harrich,	  D.,	  Hooker,	  B.,	  2002.	  Mechanistic	  aspects	  of	  HIV-­‐1	  reverse	  transcription	  initiation.	  Rev.	  Med.	  Virol.	  12,	  31–45.	  Harris,	  A.,	  Borgnia,	  M.J.,	  Shi,	  D.,	  Bartesaghi,	  A.,	  He,	  H.,	  Pejchal,	  R.,	  Kang,	  Y.K.,	  Depetris,	  R.,	  Marozsan,	  A.J.,	  Sanders,	  R.W.,	  Klasse,	  P.J.,	  Milne,	  J.L.S.,	  Wilson,	  I.	  a,	  Olson,	  W.C.,	  Moore,	  J.P.,	  Subramaniam,	  S.,	  2011.	  Trimeric	  HIV-­‐1	  glycoprotein	  gp140	  immunogens	  and	  native	  HIV-­‐1	  envelope	  glycoproteins	  display	  the	  same	  closed	  and	  open	  quaternary	  molecular	  architectures.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  108,	  11440–11445.	  	  Hatjiharissi,	  E.,	  Xu,	  L.,	  Santos,	  D.D.,	  Hunter,	  Z.R.,	  Ciccarelli,	  B.T.,	  Verselis,	  S.,	  Modica,	  M.,	  Cao,	  Y.,	  Manning,	  R.J.,	  Leleu,	  X.,	  Dimmock,	  E.A.,	  Kortsaris,	  A.,	  Mitsiades,	  C.,	  Anderson,	  K.C.,	  Fox,	  E.A.,	  Treon,	  S.P.,	  2007.	  Increased	  natural	  killer	  cell	  expression	  of	  CD16	  ,	  augmented	  binding	  and	  ADCC	  activity	  to	  rituximab	  among	  individuals	  expressing	  the	  Fc	   	  RIIIa-­‐158	  V	  /	  V	  and	  V	  /	  F	  polymorphism.	  Blood	  110,	  2561–2564.	  	  Haynes,	  B.F.,	  Gilbert,	  P.B.,	  McElrath,	  M.J.,	  Zolla-­‐Pazner,	  S.,	  Tomaras,	  G.D.,	  Alam,	  S.M.,	  Evans,	  D.T.,	  Montefiori,	  D.C.,	  Decamp,	  A.,	  Huang,	  Y.,	  Rao,	  M.,	  Billings,	  E.,	  Karasavvas,	  N.,	  Bailer,	  R.T.,	  Soderberg,	  K.A.,	  Andrews,	  C.,	  Berman,	  P.W.,	  Frahm,	  N.,	  Rosa,	  S.C.	  De,	  Alpert,	  M.D.,	  Yates,	  N.L.,	  Shen,	  X.,	  Koup,	  R.A.,	  2012.	  Immune-­‐Correlates	  Analysis	  of	  an	  HIV-­‐1	  Vaccine	  Efficacy	  Trial	  Barton.	  N.	  Engl.	  J.	  Med.	  14,1275–1286.	  Haynes,	  B.F.,	  Moody,	  M.A.,	  Liao,	  H.-­‐X.,	  Verkoczy,	  L.,	  Tomaras,	  G.D.,	  2011.	  B	  cell	  responses	  to	  HIV-­‐1	  infection	  and	  vaccination:	  pathways	  to	  preventing	  infection.	  Trends	  Mol.	  Med.	  17,	  108–116.	  	  He,	  B.,	  Qiao,	  X.,	  Klasse,	  P.J.,	  Chiu,	  A.,	  Chadburn,	  A.,	  Knowles,	  D.M.,	  Moore,	  J.P.,	  Cerutti,	  A.,	  2006.	  HIV-­‐1	  Envelope	  Triggers	  Polyclonal	  Ig	  Class	  Switch	  Recombination	  through	  a	  CD40-­‐Independent	  Mechanism	  Involving	  BAFF	  and	  C-­‐Type	  Lectin	  Receptors.	  J.	  Immunol.	  176,	  3931–3941.	  	  Hezareh,	  M.,	  Hessell,	  A.	  J.,	  Jensen,	  R.	  C.,	  van	  de	  Winkel,	  J.	  G.,	  &	  Parren,	  P.	  W.	  (2001).	  Effector	  function	  activities	  of	  a	  panel	  of	  mutants	  of	  a	  broadly	  neutralizing	  antibody	  against	  human	  immunodeficiency	  virus	  type	  1.	  Journal	  of	  Virology,	  75(24),	  12161–12168.	  	  He,	  X.,	  Li,	  D.,	  Luo,	  Z.,	  Liang,	  H.,	  Peng,	  H.,	  Zhao,	  Y.,	  Wang,	  N.,	  Liu,	  D.,	  Qin,	  C.,	  Wei,	  Q.,	  Yan,	  H.,	  Shao,	  Y.,	  2013.	  Compromised	  NK	  cell-­‐mediated	  antibody-­‐dependent	  cellular	  cytotoxicity	  in	  chronic	  SIV/SHIV	  infection.	  PLoS	  One	  8,	  e56309.	  	  
	   viii	  
Hong,	  H.S.,	  Rajakumar,	  P.	  a,	  Billingsley,	  J.M.,	  Reeves,	  R.K.,	  Johnson,	  R.P.,	  2013.	  No	  monkey	  business:	  why	  studying	  NK	  cells	  in	  non-­‐human	  primates	  pays	  off.	  Front.	  Immunol.	  4,	  32.	  	  Hoves,	  S.,	  Trapani,	  J.	  a,	  Voskoboinik,	  I.,	  2010.	  The	  battlefield	  of	  perforin/granzyme	  cell	  death	  pathways.	  J.	  Leukoc.	  Biol.	  87,	  237–243.	  	  Hubert,	  P.,	  Amigorena,	  S.,	  2012.	  Antibody-­‐dependent	  cell	  cytotoxicity	  in	  monoclonal	  antibody-­‐mediated	  tumor	  immunotherapy.	  Oncoimmunology.	  1,	  103–105.	  	  Hudspeth,	  K.,	  Silva-­‐Santos,	  B.,	  Mavilio,	  D.,	  2013.	  Natural	  cytotoxicity	  receptors:	  broader	  expression	  patterns	  and	  functions	  in	  innate	  and	  adaptive	  immune	  cells.	  Front.	  Immunol.	  4,	  69.	  	  Huth,	  T.K.,	  Brenu,	  E.W.,	  Nguyen,	  T.,	  Hardcastle,	  S.L.,	  Johnston,	  S.,	  Ramos,	  S.,	  Staines,	  D.R.,	  Sonya,	  M.,	  2014.	  Characterization	  of	  natural	  killer	  cell	  phenotypes	  in	  chronic	  fatigue	  syndrome/myalgic	  encephalomyelitis.	  Clin.	  Cell.	  Immunol.	  5,	  223.	  Hwang,	  I.,	  Zhang,	  T.,	  Scott,	  J.M.,	  Kim,	  A.A.R.,	  Lee,	  T.,	  Kakarla,	  T.,	  Sunwoo,	  J.B.,	  Kim,	  S.,	  2012.	  Identification	  of	  human	  NK	  cells	  that	  are	  deficient	  for	  signaling	  adaptor	  FcRγ	  and	  specialized	  for	  antibody-­‐dependent	  immune	  functions.	  Int.	  Immunol.	  24,	  793–802.	  	  Iannello,	  A.,	  Debbeche,	  O.,	  Samarani,	  S.,	  Ahmad,	  A.,	  2008.	  Antiviral	  NK	  cell	  responses	  in	  HIV	  infection:	  II.	  viral	  strategies	  for	  evasion	  and	  lessons	  for	  immunotherapy	  and	  vaccination.	  J.	  Leukoc.	  Biol.	  84,	  27–49.	  	  Isitman,	  G.,	  Chung,	  A.W.,	  Navis,	  M.,	  Kent,	  S.J.,	  Stratov,	  I.,	  2011.	  Pol	  as	  a	  target	  for	  antibody	  dependent	  cellular	  cytotoxicity	  responses	  in	  HIV-­‐1	  infection.	  Virology	  412,	  110–116.	  	  Isitman,	  G.,	  Stratov,	  I.,	  Kent,	  S.J.,	  2012.	  Antibody-­‐Dependent	  Cellular	  Cytotoxicity	  and	  NK	  Cell-­‐Driven	  Immune	  Escape	  in	  HIV	  Infection:	  Implications	  for	  HIV	  Vaccine	  Development.	  Adv.	  Virol.	  2012,	  637208.	  	  Jia,	  M.,	  Li,	  D.,	  He,	  X.,	  Zhao,	  Y.,	  Peng,	  H.,	  Ma,	  P.,	  Hong,	  K.,	  Liang,	  H.,	  Shao,	  Y.,	  2013.	  Impaired	  natural	  killer	  cell-­‐induced	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity	  is	  associated	  with	  human	  immunodeficiency	  virus-­‐1	  disease	  progression.	  Clin.	  Exp.	  Immunol.	  171,	  107–116.	  	  Jiang,	  Y.,	  Zhou,	  F.,	  Tian,	  Y.,	  Zhang,	  Z.,	  Kuang,	  R.,	  Liu,	  J.,	  Han,	  X.,	  Hu,	  Q.,	  Xu,	  J.,	  Shang,	  H.,	  2013.	  Higher	  NK	  Cell	  IFN-­‐γ	  Production	  is	  Associated	  with	  Delayed	  HIV	  Disease	  Progression	  in	  LTNPs.	  J.	  Clin.	  Immunol.	  10,	  1007.	  Johansson,	  S.E.,	  Rollman,	  E.,	  Chung,	  A.W.,	  Center,	  R.J.,	  Hejdeman,	  B.,	  Stratov,	  I.,	  Hinkula,	  J.,	  Wahren,	  B.,	  Kärre,	  K.,	  Kent,	  S.J.,	  Berg,	  L.,	  2011.	  NK	  cell	  function	  and	  antibodies	  mediating	  ADCC	  in	  HIV-­‐1-­‐infected	  viremic	  and	  controller	  patients.	  Viral	  Immunol.	  24,	  359–368.	  	  
	   ix	  
Jost,	  S.,	  Altfeld,	  M.,	  2012.	  Evasion	  from	  NK	  cell-­‐mediated	  immune	  responses	  by	  HIV-­‐1.	  Microbes	  Infect.	  14,	  904–915.	  	  Jost,	  S.,	  Altfeld,	  M.,	  2013.	  Control	  of	  human	  viral	  infections	  by	  natural	  killer	  cells.	  Annu.	  Rev.	  Immunol.	  31,	  163–194.	  	  Karasavvas,	  N.,	  Billings,	  E.,	  Rao,	  M.,	  Williams,	  C.,	  Zolla-­‐Pazner,	  S.,	  Bailer,	  R.T.,	  Koup,	  R.	  a,	  Madnote,	  S.,	  Arworn,	  D.,	  Shen,	  X.,	  Tomaras,	  G.D.,	  Currier,	  J.R.,	  Jiang,	  M.,	  Magaret,	  C.,	  Andrews,	  C.,	  Gottardo,	  R.,	  Gilbert,	  P.,	  Cardozo,	  T.J.,	  Rerks-­‐Ngarm,	  S.,	  Nitayaphan,	  S.,	  Pitisuttithum,	  P.,	  Kaewkungwal,	  J.,	  Paris,	  R.,	  Greene,	  K.,	  Gao,	  H.,	  Gurunathan,	  S.,	  Tartaglia,	  J.,	  Sinangil,	  F.,	  Korber,	  B.T.,	  Montefiori,	  D.C.,	  Mascola,	  J.R.,	  Robb,	  M.L.,	  Haynes,	  B.F.,	  Ngauy,	  V.,	  Michael,	  N.L.,	  Kim,	  J.H.,	  de	  Souza,	  M.S.,	  2012.	  The	  Thai	  Phase	  III	  HIV	  Type	  1	  Vaccine	  trial	  (RV144)	  regimen	  induces	  antibodies	  that	  target	  conserved	  regions	  within	  the	  V2	  loop	  of	  gp120.	  AIDS	  Res.	  Hum.	  Retroviruses	  28,	  1444–1457.	  	  Karim,	  Q.A.,	  Sibeko,	  S.,	  Baxter,	  C.,	  Abdool	  Karim,	  Q.,	  2010.	  Preventing	  HIV	  infection	  in	  women:	  a	  global	  health	  imperative.	  Clin.	  Infect.	  Dis.	  50	  Suppl	  3,	  S122–129.	  	  Karnasuta,	  C.,	  Paris,	  R.M.,	  Cox,	  J.H.,	  Nitayaphan,	  S.,	  Pitisuttithum,	  P.,	  Thongcharoen,	  P.,	  Brown,	  A.E.,	  Gurunathan,	  S.,	  Tartaglia,	  J.,	  Heyward,	  W.L.,	  McNeil,	  J.G.,	  Birx,	  D.L.,	  de	  Souza,	  M.S.,	  2005.	  Antibody-­‐dependent	  cell-­‐mediated	  cytotoxic	  responses	  in	  participants	  enrolled	  in	  a	  phase	  I/II	  ALVAC-­‐HIV/AIDSVAX	  B/E	  prime-­‐boost	  HIV-­‐1	  vaccine	  trial	  in	  Thailand.	  Vaccine	  23,	  2522–2529.	  	  Kasturi,	  S.P.,	  Skountzou,	  I.,	  Albrecht,	  R.A.,	  Koutsonanos,	  D.,	  Hua,	  T.,	  Nakaya,	  H.,	  Ravindran,	  R.,	  Stewart,	  S.,	  Alam,	  M.,	  Kwissa,	  M.,	  Villinger,	  F.,	  Murthy,	  N.,	  Steel,	  J.,	  Jacob,	  J.,	  Hogan,	  R.J.,	  García-­‐sastre,	  A.,	  Compans,	  R.,	  2011.	  responses	  with	  innate	  immunity	  470,	  543–547.	  	  Kaufmann,	  T.,	  Strasser,	  a,	  Jost,	  P.J.,	  2012.	  Fas	  death	  receptor	  signalling:	  roles	  of	  Bid	  and	  XIAP.	  Cell	  Death	  Differ.	  19,	  42–50.	  	  Keele,	  B.F.,	  Estes,	  J.D.,	  2011.	  Barriers	  to	  mucosal	  transmission	  of	  immunodeficiency	  viruses.	  Blood	  118,	  839–846.	  	  Kinchington,	  P.R.,	  Hendricks,	  R.L.,	  2008.	  Noncytotoxic	  Lytic	  Granule	  –	  Mediated	  Reactivation	  from	  Neuronal	  Latency.	  Science.	  25314,	  268–271.	  Kirchhoff,	  F.,	  2010.	  Immune	  evasion	  and	  counteraction	  of	  restriction	  factors	  by	  HIV-­‐1	  and	  other	  primate	  lentiviruses.	  Cell	  Host	  Microbe	  8,	  55–67.	  	  Koch,	  J.,	  Steinle,	  A.,	  Watzl,	  C.,	  Mandelboim,	  O.,	  2013.	  Activating	  natural	  cytotoxicity	  receptors	  of	  natural	  killer	  cells	  in	  cancer	  and	  infection.	  Trends	  Immunol.	  34,	  182–191.	  	  Koeffler,	  P.,	  Golde,	  D.W.,	  1980.	  Human	  myeloid	  leukemia	  cells.	  Blood	  56,	  344–350.	  
	   x	  
Kogan,	  M.,	  Rappaport,	  J.,	  2011.	  HIV-­‐1	  accessory	  protein	  Vpr:	  relevance	  in	  the	  pathogenesis	  of	  HIV	  and	  potential	  for	  therapeutic	  intervention.	  Retrovirology	  8,	  25.	  	  König,	  R.,	  Zhou,	  W.,	  2004.	  Signal	  Transduction	  in	  T	  Helper	  Cells :	  CD4	  Coreceptors	  Exert	  Complex	  Regulatory	  Effects	  on	  T	  Cell	  Activation	  and	  Function.	  Curr.	  Issues	  Mol.	  Biol.	  6,	  1–16.	  Krzewski,	  K.,	  Gil-­‐Krzewska,	  A.,	  Nguyen,	  V.,	  Peruzzi,	  G.,	  Coligan,	  J.E.,	  2013.	  LAMP1/CD107a	  is	  required	  for	  efficient	  perforin	  delivery	  to	  lytic	  granules	  and	  NK-­‐cell	  cytotoxicity.	  Blood.	  121,	  4672-­‐4683.	  	  Kute,	  T.,	  Stehle	  Jr,	  J.R.,	  Ornelles,	  D.,	  Walker,	  N.,	  Delbono,	  O.,	  Vaughn,	  J.P.,	  2012.	  Understanding	  key	  assay	  parameters	  that	  affect	  measurements	  of	  trastuzumab-­‐mediated	  ADCC	  against	  Her2	  positive	  breast	  cancer	  cells.	  Oncoimmunology	  1,	  810–821.	  	  Kwong,	  P.D.,	  Mascola,	  J.R.,	  Nabel,	  G.J.,	  2013.	  Broadly	  neutralizing	  antibodies	  and	  the	  search	  for	  an	  HIV-­‐1	  vaccine:	  the	  end	  of	  the	  beginning.	  Nat.	  Rev.	  Immunol.	  13,	  693–701.	  	  Kwong,	  P.D.,	  Wyatt,	  R.,	  Robinson,	  J.,	  Sweet,	  R.W.,	  Sodroski,	  J.,	  Hendrickson,	  W.	  a,	  1998.	  Structure	  of	  an	  HIV	  gp120	  envelope	  glycoprotein	  in	  complex	  with	  the	  CD4	  receptor	  and	  a	  neutralizing	  human	  antibody.	  Nature	  393,	  648–59.	  	  Lambotte,	  O.,	  Pollara,	  J.,	  Boufassa,	  F.,	  Moog,	  C.,	  Venet,	  A.,	  Haynes,	  B.F.,	  Delfraissy,	  J.-­‐F.,	  Saez-­‐Cirion,	  A.,	  Ferrari,	  G.,	  2013.	  High	  antibody-­‐dependent	  cellular	  cytotoxicity	  responses	  are	  correlated	  with	  strong	  CD8	  T	  cell	  viral	  suppressive	  activity	  but	  not	  with	  B57	  status	  in	  HIV-­‐1	  elite	  controllers.	  PLoS	  One	  8,	  e74855.	  	  Lane,	  H.C.,	  2010.	  Pathogenesis	  of	  HIV	  infection:	  total	  CD4+	  T-­‐cell	  pool,	  immune	  activation,	  and	  inflammation.	  Top.	  HIV	  Med.	  18,	  2–6.	  Lanier,	  L.L.,	  2003.	  Natural	  killer	  cell	  receptor	  signaling.	  Curr.	  Opin.	  Immunol.	  15,	  308–314.	  	  Lanier,	  L.L.,	  Phillips,	  J.H.,	  Hackett,	  J.,	  Tutt,	  M.,	  Kumar,	  V.,	  1986.	  Natural	  killer	  cells:	  definition	  of	  a	  cell	  type	  rather	  than	  a	  function.	  J.	  Immunol.	  137,	  2735–2739.	  Larson,	  B.,	  Dhawan,	  S.,	  Wadwani,	  S.,	  Pierre,	  N.,	  Martinez,	  S.,	  Degorce,	  F.,	  Banks,	  P.,	  2011.	  Novel	  ,	  Antibody-­‐Dependent	  Cell-­‐Mediated	  Cytotoxicity	  (	  ADCC	  )	  Assays	  48041312.	  Leng,	  Q.,	  Borkow,	  G.,	  Weisman,	  Z.,	  2001.	  Immune	  activation	  correlates	  better	  than	  HIV	  plasma	  viral	  load	  with	  CD4	  T-­‐cell	  decline	  during	  HIV	  infection.	  J.	  Acquir.	  Immune	  Defic.	  Syndr.	  27,	  389-­‐397.	  Li,	  Y.,	  O’Dell,	  S.,	  Wilson,	  R.,	  Wu,	  X.,	  Schmidt,	  S.D.,	  Hogerkorp,	  C.-­‐M.,	  Louder,	  M.K.,	  Longo,	  N.S.,	  Poulsen,	  C.,	  Guenaga,	  J.,	  Chakrabarti,	  B.K.,	  Doria-­‐Rose,	  N.,	  Roederer,	  M.,	  Connors,	  M.,	  Mascola,	  J.R.,	  Wyatt,	  R.T.,	  2012.	  HIV-­‐1	  neutralizing	  antibodies	  display	  
	   xi	  
dual	  recognition	  of	  the	  primary	  and	  coreceptor	  binding	  sites	  and	  preferential	  binding	  to	  fully	  cleaved	  envelope	  glycoproteins.	  J.	  Virol.	  86,	  11231–11241.	  	  Liao,	  H.-­‐X.,	  Chen,	  X.,	  Munshaw,	  S.,	  Zhang,	  R.,	  Marshall,	  D.J.,	  Vandergrift,	  N.,	  Whitesides,	  J.F.,	  Lu,	  X.,	  Yu,	  J.-­‐S.,	  Hwang,	  K.-­‐K.,	  Gao,	  F.,	  Markowitz,	  M.,	  Heath,	  S.L.,	  Bar,	  K.J.,	  Goepfert,	  P.	  a,	  Montefiori,	  D.C.,	  Shaw,	  G.C.,	  Alam,	  S.M.,	  Margolis,	  D.M.,	  Denny,	  T.N.,	  Boyd,	  S.D.,	  Marshal,	  E.,	  Egholm,	  M.,	  Simen,	  B.B.,	  Hanczaruk,	  B.,	  Fire,	  A.Z.,	  Voss,	  G.,	  Kelsoe,	  G.,	  Tomaras,	  G.D.,	  Moody,	  M.A.,	  Kepler,	  T.B.,	  Haynes,	  B.F.,	  2011.	  Initial	  antibodies	  binding	  to	  HIV-­‐1	  gp41	  in	  acutely	  infected	  subjects	  are	  polyreactive	  and	  highly	  mutated.	  J.	  Exp.	  Med.	  208,	  2237–2249.	  	  Lichtfuss,	  G.F.,	  Meehan,	  A.C.,	  Cheng,	  W.-­‐J.,	  Cameron,	  P.U.,	  Lewin,	  S.R.,	  Crowe,	  S.M.,	  Jaworowski,	  A.,	  2011.	  HIV	  inhibits	  early	  signal	  transduction	  events	  triggered	  by	  CD16	  cross-­‐linking	  on	  NK	  cells,	  which	  are	  important	  for	  antibody-­‐dependent	  cellular	  cytotoxicity.	  J.	  Leukoc.	  Biol.	  89,	  149–158.	  	  Liu,	  X.,	  Li,	  P.,	  Widlak,	  P.,	  Zou,	  H.,	  Luo,	  X.,	  Garrard,	  W.T.,	  Wang,	  X.,	  1998.	  The	  40-­‐kDa	  subunit	  of	  DNA	  fragmentation	  factor	  induces	  DNA	  fragmentation	  and	  chromatin	  condensation	  during	  apoptosis.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  95,	  8461–8466.	  Ljunggren,	  K.,	  Broliden,	  P.,	  Morfeldt-­‐Manson,	  L.,	  Jondal,	  M.,	  Wahren,	  B.,	  1988.	  IgG	  subclass	  response	  to	  HIV	  in	  relation	  to	  antibody-­‐dependent	  cellular	  cytotoxicity	  at	  different	  clinical	  stages.	  Clin.	  Exp.	  Immunol.	  73,	  343–347.	  Llano,	  A.,	  Est,	  J.A.,	  2005.	  Chemokines	  and	  other	  cytokines	  in	  human	  immunodeficiency	  virus	  type	  1	  (	  HIV-­‐1	  )	  infection.	  Immunologia	  24,	  246–260.	  Lopez-­‐verge,	  S.,	  Milush,	  J.M.,	  Pandey,	  S.,	  York,	  V.A.,	  Arakawa-­‐hoyt,	  J.,	  Pircher,	  H.,	  Norris,	  P.J.,	  Nixon,	  D.F.,	  Lanier,	  L.L.,	  2010.	  CD57	  defines	  a	  functionally	  distinct	  population	  of	  mature	  NK	  cells	  in	  the	  human	  CD56	  dim	  CD16	  ϩ	  NK-­‐cell	  subset.	  Immunobiology	  116,	  3865–3874.	  	  Long,	  O.E.,	  2002.	  Tumor	  cell	  recognition	  by	  natural	  killer	  cells.	  Cancer	  Biology.	  12,	  57-­‐61.	  Lyerly,	  H.K.I.M.,	  Reed,	  D.L.,	  Matthews,	  T.J.,	  Langlois,	  A.J.,	  Ahearne,	  P.A.,	  Petteway,	  S.R.,	  Weinhold,	  K.J.,	  1987.	  Anti-­‐GP	  120	  Antibodies	  from	  HIV	  Seropositive	  Individuals	  Mediate	  Broadly	  Reactive.	  AIDS	  Res.	  Hum.	  Retroviruses	  3,	  409–422.	  Madhavi,	  V.,	  Navis,	  M.,	  Chung,	  A.W.,	  Isitman,	  G.,	  Wren,	  L.H.,	  Rose,	  R.	  De,	  Kent,	  S.J.,	  Stratov,	  I.,	  2013.	  Role	  for	  granulocytes	  in	  expressing	  HIV-­‐1	  peptide	  epitopes	  Activation	  of	  NK	  cells	  by	  HIV-­‐specific	  ADCC	  antibodies.	  Hum.	  vaccines	  Immunother.	  1–9.	  Malim,	  M.H.,	  Emerman,	  M.,	  2008.	  HIV-­‐1	  accessory	  proteins-­‐-­‐ensuring	  viral	  survival	  in	  a	  hostile	  environment.	  Cell	  Host	  Microbe	  3,	  388–398.	  	  Mandelboim,	  O.,	  Malik,	  P.,	  Davis,	  D.M.,	  Jo,	  C.H.,	  Boyson,	  J.E.,	  Strominger,	  J.L.,	  1999.	  Human	  CD16	  as	  a	  lysis	  receptor	  mediating	  direct	  natural	  killer	  cell	  cytotoxicity.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  96,	  5640–5644.	  
	   xii	  
Marin,	  M.,	  Rose,	  K.M.,	  Kozak,	  S.L.,	  Kabat,	  D.,	  2003.	  HIV-­‐1	  Vif	  protein	  binds	  the	  editing	  enzyme	  APOBEC3G	  and	  induces	  its	  degradation.	  Nat.	  Med.	  9,	  1398–1403.	  	  Mascola,	  J.R.,	  Haynes,	  B.F.,	  2013.	  HIV-­‐1	  neutralizing	  antibodies:	  understanding	  nature’s	  pathways.	  Immunol.	  Rev.	  254,	  225–244.	  	  Mata,	  M.M.,	  Mahmood,	  F.,	  Sowell,	  R.T.,	  Baum,	  L.L.,	  2014.	  Effects	  of	  cryopreservation	  on	  effector	  cells	  for	  antibody	  dependent	  cell-­‐mediated	  cytotoxicity	  (ADCC)	  and	  natural	  killer	  (NK)	  cell	  activity	  in	  (51)Cr-­‐release	  and	  CD107a	  assays.	  J.	  Immunol.	  Methods	  406,	  1–9.	  	  Mavilio,	  D.,	  Benjamin,	  J.,	  Daucher,	  M.,	  Lombardo,	  G.,	  Kottilil,	  S.,	  Planta,	  M.	  a,	  Marcenaro,	  E.,	  Bottino,	  C.,	  Moretta,	  L.,	  Moretta,	  A.,	  Fauci,	  A.S.,	  2003.	  Natural	  killer	  cells	  in	  HIV-­‐1	  infection:	  dichotomous	  effects	  of	  viremia	  on	  inhibitory	  and	  activating	  receptors	  and	  their	  functional	  correlates.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  100,	  15011–15016.	  	  Mavilio,	  D.,	  Lombardo,	  G.,	  Benjamin,	  J.,	  Kim,	  D.,	  Follman,	  D.,	  Marcenaro,	  E.,	  Shea,	  M.A.O.,	  Kinter,	  A.,	  Kovacs,	  C.,	  Moretta,	  A.,	  Fauci,	  A.S.,	  2005.	  cells :	  A	  highly	  dysfunctional	  NK	  subset	  expanded	  in	  HIV-­‐infected	  viremic	  individuals.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  102,	  2886-­‐2891.	  McMichael,	  A.J.,	  Borrow,	  P.,	  Tomaras,	  G.D.,	  Goonetilleke,	  N.,	  Haynes,	  B.F.,	  2010.	  The	  immune	  response	  during	  acute	  HIV-­‐1	  infection:	  clues	  for	  vaccine	  development.	  Nat.	  Rev.	  Immunol.	  10,	  11–23.	  	  Melar,	  M.,	  Ott,	  D.E.,	  Hope,	  T.J.,	  2007.	  Physiological	  levels	  of	  virion-­‐associated	  human	  immunodeficiency	  virus	  type	  1	  envelope	  induce	  coreceptor-­‐dependent	  calcium	  flux.	  J.	  Virol.	  81,	  1773–1785.	  	  Mikell,	  I.,	  Sather,	  D.N.,	  Kalams,	  S.	  a,	  Altfeld,	  M.,	  Alter,	  G.,	  Stamatatos,	  L.,	  2011.	  Characteristics	  of	  the	  earliest	  cross-­‐neutralizing	  antibody	  response	  to	  HIV-­‐1.	  PLoS	  Pathog.	  7,	  e1001251.	  	  Mlisana,	  K.,	  Werner,	  L.,	  Garrett,	  N.J.,	  McKinnon,	  L.R.,	  Van	  Loggerenberg,	  F.,	  Passmore,	  J.S.,	  Gray,	  C.M.,	  Morris,	  L.,	  Williamson,	  C.,	  2014.	  Rapid	  disease	  progression	  in	  HIV-­‐1	  subtype	  C	  infected	  South	  African	  women	  Accepted.	  Clin.	  Infect.	  Adv.	  access	  1–26.	  Mogensen,	  T.H.,	  Melchjorsen,	  J.,	  Larsen,	  C.S.,	  Paludan,	  S.R.,	  2010.	  Innate	  immune	  recognition	  and	  activation	  during	  HIV	  infection.	  Retrovirology	  1–19.	  Montefiori,	  D.C.,	  Morris,	  L.,	  Ferrari,	  G.,	  Mascola,	  J.R.,	  Manuscript,	  A.,	  2011.	  Neutralizing	  and	  other	  antiviral	  antibodies	  in	  HIV-­‐1	  infection	  and	  vaccination.	  Curr.	  Opin.	  HIV	  AIDS	  2,	  169–176.	  	  Moog,	  C.,	  Fleury,	  H.J.,	  Pellegrin,	  I.,	  Kirn,	  a,	  Aubertin,	  a	  M.,	  1997.	  Autologous	  and	  heterologous	  neutralizing	  antibody	  responses	  following	  initial	  seroconversion	  in	  human	  immunodeficiency	  virus	  type	  1-­‐infected	  individuals.	  J.	  Virol.	  71,	  3734–3741.	  
	   xiii	  
Moore,	  P.L.,	  Gray,	  E.S.,	  Choge,	  I.	  a,	  Ranchobe,	  N.,	  Mlisana,	  K.,	  Abdool	  Karim,	  S.S.,	  Williamson,	  C.,	  Morris,	  L.,	  2008.	  The	  c3-­‐v4	  region	  is	  a	  major	  target	  of	  autologous	  neutralizing	  antibodies	  in	  human	  immunodeficiency	  virus	  type	  1	  subtype	  C	  infection.	  J.	  Virol.	  82,	  1860–1869.	  	  Moore,	  P.L.,	  Gray,	  E.S.,	  Wibmer,	  C.K.,	  Bhiman,	  J.N.,	  Nonyane,	  M.,	  Sheward,	  D.J.,	  Hermanus,	  T.,	  Bajimaya,	  S.,	  Tumba,	  N.L.,	  Abrahams,	  M.-­‐R.,	  Lambson,	  B.E.,	  Ranchobe,	  N.,	  Ping,	  L.,	  Ngandu,	  N.,	  Abdool	  Karim,	  Q.,	  Abdool	  Karim,	  S.S.,	  Swanstrom,	  R.I.,	  Seaman,	  M.S.,	  Williamson,	  C.,	  Morris,	  L.,	  2012.	  Evolution	  of	  an	  HIV	  glycan-­‐dependent	  broadly	  neutralizing	  antibody	  epitope	  through	  immune	  escape.	  Nat.	  Med.	  18,	  1688–1692.	  	  Morice,	  W.G.,	  2007.	  The	  immunophenotypic	  attributes	  of	  NK	  cells	  and	  NK-­‐cell	  lineage	  lymphoproliferative	  disorders.	  Am.	  J.	  Clin.	  Pathol.	  127,	  881–886.	  	  Muster,	  T.,	  Steindl,	  F.,	  Purtscher,	  M.,	  Trkola,	  A.,	  Klima,	  A.,	  Himmler,	  G.,	  Ruker,	  F.,	  Katinger,	  H.,	  1993.	  A	  Conserved	  Neutralizing	  Epitope	  on	  gp4l	  of	  Human	  Immunodeficiency	  Virus	  Type	  1.	  J.	  Virol.	  67,	  6642–6647.	  Muthukumar	  Balasubramaniam	  and	  Eric	  O.	  Freed,	  2012.	  New	  Insights	  into	  HIV	  Assembly	  and	  Trafficking.	  Physiology	  26,	  236–251.	  	  Naranbhai,	  V.,	  Altfeld,	  M.,	  Karim,	  S.S.A.,	  Ndung’u,	  T.,	  Karim,	  Q.A.,	  Carr,	  W.H.,	  2013.	  Changes	  in	  Natural	  Killer	  cell	  activation	  and	  function	  during	  primary	  HIV-­‐1	  Infection.	  PLoS	  One	  8,	  e53251.	  	  Naumann,	  S.,	  Reutzel,	  D.,	  Speicher,	  M.,	  Decker,	  H.J.,	  2001.	  Complete	  karyotype	  characterization	  of	  the	  K562	  cell	  line	  by	  combined	  application	  of	  G-­‐banding,	  multiplex-­‐fluorescence	  in	  situ	  hybridization,	  fluorescence	  in	  situ	  hybridization,	  and	  comparative	  genomic	  hybridization.	  Leuk.	  Res.	  25,	  313–322.	  Niwa,	  R.,	  Natsume,	  A.,	  Uehara,	  A.,	  Wakitani,	  M.,	  Iida,	  S.,	  Uchida,	  K.,	  Satoh,	  M.,	  Shitara,	  K.,	  2005.	  IgG	  subclass-­‐independent	  improvement	  of	  antibody-­‐dependent	  cellular	  cytotoxicity	  by	  fucose	  removal	  from	  Asn297-­‐linked	  oligosaccharides.	  J.	  Immunol.	  Methods	  306,	  151–160.	  	  Okulicz,	  J.F.,	  Marconi,	  V.C.,	  Landrum,	  M.L.,	  Wegner,	  S.,	  Weintrob,	  A.,	  Ganesan,	  A.,	  Hale,	  B.,	  Crum-­‐Cianflone,	  N.,	  Delmar,	  J.,	  Barthel,	  V.,	  Quinnan,	  G.,	  Agan,	  B.K.,	  Dolan,	  M.J.,	  2009.	  Clinical	  outcomes	  of	  elite	  controllers,	  viremic	  controllers,	  and	  long-­‐term	  nonprogressors	  in	  the	  US	  Department	  of	  Defense	  HIV	  natural	  history	  study.	  J.	  Infect.	  Dis.	  200,	  1714–1723.	  	  Overbaugh,	  J.,	  Morris,	  L.,	  2012.	  The	  Antibody	  Response	  against	  HIV-­‐1.	  Cold	  Spring	  Harb.	  Perspect.	  Med.	  2,	  a007039.	  	  Packard,	  B.Z.,	  Komoriya,	  A.,	  2008.	  Intracellular	  protease	  activation	  in	  apoptosis	  and	  cell-­‐mediated	  cytotoxicity	  characterized	  by	  cell-­‐permeable	  fluorogenic	  protease	  substrates.	  Cell	  Res.	  18,	  238–247.	  	  
	   xiv	  
Packard,	  B.Z.,	  Telford,	  W.G.,	  Komoriya,	  a.,	  Henkart,	  P.	  a.,	  2007.	  Granzyme	  B	  Activity	  in	  Target	  Cells	  Detects	  Attack	  by	  Cytotoxic	  Lymphocytes.	  J.	  Immunol.	  179,	  3812–3820.	  	  Pan,	  Q.,	  Hammarström,	  L.,	  2000.	  Molecular	  basis	  of	  IgG	  subclass	  deficiency.	  Immunol.	  Rev.	  178,	  99–110.	  Pantaleo,	  G.,	  Graziosi,	  C.,	  Demarest,	  J.F.,	  Butini,	  L.,	  Montroni,	  M.,	  Fox,	  C.H.,	  Orenstein,	  J.M.,	  Kotler,	  D.P.,	  Fauci,	  A.S.,	  1993.	  HIV	  infection	  is	  active	  and	  progressive	  in	  lymphoid	  tissue	  during	  the	  clinically	  latent	  stage	  of	  disease.	  Nature.	  362,	  355-­‐358.	  Parsons,	  M.S.,	  Boulet,	  S.,	  Song,	  R.,	  Bruneau,	  J.,	  Shoukry,	  N.H.,	  Routy,	  J.,	  Tsoukas,	  C.M.,	  Bernard,	  N.F.,	  2010.	  Mind	  the	  Gap:	  Lack	  of	  Association	  between	  KIR3DL1*004/HLA-­‐Bw4–Induced	  Natural	  Killer	  Cell	  Function	  and	  Protection	  from	  HIV	  Infection.	  J.	  Infect.	  Dis.	  202,	  S356–S360.	  	  Parsons,	  M.S.,	  Wren,	  L.,	  Isitman,	  G.,	  Navis,	  M.,	  Stratov,	  I.,	  Bernard,	  N.F.,	  Kent,	  S.J.,	  2012.	  HIV	  infection	  abrogates	  the	  functional	  advantage	  of	  natural	  killer	  cells	  educated	  through	  KIR3DL1/HLA-­‐Bw4	  interactions	  to	  mediate	  anti-­‐HIV	  antibody-­‐dependent	  cellular	  cytotoxicity.	  J.	  Virol.	  86,	  4488–4495.	  	  Pegu,	  P.,	  Vaccari,	  M.,	  Gordon,	  S.,	  Keele,	  B.F.,	  Doster,	  M.,	  Guan,	  Y.,	  Ferrari,	  G.,	  Pal,	  R.,	  Ferrari,	  M.G.,	  Whitney,	  S.,	  Hudacik,	  L.,	  Billings,	  E.,	  Rao,	  M.,	  Montefiori,	  D.,	  Tomaras,	  G.,	  Alam,	  S.M.,	  Fenizia,	  C.,	  Lifson,	  J.D.,	  Stablein,	  D.,	  Tartaglia,	  J.,	  Michael,	  N.,	  Kim,	  J.,	  Venzon,	  D.,	  Franchini,	  G.,	  2013.	  Antibodies	  with	  high	  avidity	  to	  the	  gp120	  envelope	  protein	  in	  protection	  from	  simian	  immunodeficiency	  virus	  SIV(mac251)	  acquisition	  in	  an	  immunization	  regimen	  that	  mimics	  the	  RV-­‐144	  Thai	  trial.	  J.	  Natl.	  Cancer	  Inst.	  87,	  1708–1719.	  	  Penack,	  O.,	  Gentilini,	  C.,	  Fischer,	  L.,	  Asemissen,	  a	  M.,	  Scheibenbogen,	  C.,	  Thiel,	  E.,	  Uharek,	  L.,	  2005.	  CD56dimCD16neg	  cells	  are	  responsible	  for	  natural	  cytotoxicity	  against	  tumor	  targets.	  Leukemia	  19,	  835–840.	  	  Pilgrim,	  A.K.,	  Pantaleo,	  G.,	  Cohen,	  O.J.,	  Fink,	  L.M.,	  Zhou,	  J.Y.T.,	  Bolognesi,	  D.P.,	  Fauci,	  A.S.,	  Montefiori,	  D.C.,	  1996.	  Neutralizing	  Antibody	  Responses	  to	  Human	  Immunodeficiency	  Virus	  Type	  1	  in	  Primary	  Infection	  and	  Long-­‐Term	  –	  Nonprogressive	  Infection.	  J.	  Infect.	  Dis.	  924–932.	  Poli,	  A.,	  Michel,	  T.,	  Thérésine,	  M.,	  Andrès,	  E.,	  Hentges,	  F.,	  Zimmer,	  J.,	  2009.	  CD56bright	  natural	  killer	  (NK)	  cells:	  an	  important	  NK	  cell	  subset.	  Immunology	  126,	  458–465.	  	  Pollara,	  J.,	  Bonsignori,	  M.,	  Moody,	  M.A.,	  Pazgier,	  M.,	  Haynes,	  B.F.,	  Ferrari,	  G.,	  2013a.	  Epitope	  Specificity	  of	  Human	  Immunodeficiency	  Virus-­‐1	  Antibody	  Dependent	  Cellular	  Cytotoxicity	  [	  ADCC	  ]	  Responses	  Ab-­‐Fab	  Ab-­‐Fc	  HIV-­‐1.	  Curr.	  HIV	  Res.	  378–387.	  Pollara,	  J.,	  Hart,	  L.,	  Brewer,	  F.,	  Pickeral,	  J.,	  Packard,	  B.Z.,	  Hoxie,	  J.	  a,	  Komoriya,	  A.,	  Ochsenbauer,	  C.,	  Kappes,	  J.C.,	  Roederer,	  M.,	  Huang,	  Y.,	  Weinhold,	  K.J.,	  Tomaras,	  G.D.,	  Haynes,	  B.F.,	  Montefiori,	  D.C.,	  Ferrari,	  G.,	  2011.	  High-­‐throughput	  quantitative	  
	   xv	  
analysis	  of	  HIV-­‐1	  and	  SIV-­‐specific	  ADCC-­‐mediating	  antibody	  responses.	  Cytometry.	  A	  79,	  603–612.	  	  Pollard,	  V.W.,	  Malim,	  M.H.,	  1998.	  THE	  HIV-­‐1	  REV	  PROTEIN	  Overview	  of	  the	  Retroviral	  Life	  Cycle.	  Annu.	  Rev.	  Microbiol.	  491–532.	  Rauf,	  A.,	  Khatri,	  M.,	  Murgia,	  M.	  V.,	  Saif,	  Y.M.,	  2012.	  Fas/FasL	  and	  perforin–granzyme	  pathways	  mediated	  T	  cell	  cytotoxic	  responses	  in	  infectious	  bursal	  disease	  virus	  infected	  chickens.	  Results	  Immunol.	  2,	  112–119.	  	  Ray,	  K.,	  Gupta,	  S.M.,	  Bala,	  M.,	  Muralidhar,	  S.,	  Kumar,	  J.,	  2006.	  CD4/CD8	  lymphocyte	  counts	  in	  healthy,	  HIV-­‐positive	  individuals	  &	  AIDS	  patients.	  Indian	  J.	  Med.	  Res.	  124,	  319–330.	  Rerks-­‐Ngarm,	  S.,	  Pitisuttithum,	  P.,	  Nitayaphan,	  S.,	  Kaewkungwal,	  J.,	  Chiu,	  J.,	  Paris,	  R.M.,	  Souza,	  M.	  De,	  Adams,	  E.,	  Benenson,	  M.,	  Gurunathan,	  S.,	  Tartaglia,	  J.,	  Mcneil,	  J.G.,	  Francis,	  D.P.,	  Stablein,	  D.,	  Birx,	  D.L.,	  2009.	  Vaccination	  with	  ALVAC	  and	  AIDSVAX	  to	  Prevent	  HIV-­‐1	  Infection	  in	  Thailand.	  N.	  Engl.	  J.	  Med.	  361,	  2209–2220.	  Richard,	  J.,	  Veillette,	  M.,	  Batraville,	  L.-­‐A.,	  Coutu,	  M.,	  Chapleau,	  J.-­‐P.,	  Bonsignori,	  M.,	  Bernard,	  N.,	  Tremblay,	  C.,	  Roger,	  M.,	  Kaufmann,	  D.E.,	  Finzi,	  A.,	  2014.	  Flow	  cytometry-­‐based	  assay	  to	  study	  HIV-­‐1	  gp120	  specific	  antibody-­‐dependent	  cellular	  cytotoxicity	  responses.	  J.	  Virol.	  Methods	  208,	  107–114.	  	  Romee,	  R.,	  Foley,	  B.,	  Lenvik,	  T.,	  Wang,	  Y.,	  Zhang,	  B.,	  Ankarlo,	  D.,	  Luo,	  X.,	  Cooley,	  S.,	  Verneris,	  M.,	  Walcheck,	  B.,	  Miller,	  J.,	  2013.	  NK	  cell	  CD16	  surface	  expression	  and	  function	  is	  regulated	  by	  a	  disintegrin	  and	  metalloprotease-­‐17	  (ADAM17).	  Blood	  121,	  3599–3608.	  	  Sanders,	  R.W.,	  Venturi,	  M.,	  Schiffner,	  L.,	  Kalyanaraman,	  R.,	  Katinger,	  H.,	  Lloyd,	  K.O.,	  Kwong,	  P.D.,	  Moore,	  J.P.,	  2002.	  The	  mannose-­‐dependent	  epitope	  for	  neutralizing	  antibody	  2G12	  on	  human	  immunodeficiency	  virus	  type	  1	  glycoprotein	  gp120.	  J.	  Virol.	  76,	  7293–7305.	  	  Sansoni,	  P.,	  Cossarizza,	  a,	  Brianti,	  V.,	  Fagnoni,	  F.,	  Snelli,	  G.,	  Monti,	  D.,	  Marcato,	  a,	  Passeri,	  G.,	  Ortolani,	  C.,	  Forti,	  E.,	  1993.	  Lymphocyte	  subsets	  and	  natural	  killer	  cell	  activity	  in	  healthy	  old	  people	  and	  centenarians.	  Blood	  82,	  2767–2773.	  Sarnquist,	  C.C.,	  Rahangdale,	  L.,	  Maldonado,	  Y.,	  2013.	  Reproductive	  health	  and	  family	  planning	  needs	  among	  HIV-­‐infected	  women	  in	  Sub-­‐Saharan	  Africa.	  Curr.	  HIV	  Res.	  11,	  160–168.	  Schubert,	  U.,	  Antón,	  L.C.,	  Bacík,	  I.,	  Cox,	  J.H.,	  Bour,	  S.,	  Bennink,	  J.R.,	  Orlowski,	  M.,	  Strebel,	  K.,	  Yewdell,	  J.W.,	  Bac,	  I.,	  1998.	  CD4	  Glycoprotein	  Degradation	  Induced	  by	  Human	  Immunodeficiency	  Virus	  Type	  1	  Vpu	  Protein	  Requires	  the	  Function	  of	  Proteasomes	  and	  the	  Ubiquitin-­‐Conjugating	  Pathway	  CD4	  Glycoprotein	  Degradation	  Induced	  by	  Human	  Immunodeficiency	  Virus	  Type	  1	  Vpu	  Protein	  Requ.	  J.	  Virol.	  72,	  2280-­‐2288.	  
	   xvi	  
Screpanti,	  V.,	  Wallin,	  R.P.	  a.,	  Ljunggren,	  H.-­‐G.,	  Grandien,	  a.,	  2001.	  A	  Central	  Role	  for	  Death	  Receptor-­‐Mediated	  Apoptosis	  in	  the	  Rejection	  of	  Tumors	  by	  NK	  Cells.	  J.	  Immunol.	  167,	  2068–2073.	  	  Seidel,	  U.J.E.,	  Schlegel,	  P.,	  Lang,	  P.,	  2013.	  Natural	  killer	  cell	  mediated	  antibody-­‐dependent	  cellular	  cytotoxicity	  in	  tumor	  immunotherapy	  with	  therapeutic	  antibodies.	  Front.	  Immunol.	  4,	  76.	  	  Shannon,	  K.,	  Leiter,	  K.,	  Phaladze,	  N.,	  Hlanze,	  Z.,	  Tsai,	  A.C.,	  Heisler,	  M.,	  Iacopino,	  V.,	  Weiser,	  S.D.,	  2012.	  Gender	  inequity	  norms	  are	  associated	  with	  increased	  male-­‐perpetrated	  rape	  and	  sexual	  risks	  for	  HIV	  infection	  in	  Botswana	  and	  Swaziland.	  PLoS	  One	  7,	  e28739.	  	  Sharif-­‐Askari,	  E.,	  Alam,	  a,	  Rhéaume,	  E.,	  Beresford,	  P.J.,	  Scotto,	  C.,	  Sharma,	  K.,	  Lee,	  D.,	  DeWolf,	  W.E.,	  Nuttall,	  M.E.,	  Lieberman,	  J.,	  Sékaly,	  R.P.,	  2001.	  Direct	  cleavage	  of	  the	  human	  DNA	  fragmentation	  factor-­‐45	  by	  granzyme	  B	  induces	  caspase-­‐activated	  DNase	  release	  and	  DNA	  fragmentation.	  EMBO	  J.	  20,	  3101–3113.	  	  Sharp,	  P.M.,	  Hahn,	  B.H.,	  Swanstrom,	  R.,	  Coffin,	  J.,	  Walker,	  B.,	  Mcmichael,	  A.,	  Wilen,	  C.B.,	  Tilton,	  J.C.,	  Doms,	  R.W.,	  Craigie,	  R.,	  Bushman,	  F.D.,	  Connell,	  R.J.O.,	  Kim,	  J.H.,	  Shaw,	  G.M.,	  Hunter,	  E.,	  2011.	  Origins	  of	  HIV	  and	  the	  AIDS	  pandemic.	  Cold	  Spring	  Harb.	  Perspect.	  Med.	  1,	  a006841.	  	  Shinkawa,	  T.,	  Nakamura,	  K.,	  Yamane,	  N.,	  Shoji-­‐Hosaka,	  E.,	  Kanda,	  Y.,	  Sakurada,	  M.,	  Uchida,	  K.,	  Anazawa,	  H.,	  Satoh,	  M.,	  Yamasaki,	  M.,	  Hanai,	  N.,	  Shitara,	  K.,	  2003.	  The	  absence	  of	  fucose	  but	  not	  the	  presence	  of	  galactose	  or	  bisecting	  N-­‐acetylglucosamine	  of	  human	  IgG1	  complex-­‐type	  oligosaccharides	  shows	  the	  critical	  role	  of	  enhancing	  antibody-­‐dependent	  cellular	  cytotoxicity.	  J.	  Biol.	  Chem.	  278,	  3466–3473.	  	  Sierra,	  S.,	  Kupfer,	  B.,	  Kaiser,	  R.,	  2005.	  Basics	  of	  the	  virology	  of	  HIV-­‐1	  and	  its	  replication.	  J.	  Clin.	  Virol.	  34,	  233–244.	  	  Sips,	  M.,	  Sciaranghella,	  G.,	  Diefenbach,	  T.,	  Dugast,	  a-­‐S.,	  Berger,	  C.T.,	  Liu,	  Q.,	  Kwon,	  D.,	  Ghebremichael,	  M.,	  Estes,	  J.D.,	  Carrington,	  M.,	  Martin,	  J.N.,	  Deeks,	  S.G.,	  Hunt,	  P.W.,	  Alter,	  G.,	  2012.	  Altered	  distribution	  of	  mucosal	  NK	  cells	  during	  HIV	  infection.	  Mucosal	  Immunol.	  5,	  30–40.	  	  Smalls-­‐Mantey,	  A.,	  Doria-­‐Rose,	  N.,	  Klein,	  R.,	  Patamawenu,	  A.,	  Migueles,	  S.	  a,	  Ko,	  S.-­‐Y.,	  Hallahan,	  C.W.,	  Wong,	  H.,	  Liu,	  B.,	  You,	  L.,	  Scheid,	  J.,	  Kappes,	  J.C.,	  Ochsenbauer,	  C.,	  Nabel,	  G.J.,	  Mascola,	  J.R.,	  Connors,	  M.,	  2012.	  Antibody-­‐dependent	  cellular	  cytotoxicity	  against	  primary	  HIV-­‐infected	  CD4+	  T	  cells	  is	  directly	  associated	  with	  the	  magnitude	  of	  surface	  IgG	  binding.	  J.	  Virol.	  86,	  8672–8680.	  	  Smalls-­‐Mantey,	  A.,	  Connors,	  M.,	  Sattentau,	  Q.J.,	  2013.	  Comparative	  efficiency	  of	  HIV-­‐1	  infected	  T	  cell	  killing	  by	  NK	  cells,	  monocytes	  and	  neutrophils.	  Plos	  One.	  8,	  e74858.	  Trapani,	  T.A.,	  Smy,	  J.,	  2002.	  Functional	  significance	  of	  the	  perforin/granzyme	  cell	  death	  pathway.	  Nat.	  Rev.	  Immunol.	  2,	  735–747.	  
	   xvii	  
Smyth,	  M.J.,	  Cretney,	  E.,	  Kelly,	  J.M.,	  Westwood,	  J.	  a,	  Street,	  S.E.	  a,	  Yagita,	  H.,	  Takeda,	  K.,	  van	  Dommelen,	  S.L.H.,	  Degli-­‐Esposti,	  M.	  a,	  Hayakawa,	  Y.,	  2005.	  Activation	  of	  NK	  cell	  cytotoxicity.	  Mol.	  Immunol.	  42,	  501–510.	  	  Srisurapanon,	  S.,	  Louisirirotchanakul,	  S.,	  Sumransurp,	  K.,	  Ratanasrithong,	  M.,	  Chuenchitra,	  T.,	  Jintakatkorn,	  S.,	  Wasi,	  C.,	  2005.	  Binding	  antibody	  to	  neutralizing	  epitope	  gp41	  in	  HIV-­‐1	  subtype	  CRF	  01_AE	  infection	  related	  to	  stage	  of	  disease.	  Southeast	  Asian	  J.	  Trop.	  Med.	  Public	  Health	  36,	  221–227.	  Sterjovski,	  J.,	  Churchill,	  M.J.,	  Roche,	  M.,	  Ellett,	  A.,	  Farrugia,	  W.,	  Wesselingh,	  S.L.,	  Cunningham,	  A.L.,	  Ramsland,	  P.	  a,	  Gorry,	  P.R.,	  2011.	  CD4-­‐binding	  site	  alterations	  in	  CCR5-­‐using	  HIV-­‐1	  envelopes	  influencing	  gp120-­‐CD4	  interactions	  and	  fusogenicity.	  Virology.	  410,	  418–428.	  	  	  Stiegler,	  G.,	  Kunert,	  R.,	  Purtscher,	  M.,	  Wolbank,	  S.,	  Voglauer,	  R.,	  Steindl,	  F.,	  Katinger,	  H.,	  2001.	  A	  potent	  cross-­‐clade	  neutralizing	  human	  monoclonal	  antibody	  against	  a	  novel	  epitope	  on	  gp41	  of	  human	  immunodeficiency	  virus	  type	  1.	  AIDS	  Res.	  Hum.	  Retroviruses.	  17,	  1757–1765.	  	  Stoermer,	  K.	  a,	  Morrison,	  T.E.,	  2011.	  Complement	  and	  viral	  pathogenesis.	  Virology.	  411,	  362–373.	  	  Stratov,	  I.,	  Chung,	  A.,	  Kent,	  S.J.,	  2008.	  Robust	  NK	  cell-­‐mediated	  human	  immunodeficiency	  virus	  (HIV)-­‐specific	  antibody-­‐dependent	  responses	  in	  HIV-­‐infected	  subjects.	  J.	  Virol.	  82,	  5450–5459.	  	  Su,	  B.,	  Moog,	  C.,	  2014.	  Which	  Antibody	  Functions	  are	  Important	  for	  an	  HIV	  Vaccine?	  Front.	  Immunol.	  5,	  289.	  Suhasini,	  M.,	  Reddy,	  T.R.,	  2009.	  Cellular	  proteins	  and	  HIV-­‐1	  Rev	  function.	  Curr.	  HIV	  Res.	  7,	  91–100.	  The	  South	  African	  Antiretroviral	  Treatment	  Guidelines,	  2013.	  [Online:http://www.sahivsoc.org/upload/documents/2013%20ART%20Guidelines-­‐ˇ-­‐	  Short%20Combined%20FINAL%20draft%20guidelines%2014%20March%20201	  3.pdf	  Thobakgale,	  C.F.,	  Fadda,	  L.,	  Lane,	  K.,	  Toth,	  I.,	  Pereyra,	  F.,	  Bazner,	  S.,	  Ndung’u,	  T.,	  Walker,	  B.D.,	  Rosenberg,	  E.S.,	  Alter,	  G.,	  Carrington,	  M.,	  Allen,	  T.M.,	  Altfeld,	  M.,	  2012.	  Frequent	  and	  strong	  antibody-­‐mediated	  natural	  killer	  cell	  activation	  in	  response	  to	  HIV-­‐1	  Env	  in	  individuals	  with	  chronic	  HIV-­‐1	  infection.	  J.	  Virol.	  86,	  6986–6993.	  	  Thomas,	  D.	  a,	  Du,	  C.,	  Xu,	  M.,	  Wang,	  X.,	  Ley,	  T.J.,	  2000.	  DFF45/ICAD	  can	  be	  directly	  processed	  by	  granzyme	  B	  during	  the	  induction	  of	  apoptosis.	  Immunity	  12,	  621–632.	  	  
	   xviii	  
Tiemessen,	  C.T.,	  Shalekoff,	  S.,	  Meddows-­‐Taylor,	  S.,	  Schramm,	  D.B.,	  Papathanasopoulos,	  M.	  a,	  Gray,	  G.E.,	  Sherman,	  G.G.,	  Coovadia,	  A.H.,	  Kuhn,	  L.,	  2009.	  Cutting	  Edge:	  Unusual	  NK	  cell	  responses	  to	  HIV-­‐1	  peptides	  are	  associated	  with	  protection	  against	  maternal-­‐infant	  transmission	  of	  HIV-­‐1.	  J.	  Immunol.	  182,	  5914–5918.	  	  Timmons,	  B.W.,	  Cieslak,	  T.,	  2008.	  Human	  natural	  killer	  cell	  subsets	  and	  acute	  exercise:	  a	  brief	  review.	  Exerc.	  Immunol.	  Rev.	  14,	  8–23.	  Tomaras,	  G.D.,	  Ferrari,	  G.,	  Shen,	  X.,	  Alam,	  S.M.,	  Liao,	  H.-­‐X.,	  Pollara,	  J.,	  Bonsignori,	  M.,	  Moody,	  M.A.,	  Fong,	  Y.,	  Chen,	  X.,	  Poling,	  B.,	  Nicholson,	  C.O.,	  Zhang,	  R.,	  Lu,	  X.,	  Parks,	  R.,	  Kaewkungwal,	  J.,	  Nitayaphan,	  S.,	  Pitisuttithum,	  P.,	  Rerks-­‐Ngarm,	  S.,	  Gilbert,	  P.B.,	  Kim,	  J.H.,	  Michael,	  N.L.,	  Montefiori,	  D.C.,	  Haynes,	  B.F.,	  2013.	  Vaccine-­‐induced	  plasma	  IgA	  specific	  for	  the	  C1	  region	  of	  the	  HIV-­‐1	  envelope	  blocks	  binding	  and	  effector	  function	  of	  IgG.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A.	  110,	  9019–9024.	  	  Tomaras,	  G.D.,	  Yates,	  N.L.,	  Liu,	  P.,	  Qin,	  L.,	  Fouda,	  G.G.,	  Chavez,	  L.L.,	  Decamp,	  A.C.,	  Parks,	  R.J.,	  Ashley,	  V.C.,	  Lucas,	  J.T.,	  Cohen,	  M.,	  Eron,	  J.,	  Hicks,	  C.B.,	  Liao,	  H.-­‐X.,	  Self,	  S.G.,	  Landucci,	  G.,	  Forthal,	  D.N.,	  Weinhold,	  K.J.,	  Keele,	  B.F.,	  Hahn,	  B.H.,	  Greenberg,	  M.L.,	  Morris,	  L.,	  Karim,	  S.S.A.,	  Blattner,	  W.	  a,	  Montefiori,	  D.C.,	  Shaw,	  G.M.,	  Perelson,	  A.S.,	  Haynes,	  B.F.,	  2008.	  Initial	  B-­‐cell	  responses	  to	  transmitted	  human	  immunodeficiency	  virus	  type	  1:	  virion-­‐binding	  immunoglobulin	  M	  (IgM)	  and	  IgG	  antibodies	  followed	  by	  plasma	  anti-­‐gp41	  antibodies	  with	  ineffective	  control	  of	  initial	  viremia.	  J.	  Virol.	  82,	  12449–12463.	  	  Trapani,	  J.	  a,	  Sutton,	  V.R.,	  2003.	  Granzyme	  B:	  pro-­‐apoptotic,	  antiviral	  and	  antitumor	  functions.	  Curr.	  Opin.	  Immunol.	  15,	  533–543.	  	  Trkola,	  a,	  Matthews,	  J.,	  Gordon,	  C.,	  Ketas,	  T.,	  Moore,	  J.P.,	  1999.	  A	  cell	  line-­‐based	  neutralization	  assay	  for	  primary	  human	  immunodeficiency	  virus	  type	  1	  isolates	  that	  use	  either	  the	  CCR5	  or	  the	  CXCR4	  coreceptor.	  J.	  Virol.	  73,	  8966–8974.	  Trkola,	  A.,	  Purtscher,	  M.,	  Muster,	  T.,	  Ballaun,	  C.,	  Buchacher,	  A.,	  Sullivan,	  N.,	  Srinivasan,	  K.,	  Sodroski,	  J.,	  Moore,	  J.P.,	  Katinger,	  H.,	  1996.	  Human	  monoclonal	  antibody	  2G12	  defines	  a	  distinctive	  neutralization	  epitope	  on	  the	  gp120	  glycoprotein	  of	  human	  immunodeficiency	  virus	  type	  1.	  J.	  Virol.	  70,	  1100–1108.	  Valiante,	  N.M.,	  Lienert,	  K.,	  Shilling,	  H.G.,	  Smits,	  B.J.,	  Parham,	  P.,	  1997.	  Killer	  cell	  receptors:	  keeping	  pace	  with	  MHC	  class	  I	  evolution.	  Immunol.	  Rev.	  155,	  155–164.	  Van	  Domselaar,	  R.,	  Bovenschen,	  N.,	  2011.	  Cell	  death-­‐independent	  functions	  of	  granzymes:	  hit	  viruses	  where	  it	  hurts.	  Rev.	  Med.	  Virol.	  21,	  301–314.	  	  Veillette,	  M.,	  Désormeaux,	  A.,	  Medjahed,	  H.,	  Gharsallah,	  N.-­‐E.,	  Coutu,	  M.,	  Baalwa,	  J.,	  Guan,	  Y.,	  Lewis,	  G.,	  Ferrari,	  G.,	  Hahn,	  B.H.,	  Haynes,	  B.F.,	  Robinson,	  J.E.,	  Kaufmann,	  D.E.,	  Bonsignori,	  M.,	  Sodroski,	  J.,	  Finzi,	  A.,	  2014.	  Interaction	  with	  cellular	  CD4	  exposes	  HIV-­‐1	  envelope	  epitopes	  targeted	  by	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity.	  J.	  Virol.	  88,	  2633–2644.	  	  
	   xix	  
Vivier,	  E.,	  Nunès,	  J.	  a,	  Vély,	  F.,	  2004.	  Natural	  killer	  cell	  signaling	  pathways.	  Science.	  306,	  1517–1519.	  	  Vivier,	  E.,	  Raulet,	  D.H.,	  Moretta,	  A.,	  Caligiuri,	  M.	  a,	  Zitvogel,	  L.,	  Lanier,	  L.L.,	  Yokoyama,	  W.M.,	  Ugolini,	  S.,	  2011.	  Innate	  or	  adaptive	  immunity?	  The	  example	  of	  natural	  killer	  cells.	  Science	  (80-­‐.	  ).	  331,	  44–49.	  	  Walzer,	  T.,	  Dalod,	  M.,	  Robbins,	  S.H.,	  Zitvogel,	  L.,	  Vivier,	  E.,	  2005.	  Review	  article	  Natural-­‐killer	  cells	  and	  dendritic	  cells :	  “	  l	  ’	  union	  fait	  la	  force	  ”	  Blood	  106,	  2252–2258.	  	  Ward,	  J.P.,	  Bonaparte,	  M.I.,	  Barker,	  E.,	  2004.	  HLA-­‐C	  and	  HLA-­‐E	  reduce	  antibody-­‐dependent	  natural	  killer	  cell-­‐mediated	  cytotoxicity	  of	  HIV-­‐infected	  primary	  T	  cell	  blasts.	  AIDS	  18,	  1769–1779.	  Weber,	  J.,	  2001.	  The	  pathogenesis	  of	  HIV-­‐1	  infection.	  Br.	  Med.	  Bull.	  58,	  61–72.	  Wei,	  X.,	  Decker,	  J.M.,	  Wang,	  S.,	  Hui,	  H.,	  Kappes,	  J.C.,	  Wu,	  X.,	  Salazar-­‐Gonzalez,	  J.F.,	  Salazar,	  M.G.,	  Kilby,	  J.M.,	  Saag,	  M.S.,	  Komarova,	  N.L.,	  Nowak,	  M.	  a,	  Hahn,	  B.H.,	  Kwong,	  P.D.,	  Shaw,	  G.M.,	  2003.	  Antibody	  neutralization	  and	  escape	  by	  HIV-­‐1.	  Nature	  422,	  307–312.	  	  WHO,	  2008.	  Towards	  Universal	  access.	  Wilen,	  C.B.,	  Tilton,	  J.C.,	  Doms,	  R.W.,	  2012.	  HIV:	  cell	  binding	  and	  entry.	  Cold	  Spring	  Harb.	  Perspect.	  Med.	  2,	  1-­‐13.	  Williams,	  L.,	  2007.	  Dysfunctional	  natural	  killer	  cells,	  in	  vivo,	  are	  governed	  by	  HIV	  viremia	  regardless	  of	  whether	  the	  infected	  individual	  is	  on	  antiretroviral	  therapy.	  AIDS.	  21,	  2355–2367.	  Woof,	  J.M.,	  Burton,	  D.R.,	  2004.	  Human	  antibody-­‐Fc	  receptor	  interactions	  illuminated	  by	  crystal	  structures.	  Nat	  Rev	  Immunol	  4,	  89–99.	  UNAIDS,	  2011.	  Faster.	  Smarter.	  Better.	  UNAIDS,	  2013.	  Global	  Report.	  Wren,	  L.,	  Parsons,	  M.S.,	  Isitman,	  G.,	  Center,	  R.J.,	  Kelleher,	  A.D.,	  Stratov,	  I.,	  Bernard,	  N.F.,	  Kent,	  S.J.,	  2012.	  Influence	  of	  cytokines	  on	  HIV-­‐specific	  antibody-­‐dependent	  cellular	  cytotoxicity	  activation	  profile	  of	  natural	  killer	  cells.	  PLoS	  One	  7,	  e38580.	  	  Wren,	  L.H.,	  Chung,	  A.W.,	  Isitman,	  G.,	  Kelleher,	  A.D.,	  Parsons,	  M.S.,	  Amin,	  J.,	  Cooper,	  D.	  a,	  Stratov,	  I.,	  Navis,	  M.,	  Kent,	  S.J.,	  2013a.	  Specific	  antibody-­‐dependent	  cellular	  cytotoxicity	  responses	  associated	  with	  slow	  progression	  of	  HIV	  infection.	  J.	  Immunol.	  138,	  116–23.	  	  Wren,	  L.H.,	  Stratov,	  I.,	  Kent,	  S.J.,	  Parsons,	  M.S.,	  2013b.	  Obstacles	  to	  ideal	  anti-­‐HIV	  antibody-­‐dependent	  cellular	  cytotoxicity	  responses.	  Vaccine	  31,	  5506–5517.	  	  
	   xx	  
Wyatt,	  R.,	  Moore,	  J.,	  Accola,	  M.,	  Desjardin,	  E.,	  Robinson,	  J.,	  Wyatt,	  R.,	  Moore,	  J.,	  Accola,	  M.,	  Desjardin,	  E.,	  Robinson,	  J.,	  Sodroski,	  J.,	  1995.	  Involvement	  of	  the	  V1	  /	  V2	  variable	  loop	  structure	  in	  the	  exposure	  of	  human	  immunodeficiency	  virus	  type	  1	  gp120	  epitopes	  induced	  by	  receptor	  binding	  .	  Involvement	  of	  the	  V1	  /	  V2	  Variable	  Loop	  Structure	  in	  the	  Exposure	  of	  Human	  Immunodeficiency	  Virus	  Type.	  Journal	  of	  Virology	  69,	  5723-­‐5733.	  Xiang,	  S.,	  Pacheco,	  B.,	  Bowder,	  D.,	  Yuan,	  W.,	  Sodroski,	  J.,	  Shi-­‐hua	  Xiang,	  Beatriz	  Pacheco,	  Dane	  Bowder,	  Wen	  Yuan,	  J.,	  Sodroski,	  2014.	  Characterization	  of	  a	  Dual-­‐tropic	  Human	  Immunodeficiency	  Virus	  (HIV-­‐1)	  Strain	  Derived	  from	  the	  Prototypical	  X4	  Isolate	  HXBc2.	  Virology	  438,	  5–13.	  	  Yates,	  N.L.,	  Lucas,	  J.T.,	  Nolen,	  T.L.,	  Vandergrift,	  N.A.,	  Soderberg,	  K.A.,	  Seaton,	  K.E.,	  Denny,	  T.N.,	  Haynes,	  B.F.,	  Cohen,	  M.S.,	  Tomaras,	  G.D.,	  2011.	  Multiple	  HIV-­‐1	  specific	  IgG3	  responses	  decline	  during	  acute	  HIV-­‐1:	  implications	  for	  detection	  of	  incident	  HIV	  infection.	  AIDS	  25,	  2089-­‐2097.	  Zaritskaya,	  L.,	  Shurin,	  M.R.,	  Sayers,	  T.J.,	  Malyguine,	  A.M.,	  2010.	  New	  flow	  cytometric	  assays	  for	  monitoring	  cell-­‐mediated	  cytotoxicity.	  Science	  9,	  601–616.	  	  Zhang,	  M.-­‐Y.,	  Yuan,	  T.,	  Li,	  J.,	  Rosa	  Borges,	  A.,	  Watkins,	  J.D.,	  Guenaga,	  J.,	  Yang,	  Z.,	  Wang,	  Y.,	  Wilson,	  R.,	  Li,	  Y.,	  Polonis,	  V.R.,	  Pincus,	  S.H.,	  Ruprecht,	  R.M.,	  Dimitrov,	  D.S.,	  2012.	  Identification	  and	  characterization	  of	  a	  broadly	  cross-­‐reactive	  HIV-­‐1	  human	  monoclonal	  antibody	  that	  binds	  to	  both	  gp120	  and	  gp41.	  PLoS	  One	  7,	  e44241.	  	  




Table	  A1.1.	  Laboratory	  reagents	  prepared	  for	  this	  study	  
Reagent	   Composition	   Supplier	  
Fetal	   Bovine	   Serum	  (FBS;	  100	  ml)	   -­‐	   Invitrogen	  
RPMI-­‐1640	  Medium.(1X)	   200	  mM	  L-­‐glutamine,	  	  25	  mM	  HEPES,	  pH	  indicator	   Invitrogen	  	  	  
Phosphate	   Buffer	   Saline	  (PBS;	  1X)	   0.138M	  NaCl,	  0.0027M	  KCl	  (pH	  7.2)	   Invitrogen	  
Penicillin/	   Streptomycin	  (100	  ml)	   100	   units/ml	   penicillin,100µg	  streptomycin	   Invitrogen	  
R1	  	   1	  %	  FBS	  in	  RPMI	   	  
R10	  	   10	  %	  FBS	  in	  RPMI	   	  
R20	  	   20	  %	  FBS	  in	  RPMI	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Appendix	  II	  
A2.1.	  CD107a	  flow	  cytometry	  
A.2.1.1.	  Titrating	  antibodies	  Titration	  for	  all	  antibodies	  included	  in	  the	  CD107a	  degranulation	  panel	  were	  carried	  out	  to	  ensure	  the	  volumes	  used	  in	  each	  experiment	  allowed	  for	  optimal	  separation	  between	  the	   positive	   and	   negative	   populations,	   and	   also	   to	   exclude	   maximum	   background	  fluorescence	  possible.	  Titrating	  the	  antibodies	  by	  6	  fold	  dilutions	  allowed	  determination	  of	  each	  antibody	  saturation	  titre	  (volume	  of	  antibody	  that	  allows	  complete	  staining	  of	  the	   particular	   cellular	   marker	   in	   a	   sample).	   Pseudo-­‐colour	   plots	   were	   generated	   to	  determine	   the	   degree	   of	   separation	   and	   amount	   of	   fluorescence	   with	   each	   antibody	  volume	  (Figure	  A2.1).	  
	  
	  
Figure	   A2.1.	   CD4-­‐PerCP-­‐Cy5-­‐5	   antibody	   titration.	   (A)	   Pseudo-­‐colour	   plots	   with	   gates	  
showing	  the	  position	  of	   the	  positive	  and	  negative	  populations	  and	   the	  separation	  between	  the	   two.	   (B)	  Graph	  of	  CD4	  median	   fluorescence	   intensity	  at	  different	  antibody	  concentrations.	  One	  μl	  (dotted	  line)	  was	  chosen	  as	  the	  optimal	  volume	  for	  the	  CD4	  antibody.	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A.2.1.2.	  Fluorescence	  Minus	  One	  (FMO)	  controls	  To	  set	   the	  gates	  accurately,	  FMO	  controls	   for	  all	   the	  antibodies	  were	   included	   in	  each	  experiment.	   FMO	   controls	   provide	   a	   means	   to	   measure	   the	   effect	   of	   spillover	   from	  populations	   in	   other	   dye	   dimensions	   in	   the	   channel	   of	   interest.	   To	   prepare	   the	   FMO	  tubes,	  1x106	  PBMCs	  were	  stained	  with	  all	  antibodies	  excluding	  one	  individual	  antibody	  (Figure	  A2.2).	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Appendix	  III	  
A3.1.	  GranToxilux	  and	  PanToxilux	  assays	  
A3.1.1.	   Optimising	   the	   flow	   cytometry	   settings	   for	   APC,	   PacBlue	   and	  
FITC	  channels	  After	   optimising	   the	   concentration	   of	   TFL4	   for	   staining	   CEM.NKRCCR5	   cells,	   an	  experiment	   combining	  CEM.NKRCCR5	  only	   and	  PBMCs	  only	  was	   carried	  out	   to	  position	  the	  populations	  at	  the	  right	  Pacblue	  and	  FITC	  channels.	  The	  PBMCs	  were	  positioned	  in	  the	   lower	   left	   quadrant	   on	   the	   Pacblue	   and	   FITC	   channels	   (101-­‐103),	   and	   the	  CEM.NKRCCR5	  cells	  stained	  with	  TFL4	  were	  positioned	  in	  the	  upper	  left	  quadrant	  on	  the	  Pacblue	  and	  FITC	  channels	  (101-­‐103)	  (Figure	  A3.1).	  	  
	  
	  
Figure	   A3.1.	   Positioning	   PBMCs	   and	   CEM.NKRCCR5	   in	   the	   right	   APC,	   Pacblue	   and	   FITC	  
quadrants	   on	   the	   flow	   plots.	   (A)	   The	   first	   column	   shows	   PBMCs	   only,	   the	   second	   column	  shows,	  CEM.NKRCCR5	  cells	  only,	  and	  the	  third	  column	  shows	  a	  combination	  of	  effector	  and	  target	  cells.	   The	   first	   row	   shows	   PBMCs	   and	   CEM.NKRCCR5	   cells	   positioned	   on	   the	   APC	   and	   Pacblue	  channels.	  The	   second	   row	  shows	  positioned	  PBMCs	  and	  CEM.NKRCCR5	   cells	  using	   the	  APC	  and	  FITC	  channels.	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